
<html lang="en"     class="pb-page"  data-request-id="b2d7c3da-6fe3-4948-a7d4-c067577976ff"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01965;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy" /></meta><meta name="dc.Creator" content="Donghwa  Kim" /></meta><meta name="dc.Creator" content="Sang Won  Choi" /></meta><meta name="dc.Creator" content="Jihee  Cho" /></meta><meta name="dc.Creator" content="Jae-Hui  Been" /></meta><meta name="dc.Creator" content="Kyoungsun  Choi" /></meta><meta name="dc.Creator" content="Wenzhe  Jiang" /></meta><meta name="dc.Creator" content="Jaeho  Han" /></meta><meta name="dc.Creator" content="Jedo  Oh" /></meta><meta name="dc.Creator" content="Changmin  Park" /></meta><meta name="dc.Creator" content="Soongyu  Choi" /></meta><meta name="dc.Creator" content="Songyi  Seo" /></meta><meta name="dc.Creator" content="Koung Li  Kim" /></meta><meta name="dc.Creator" content="Wonhee  Suh" /></meta><meta name="dc.Creator" content="Sang Kook  Lee" /></meta><meta name="dc.Creator" content="Sanghee  Kim" /></meta><meta name="dc.Description" content="Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to ..." /></meta><meta name="Description" content="Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 27, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01965" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01965" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01965" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01965" /></link>
        
    
    

<title>Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01965" /></meta><meta property="og:title" content="Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0019.jpeg" /></meta><meta property="og:description" content="Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to develop a novel type of antiangiogenesis agent that possesses minimized cytotoxicity. To overcome its poor pharmaceutical properties, we further modified the structure. A new scaffold was derived in which the stereogenic carbon was changed to nitrogen and the 1,2,3-triazole ring was replaced by an alkyl chain. By comparing the bioactivity versus cytotoxicity, compound 31 was selected, which has improved aqueous solubility and an enhanced selectivity index. Mechanistically, 31 suppressed angiopoietin-2 (ANGPT2) expression induced by high glucose in retinal cells and exhibited in vivo antiangiogenic activity in choroidal neovascularization and oxygen-induced retinopathy mouse models. These results suggest the potential of 31 as a lead to develop antiangiogenic small-molecule drugs to treat diabetic retinopathy and as a chemical tool to elucidate new mechanisms of angiogenesis." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01965"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01965">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01965&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01965&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01965&amp;href=/doi/10.1021/acs.jmedchem.0c01965" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 5535-5550</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01958" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02018" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Donghwa Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donghwa Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donghwa++Kim">Donghwa Kim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1425-213X" title="Orcid link">http://orcid.org/0000-0003-1425-213X</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Sang Won Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sang Won Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sang+Won++Choi">Sang Won Choi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jihee Cho</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jihee Cho</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jihee++Cho">Jihee Cho</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1814-7794" title="Orcid link">http://orcid.org/0000-0002-1814-7794</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jae-Hui Been</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jae-Hui Been</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jae-Hui++Been">Jae-Hui Been</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Kyoungsun Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kyoungsun Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kyoungsun++Choi">Kyoungsun Choi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wenzhe Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhe Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhe++Jiang">Wenzhe Jiang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jaeho Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaeho Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaeho++Han">Jaeho Han</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Jedo Oh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jedo Oh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hana Pharmaceutical Co., Pangyo 13486, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jedo++Oh">Jedo Oh</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Changmin Park</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Changmin Park</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hana Pharmaceutical Co., Pangyo 13486, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Changmin++Park">Changmin Park</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Soongyu Choi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Soongyu Choi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hana Pharmaceutical Co., Pangyo 13486, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Soongyu++Choi">Soongyu Choi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Songyi Seo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Songyi Seo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Global Innovative Drug, Graduate School of Chung-Ang University, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Songyi++Seo">Songyi Seo</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Koung Li Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Koung Li Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Global Innovative Drug, Graduate School of Chung-Ang University, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Koung+Li++Kim">Koung Li Kim</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wonhee Suh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wonhee Suh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Global Innovative Drug, Graduate School of Chung-Ang University, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wonhee++Suh">Wonhee Suh</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5811-0833" title="Orcid link">http://orcid.org/0000-0001-5811-0833</a></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Sang Kook Lee</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sang Kook Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#790a12151c1c4f48390a170c57181a57120b"><span class="__cf_email__" data-cfemail="c7b4acaba2a2f1f687b4a9b2e9a6a4e9acb5">[emailÂ protected]</span></a>. Phone: +82-2-880-2475.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sang+Kook++Lee">Sang Kook Lee</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4306-7024" title="Orcid link">http://orcid.org/0000-0002-4306-7024</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Sanghee Kim</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sanghee Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy, Seoul National University, Seoul 08826, Korea</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9bebfef5f5f0f2f6dbe8f5eeb5faf8b5f0e9"><span class="__cf_email__" data-cfemail="f383969d9d989a9eb3809d86dd9290dd9881">[emailÂ protected]</span></a>. Phone: +82-2-880-2487.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sanghee++Kim">Sanghee Kim</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9125-9541" title="Orcid link">http://orcid.org/0000-0001-9125-9541</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01965&amp;href=/doi/10.1021%2Facs.jmedchem.0c01965" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 5535â5550</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 26, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>13 November 2020</li><li><span class="item_label"><b>Published</b> online</span>27 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01965" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01965</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5535%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDonghwa%2BKim%252C%2BSang%2BWon%2BChoi%252C%2BJihee%2BCho%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.0c01965%26title%3DDiscovery%2Bof%2BNovel%2BSmall-Molecule%2BAntiangiogenesis%2BAgents%2Bto%2BTreat%2BDiabetic%2BRetinopathy%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5550%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01965"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">693</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01965" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Small-Molecule Antiangiogenesis Agents to Treat Diabetic Retinopathy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Donghwa&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Sang&quot;,&quot;last_name&quot;:&quot;Won Choi&quot;},{&quot;first_name&quot;:&quot;Jihee&quot;,&quot;last_name&quot;:&quot;Cho&quot;},{&quot;first_name&quot;:&quot;Jae-Hui&quot;,&quot;last_name&quot;:&quot;Been&quot;},{&quot;first_name&quot;:&quot;Kyoungsun&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Wenzhe&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Jaeho&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Jedo&quot;,&quot;last_name&quot;:&quot;Oh&quot;},{&quot;first_name&quot;:&quot;Changmin&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Soongyu&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Songyi&quot;,&quot;last_name&quot;:&quot;Seo&quot;},{&quot;first_name&quot;:&quot;Koung&quot;,&quot;last_name&quot;:&quot;Li Kim&quot;},{&quot;first_name&quot;:&quot;Wonhee&quot;,&quot;last_name&quot;:&quot;Suh&quot;},{&quot;first_name&quot;:&quot;Sang&quot;,&quot;last_name&quot;:&quot;Kook Lee&quot;},{&quot;first_name&quot;:&quot;Sanghee&quot;,&quot;last_name&quot;:&quot;Kim&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;5535-5550&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01965&quot;},&quot;abstract&quot;:&quot;Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to develop a novel type of antiangiogenesis agent that possesses minimized cytotoxicity. To overcome its poor pharmaceutical properties, we further modified the structure. A new scaffold was derived in which the stereogenic carbon was changed to nitrogen and the 1,2,3-triazole ring was replaced by an alkyl chain. By comparing the bioactivity versus cytotoxicity, compound 31 was selected, which has improved aqueous solubility and an enhanced selectivity index. Mechanistically, 31 suppressed angiopoietin-2 (ANGPT2) expression induced by high glucose in retinal cells and exhibited in vivo antiangiogenic activity in choroidal neovascularization and oxygen-induced retinopathy mouse models. These results suggest the potential of 31 as a lead to develop antiangiogenic small-molecule drugs to treat diabetic retinopathy and as &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01965&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01965" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01965&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01965" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01965&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01965" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01965&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01965&amp;href=/doi/10.1021/acs.jmedchem.0c01965" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01965" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01965" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01965%26sid%3Dliteratum%253Aachs%26pmid%3D33902285%26genre%3Darticle%26aulast%3DKim%26date%3D2021%26atitle%3DDiscovery%2Bof%2BNovel%2BSmall-Molecule%2BAntiangiogenesis%2BAgents%2Bto%2BTreat%2BDiabetic%2BRetinopathy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D5535%26epage%3D5550%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292201" title="Scaffolds">Scaffolds</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis. Using the structure of wondonin marine natural products, we previously created a scaffold to develop a novel type of antiangiogenesis agent that possesses minimized cytotoxicity. To overcome its poor pharmaceutical properties, we further modified the structure. A new scaffold was derived in which the stereogenic carbon was changed to nitrogen and the 1,2,3-triazole ring was replaced by an alkyl chain. By comparing the bioactivity versus cytotoxicity, compound <b>31</b> was selected, which has improved aqueous solubility and an enhanced selectivity index. Mechanistically, <b>31</b> suppressed angiopoietin-2 (ANGPT2) expression induced by high glucose in retinal cells and exhibited <i>in vivo</i> antiangiogenic activity in choroidal neovascularization and oxygen-induced retinopathy mouse models. These results suggest the potential of <b>31</b> as a lead to develop antiangiogenic small-molecule drugs to treat diabetic retinopathy and as a chemical tool to elucidate new mechanisms of angiogenesis.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Angiogenesis is the formation of new blood vessels from existing blood vessels, and it plays an important role in embryonic development, wound healing, and the reproductive cycles of women.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> However, uncontrolled angiogenesis increases the risk of various diseases, such as cancer, retinopathy, myocardial infarction, and cerebral infarction.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Angiogenesis is finely regulated by various factors such as vascular endothelial growth factor (VEGF), angiopoietin (ANGPT), matrix metalloproteinases (MMPs), platelet-derived growth factor (PDGF), tissue inhibitors of metalloproteinases (TIMPs), interferon-alpha/beta/gamma, plasminogen activators, and cyclooxygenase-2 (COX-2).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Patient data also suggest that the expression of angiopoietin-2 (ANGPT2) is higher in eyes with retinal detachment than eyes with completely attached retina, and the levels of ANGPT2 are associated with upregulated expressions of matrix metalloproteinase-9 (MMP-9), VEGF, and transforming growth factor beta 1 (TGFÎ²1).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Diabetic retinopathy is a microvascular complication of diabetes and a leading cause of blindness.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> High blood sugar levels in diabetic patients can damage blood vessels causing them to swell, leak, and grow quickly, which contributes to the excessive neovascularization and progression of diabetic retinopathy.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Almost all patients with type 1 diabetes and more than 60% of patients with type 2 diabetes develop retinopathy over time.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Diabetic retinopathy is often treated with surgery, laser therapy, and intravitreous injections of steroids or anti-VEGF biologic drugs such as ranibizumab, bevacizumab, and aflibercept.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Anti-VEGFs decrease the severity of the disease and vision, but multiple adverse effects are reported, such as infections from intravitreal injections, inflammation, retinal detachment, and cerebrovascular disease.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Therefore, the findings of antiangiogenic small molecules might help overcome the drawbacks of biologic drugs. Currently, no U.S. Food and Drug Administration (FDA)-approved small-molecule drugs are available to treat diabetic retinopathy.</div><div class="NLM_p">Wondonins (<b>1</b> and <b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) are marine natural products possessing novel antiangiogenic properties without overt cytotoxicity. We conceived that these biological properties may have a benefit to develop novel antiangiogenic agents with reduced side effects. In our previous work, we modified the structure of wondonins using a medicinal chemical rationale to overcome their physicochemical drawbacks.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Our efforts led to the discovery of compound <b>3</b> with more potent antiangiogenic activity and without overt cytotoxicity to human umbilical vein endothelial cells (HUVECs). Compound <b>3</b> is more stable and easily synthesized than the parent natural-product wondonins. However, compound <b>3</b> still has a chiral center in its structure, yielding enantiomers. We attempted to obtain <b>3</b> in the enantiomerically pure form to investigate the pharmacological difference between the two enantiomers. The enantioselective synthesis of two enantiomers of <b>3</b> was not easily accessible by conventional methods. Additionally, the chiral center is prone to epimerization, presumably because it is located adjacent to three aromatic rings.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of wondonins and schematic representation of the structural design of the new wondonin analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the present study, we further modified the structure of wondonins and compound <b>3</b> to create more drug-like scaffolds without an epimerizable chiral center. Our efforts resulted in the discovery of new drug-like small compounds that exhibited similar antiangiogenic activity to <b>3</b> and sunitinib without notable cytotoxicity. This new type of compound has reduced scaffold complexity and is easily accessible in short synthetic pathways. The molecular mechanisms were also investigated in HUVECs and ocular cells, such as human retinal microvascular endothelial cells (HRMECs) and adult retinal pigment epithelial cell line-19 (ARPE-19) cells, and the <i>in vivo</i> efficacy was examined in oxygen-induced retinopathy (OIR) and choroidal neovascularization (CNV) mouse models. Herein, we present our work on a successful scaffold jump of wondonins.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and SAR Study</h3><div class="NLM_p">The biological properties of the synthetic wondonin derivatives were assessed by measuring their effects on VEGF-induced tube formation and cytotoxicity in HUVECs. In our previous study, each image of tube formation was quantified by counting the number of branches. To obtain more accurate data, we modified the method to calculate the total segment lengths per image, as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. We aimed to identify noncytotoxic antiangiogenic compounds. Therefore, each compound was compared using the selectivity index, which is the ratio of the IC<sub>50</sub> for tube formation to the IC<sub>50</sub> for cytotoxicity in HUVECs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>â<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Figures S1âS4</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. VEGF-Induced Tube Formation and Cell Viability in HUVECs According to Amino Group Modifications of Scaffold <b>I</b> (<b>4â7</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0013.gif" alt="" id="GRAPHIC-d7e418-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0014.gif" alt="" id="gr" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> data are expressed as the means of duplicate experiments.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Selectivity index was calculated as the ratio of the IC<sub>50</sub> values of cell viability and tube formation.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">The structure of <b>3</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. VEGF-Induced Tube Formation and Cell Viability of Scaffold <b>II-A</b> (<b>8â11</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0015.gif" alt="" id="GRAPHIC-d7e461-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd</th><th class="colsep0 rowsep0" align="center" char=".">tube formation</th><th class="colsep0 rowsep0" align="center">cell viability</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b>, <i>n</i>Â =Â 1</td><td class="colsep0 rowsep0" align="char" char=".">9.04</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">11.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b>, <i>n</i>Â =Â 2</td><td class="colsep0 rowsep0" align="char" char=".">2.31</td><td class="colsep0 rowsep0" align="left">49.95</td><td class="colsep0 rowsep0" align="char" char=".">21.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b>, <i>n</i>Â =Â 3</td><td class="colsep0 rowsep0" align="char" char=".">3.28</td><td class="colsep0 rowsep0" align="left">55.06</td><td class="colsep0 rowsep0" align="char" char=".">16.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b>, <i>n</i>Â =Â 4</td><td class="colsep0 rowsep0" align="char" char=".">3.47</td><td class="colsep0 rowsep0" align="left">38.19</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> data are expressed as the means of duplicate experiments.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Selectivity index was calculated as the ratio of the IC<sub>50</sub> values of cell viability and tube formation.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. VEGF-Induced Tube Formation and Cell Viability in HUVECs According to the Phenyl Moiety Modification of the Piperidine-Introduced Scaffold <b>II</b> (<b>12â14</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0016.gif" alt="" id="GRAPHIC-d7e578-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">AÂ moiety</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center" char=".">tube formation</th><th class="colsep0 rowsep0" align="center" char=".">cell viability</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="center">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="char" char=".">5.17</td><td class="colsep0 rowsep0" align="char" char=".">17.34</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">F</td><td class="colsep0 rowsep0" align="center">F</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="char" char=".">10.60</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">H</td><td class="colsep0 rowsep0" align="center">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char=".">8.50</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> data are expressed as the mean of duplicate experiments.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Selectivity index was calculated as the ratio of the IC<sub>50</sub> values of cell viability and tube formation.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. VEGF-Induced Tube Formation and Cell Viability in HUVECs According to Changes in the Amino Group and Alkylchain Length of Scaffold <b>II</b> (<b>15â34</b>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0017.gif" alt="" id="GRAPHIC-d7e694-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0018.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The IC<sub>50</sub> data are expressed as the means of duplicate experiments.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Selectivity index was calculated as the ratio of the IC<sub>50</sub> values of cell viability and tube formation.</p></div></div><div></div></div><div class="NLM_p">As an initial and major structural modification of <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), the stereogenic carbon atom was replaced by a nitrogen atom. The 1,2,3-triazole and aliphatic amine moieties were maintained, although their bond connectivity was altered. Such structural modification resulted in scaffold <b>I</b>. The first compound with this scaffold was <b>4</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) with a piperidine ring, showing notable inhibitory activity against tube formation in VEGF-induced HUVECs. However, <b>4</b> exhibited a lower selectivity index than its parent compound <b>3</b>.</div><div class="NLM_p">Because we previously showed that the inhibitory effects on both tube formation and cytotoxicity were sensitive to amino group modifications, several amino groups other than piperidine were screened to further evaluate the possibility of using <b>I</b> as a new scaffold of novel antiangiogenesis agents. Compound <b>5</b> with a cyclopentylamino group showed an approximately twofold increase in tube formation inhibition and a threefold decrease in cytotoxicity compared with <b>4</b>. The propyl amine analogue <b>6</b> displayed a similar activity profile to <b>4</b>. Notably, compound <b>7</b>, with a pyrrolidine moiety, was three times more potent than the piperidine analogue <b>4</b> and three times less cytotoxic against HUVECs, exhibiting a selectivity index of 19 similar to that of <b>3</b>. These results indicate that eliminating the stereocenter by replacing the carbon atom with the nitrogen atom in the structure of <b>3</b> is viable.</div><div class="NLM_p">The next structural change was performed on the 1,2,3-triazole moiety in <b>I</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The 1,2,3-triazole group is one of the important connecting units in medicinal chemistry due to its several attractive features, such as large dipole moments and stability to metabolic degradation. However, a profound disadvantage of the 1,2,3-triazole compounds is their low aqueous solubility.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Parent compound <b>3</b> exhibited low aqueous solubility (0.024 mM, as measured by the CheqSol method at 25 Â°C).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Thus, the 1,2,3-triazole moiety was removed and replaced with another functional group. Many types of nonclassical bioisosteres of 1,2,3-triazole are known including amide, isoxazole, and pyrazole. However, we selected a simple alkyl group because it is flexible and not significantly electronically biased. Although alkyl might not be an optimal substituent, this replacement might provide a basis for further optimization. This structural modification resulted in scaffold <b>II</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><div class="NLM_p">The first series of analogues with scaffold <b>II</b> was <b>II-A</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), comprising compounds <b>8</b>â<b>11</b> with piperidine rings and alkyl chain lengths of 2â5 carbon atoms between the two nitrogen atoms. They showed comparable or improved potency in tube formation inhibition compared with that of the parent triazole <b>4</b> with a piperidine ring. Furthermore, they were less cytotoxic to the cells. These results suggest that scaffold <b>II</b> is a good platform for further optimization.</div><div class="NLM_p">In a previous study,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> the modification of the dimethoxyphenyl moiety was not investigated due to its lengthy synthesis. The simplified new structure allowed the rapid synthesis and evaluation of the structureâactivity relationship (SAR) around the dimethoxyphenyl moiety (marked as âAâ in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Several analogues with the generic structure <b>II-B</b> were prepared (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The alkyl chain length of three carbon atoms was adopted because of the higher potency of <b>9</b> than other analogues (<b>8</b>, <b>10</b>, and <b>11</b>) with different chain lengths. Removing one methoxy group at the para position yielded analogue <b>12</b>, which was found to exhibit a twofold decrease in potency in the inhibition of tube formation. Replacing the two methoxy groups of <b>9</b> with two fluoride atoms produced analogue <b>13</b> with similar potency. Analogue <b>14</b>, with a strong electron-withdrawing trifluoromethyl group, was approximately twofold more active than <b>9</b>. However, the replacement of the dimethoxy group resulted in substantially increased cytotoxicity to HUVECs. Analogues with various substituents were also synthesized, but they were not advantageous regarding cytotoxicity (data not shown). With the valuable SAR insights obtained from these studies, we advanced to evaluating the amino moiety to identify other opportunities to improve the potency without increasing the cytotoxicity.</div><div class="NLM_p">Encouraged by the biological results of the generic structure <b>II-A</b>, we systematically investigated the influence of the nature and position of the amino moiety (depicted as âBâ in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) on the activity. Additionally, five different amino groups were selected, and a length of 2â5 carbon atoms was adopted. Twenty analogues with the generic structure <b>II-C</b> were synthesized in a combinatorial manner. Their activity profiles are shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</div><div class="NLM_p">No clear relationship could be drawn between the alkyl chain length and activities. However, in general, the increase in chain length resulted in decreased activity against tube formation inhibition. As the chain length increased, the effect on cytotoxicity was increased. These results indicate that these two effects are not correlated. Again, no clear relationship could be drawn between the types of amino groups and activities. Among the tested amino groups, piperidine resulted in a higher level of cytotoxicity and inhibitory potency against tube formation (<b>8â11</b> vs <b>15â22</b>). The diethyl amino group-containing compounds (<b>23â26</b>) exhibited the least cytotoxicity.</div><div class="NLM_p last">Within the series of straight-chain analogues, the most potent molecule to inhibit tube formation was compound <b>29</b> with a cyclohexylamino group. However, based on the selectivity index, the cyclopentylamine analogue <b>31</b> had more desired biological properties than the other analogues. In contrast to <b>29</b>, analogue <b>31</b> did not exhibit notable cytotoxicity against HUVECs, showing the highest selectivity index, with potent inhibitory activity (IC<sub>50</sub> = 2.95 Î¼M) in the tube formation assay.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Chemistry</h3><div class="NLM_p">The synthetic route is outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>â<named-content content-type="anchor" rid="sch2" type="simple"></named-content><named-content content-type="anchor" rid="sch3" type="simple"></named-content><a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Compound <b>35</b> was a fundamental intermediate required for the synthesis of most of the analogues. The synthesis of <b>35</b> and its relatives <b>36</b>â<b>38</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Copper-mediated ChanâLam coupling of aminothiazole <b>39</b><a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> with commercially available phenylboronic acids (<b>40</b>â<b>43</b>) provided <b>35</b>â<b>38</b> in modest to good yield.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Phenylaminothiazolines <b>35â38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: Cu(OAc)<sub>2</sub>, 2,2â²-bipyridine, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 70 Â°C, 14 h, 45â62%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1,2,3-Triazole Analogues <b>4â7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, propargyl bromide, DMF, 0 Â°C to rt, 16 h, 92%; (b) CuSO<sub>4</sub>Â·5H<sub>2</sub>O, sodium ascorbate, EtOH/<i>t</i>-BuOH/H<sub>2</sub>O, 60 Â°C, 20 min, 87%; (c) CBr<sub>4</sub>, PPh<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 88%; and (d) different amines, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN (1:1), 50 Â°C, 16â19 h, 63â95%.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Straight-Chain Alkyl Analogues <b>8â11</b> and <b>15â34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 50 Â°C, 13 h, 53â79% and (b) different amines, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN (1:1), 50 Â°C, 12â18 h, 37â98%.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Straight-Chain Alkyl Analogues <b>12â14</b> with Modification on the Phenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) 1,3-dibromo-propane, NaH, DMF, 50 Â°C, 14 h, 54â70% and (b) piperidine, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN, 50 Â°C, 14â16 h, 42â56%.</p></p></figure><div class="NLM_p">The synthesis of 1,2,3-triazole analogues (<b>4</b>â<b>7</b>) started with the alkylation of <b>35</b> with propargyl bromide to produce <b>44</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). 1,3-Dipolar cycloaddition of alkyne <b>44</b> and azide <b>45</b><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> in the presence of a catalytic amount of Cu salt produced 1,2,3-triazole intermediate <b>46</b>, which was converted to bromide <b>47</b> via an Appel reaction. The resulting bromide <b>47</b> reacted with various amines to generate the corresponding amino-substituted 1,2,3-triazole analogues (<b>4</b>â<b>7</b>).</div><div class="NLM_p">Straight-chain analogues (<b>8</b>â<b>11</b> and <b>15</b>â<b>34</b>) were synthesized using <b>35</b> as the starting material (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The alkylation of <b>35</b> with dibromoalkanes <b>48</b> in the presence of NaH provided bromides <b>49</b>â<b>52</b>. The obtained <b>49</b>â<b>52</b> were converted into amino-substituted analogues (<b>8</b>â<b>11</b> and <b>15</b>â<b>34</b>) through nucleophilic substitution with various amines.</div><div class="NLM_p last">As shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>, the synthesis of analogues <b>12</b>â<b>14</b> with a modified phenyl moiety started with the alkylation of the corresponding aminothiazole <b>36</b>â<b>38</b> with 1,3-dibromo-propane to produce <b>53</b>â<b>55</b>. The resulting bromides <b>53</b>â<b>55</b> were treated with piperidine and K<sub>2</sub>CO<sub>3</sub> to produce the corresponding piperidine-substituted analogues <b>12</b>â<b>14</b>, respectively.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preliminary Pharmaceutical Properties of Compound <b>31</b></h3><div class="NLM_p">To assess the basic pharmaceutical properties of <b>31</b>, the aqueous solubility, plasma stability, and metabolic stability were examined (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compared with its parent compound <b>3</b>, a notable property of <b>31</b> is its higher aqueous solubility, probably due to removing the 1,2,3-triazole moiety. The aqueous solubility of <b>31</b> increased approximately 10 times (0.21 mM, as measured by the CheqSol method at 25 Â°C). Compound <b>31</b> showed excellent plasma stability with >99% remaining after 30 min incubation with human plasma. In the metabolic stability study using human liver microsomes, good microsomal stability was also observed.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Preliminary ADME Study of <b>31</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub></th><th class="colsep0 rowsep0" align="center">solub (mM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">plasma stability (%)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">microsomal stability (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b><a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">9.24</td><td class="colsep0 rowsep0" align="center">0.024</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="center">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="center">11.9</td><td class="colsep0 rowsep0" align="center">0.21</td><td class="colsep0 rowsep0" align="center">107.1Â Â±Â 1.8Â (2)</td><td class="colsep0 rowsep0" align="center">52.2Â Â±Â 2.3Â (2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Measured by the CheqSol method at 25 Â°C.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Percentage of the compound remaining after 30 min in human plasma. The number of replicates is in parentheses.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Percentage of the compound remaining after 120 min in human liver. The number of replicates is in parentheses.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">The data were taken from ref <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> for comparison.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Evaluation of Antiangiogenic Activity and Cytotoxicity of <b>31</b></h3><div class="NLM_p">The tube formation activity and cell viability of <b>31</b> were compared with those of sunitinib. The calculated IC<sub>50</sub> values for VEGF-induced tube formation were 2.95 Â± 0.59 for <b>31</b> and 2.54 Â± 0.6 for sunitinib in HUVEC cells. Under the same experimental conditions, the two compounds showed similar inhibitory activity against tube formation induced by VEGF (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), while <b>31</b> exhibited much lower cytotoxicity against HUVECs and HRMECs (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Figure S5</a>). The calculated selectivity index values for <b>31</b> and sunitinib were 33.9 and 3.9, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Although sunitinib is a potent vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, its inhibitory effects against tube formation were largely due to cytotoxicity.</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) VEGF-induced tube formation on Matrigel in HUVECs. (B) Chemical structures of <b>31</b> and sunitinib and their effects on VEGF-induced tube formation and cell viability in HUVECs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Compound <b>31</b> Inhibits <i>p</i>-VEGFR2 Expression and Cell Migration in HUVECs</h3><div class="NLM_p">Our structural modification provided meaningful insights into the SAR of this class of compounds and complexity-reduced, drug-like scaffold with antiangiogenic activity without apparent cytotoxicity against HUVECs. Further biological studies were performed with compound <b>31</b> to understand the precise molecular mechanism of action and evaluate the antiangiogenic activity in <i>in vivo</i> animal models. VEGF binds to VEGFR2 and activates the downstream signaling pathway, which plays a major role in angiogenesis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Therefore, the effect of <b>31</b> on <i>p</i>-VEGFR2 expression was evaluated using Western blot analysis in HUVECs. VEGF (50 ng/mL) induced the expression of <i>p</i>-VEGFR2, and <b>31</b> effectively suppressed the phosphorylation of VEGFR2 in a concentration-dependent manner without impacting VEGFR2 expression (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Compound <b>31</b> showed mild inhibitory activity in direct VEGFR-2 kinase assay, indicating the existence of alternative molecular mechanism regulated by <b>31</b> independent of VEGFR2 kinase activity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Figure S6</a>). Additionally, KINOMEscan kinase-small molecule binding assay was performed against 468 kinases, and no significant inhibition of kinase activity was observed (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Table S1</a>). The effect of <b>31</b> on cell migration, which is a fundamental process in angiogenesis,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> was assessed using scratch migration assay. <b>31</b> inhibited cell migration without affecting cell viability and morphology (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) After cells reached 90% confluency, HUVECs were starved overnight, and the medium was changed to endothelial basal medium (EBM) containing 2% fetal bovine serum (FBS). <b>31</b> was pretreated for 30 min, followed by VEGF (50 ng/mL) treatment for 30 min. Western bands were quantified using ImageJ, and then, we calculated the relative intensity. The data are presented as the mean fold changes Â± SD of two independent experiments. (B) Scratches were induced in HUVECs, and the medium was changed to EBM containing 2% FBS. Dimethyl sulfoxide (DMSO) or indicated concentrations of <b>31</b> were treated for 18 h, and the cells were photographed using microscopy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Compound <b>31</b> Suppresses ANGPT2 Expression Induced by <span class="smallcaps smallerCapital">d</span>-Glucose</h3><div class="NLM_p">ANGPT2 is a ligand of the tunica interna endothelial cell kinase 2 (TIE2) receptor, which is involved in vascular remodeling, pericyte dropout, and neovascularization.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17â19)</a> Patient data suggest that the expression of ANGPT2 is higher in eyes with retinal detachment than in those with a completely attached retina, and the levels of ANGPT2 are associated with upregulated expression of MMP-9, VEGF, and TGFÎ²1.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Cells were incubated with high glucose to mimic diabetic conditions. We found that high glucose (30 mM) treatment for 48 h induced ANGPT2 expression in both HRMECs and ARPE19 cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Treatment with <b>31</b> significantly suppressed the ANGPT2 gene expression induced by high glucose (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Additionally, <b>31</b> suppressed the protein expression of ANGPT2 in a concentration-dependent manner in both HRMECs and ARPE-19 cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Crosstalk occurs between ANGPT2 and VEGF, synergistically increasing vascular permeability in diabetic macular edema (DME).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Currently, anti-ANGPT2 monoclonal antibodies are under investigation to treat wet age-related macular degeneration (AMD), DME, and cancer.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21â23)</a> Although small-molecule Tie-2 kinase inhibitors are available to regulate ANGPT2/Tie2 signaling, their efficacy has only been examined for cancer treatment.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Recent clinical data suggest that patients with DME treated with bispecific antibodies targeting both ANGPT2 and VEGF-A show better outcomes than DME patients treated with ranibizumab, an antibody targeting VEGF-A.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>31</b> is a potent inhibitor of VEGF-stimulated <i>p</i>-VEGFR2 expression and high glucose-induced ANGPT2 expression, which are highly associated with the angiogenesis of retinopathic processes. These data suggest that <b>31</b> has the potential to have superior efficacy over drugs with a single target.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>31</b> on ANGPT2 expression induced by high glucose in HRMECs and ARPE-19 cells. (A) HRMECs and ARPE-19 cells were stimulated with <span class="smallcaps smallerCapital">d</span>-glucose for 48 h. The level of ANGPT2 gene expression was analyzed by real-time PCR. The cells were pretreated with <b>31</b> for 30 min and further incubated with <span class="smallcaps smallerCapital">d</span>-glucose (30 mM) for 48 h. The expression levels of ANGPT2 gene and protein were analyzed by (B) real-time PCR and (C) Western blotting analysis, respectively. Western bands were quantified using ImageJ and presented as the mean fold changes Â± SD of two independent experiments. Real-time PCR data are presented as the mean fold changes Â± SD of three independent experiments. (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.005).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Compound <b>31</b> Modulates the c-Abl/STAT5/PI3K Pathway</h3><div class="NLM_p">To investigate the molecular mechanism of <b>31</b>, protein interaction network analysis of ANGPT2 was performed using STRING v.11 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> STRING analysis provides information on both the physical and functional associations of different proteins. The protein network analysis suggests that ANGPT2 is associated with TEK Receptor tyrosine kinase (TEK/Tie-2), signal transducer and activator of transcription 5A (STAT5A), STAT5B, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1), tyrosine-protein kinase Fes/Fps (FES), kinase insert domain receptor (KDR/VEGFR2), tyrosine-protein kinase Fyn (FYN), vascular endothelial growth factor A (VEGFA), and mitogen-activated protein kinase 14 (MAPK14). In particular, STAT5 promotes angiogenesis, and its expression is increased in the retina of diabetic rats compared with that in normal rats.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28â30)</a> Phosphatidylinositol 3-kinase (PI3K) regulates various proangiogenic factors and is involved in the migration activity of endothelial cells.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> High glucose induced c-Abl, phosphorylation of STAT5, and PI3K in HRMEC cells but not in ARPE19 cells, which suggests that two cell lines may have different sensitivities to glucose. Treatment with <b>31</b> suppressed p-STAT5 and p-PI3K expression in a concentration-dependent manner without suppressing total expressions of STAT5 and PI3K (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). In addition, abelson tyrosine kinase (c-Abl), which regulates STAT5<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and PI3K,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was also downregulated by <b>31</b>. Increased levels of cytokines and proinflammatory biomarkers are positively correlated with the progression of angiogenesis in diabetic retinopathy patients.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35â37)</a> Treatment with <b>31</b> inhibited proinflammatory biomarkers induced by high glucose, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NFÎºB) p50, NFÎºB p65, and interleukin 1 beta (IL-1Î²) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). These data suggest that the molecular mechanism of <b>31</b> is associated, in part, with the suppression of the c-Abl/STAT5/PI3K signaling pathway.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Protein interaction network analysis associated with ANGPT2 was performed using STRING v.11. (B) Cells were pretreated with <b>31</b> for 30 min and incubated with the indicated concentration of <span class="smallcaps smallerCapital">d</span>-glucose for 48 h. The effects of <b>31</b> on ANGPT2-linked biomarker expression were evaluated by Western blot analysis in <span class="smallcaps smallerCapital">d</span>-glucose-stimulated HRMECs and ARPE-19 cells. Western bands were quantified using ImageJ and presented as the mean fold changes Â± SD of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Intravitreal Injection of Compound <b>31</b> Ameliorates Pathological Retinal Neovascularization in the OIR Mouse Model</h3><div class="NLM_p">VEGF and its receptors exert key roles in pathological neovascularization in various diseases. In retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR), VEGF and its receptors have been recognized as main disease targets in that enhanced VEGF signaling induces the excessive growth of a leaky retinal vasculature, leading to vision impairment and loss. Thus, we determined the effect of <b>31</b> on pathological neovascularization in the retina using an OIR model, a common animal model of ROP and PDR. Newborn mice were exposed to 75% oxygen from P7 to P12. At P12, they were returned to a room with normal air and received intravitreal administration of <b>31</b> and DMSO (control vehicle). At P17, the extent of neovascularization was assessed by quantifying the formation of neovascular tufts, reflecting pathological retinal neovascularization (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). Although DMSO-injected eyes displayed pronounced tuft formation in the retina, the eyes of <b>31</b>-injected mice exhibited a significant decrease in retinal neovascularization. These results indicate that <b>31</b> efficiently blocks VEGF-induced pathological retinal neovascularization in mice with OIR.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Schematic diagram of OIR experiments. At P12, mice received a single intravitreal injection of <b>31</b> (3 Î¼g in 1 Î¼L DMSO) or DMSO (1 Î¼L). Five days later (P17), the eyes were harvested for further analysis. (B) Representative images of whole-mounted retinas of mice with OIR at P17. The retinal vasculature was visualized by staining with isolectin B4 (IB4; black). High-magnification views of the boxed areas are shown at the bottom. Scale bars = 100 Î¼m. (C) Retinal neovascularization and vaso-obliteration in mice with OIR were quantified as a percentage of the number of pixels in the neovascular tuft and avascular regions of retinas with intravitreal injections compared to those of uninjected contralateral controls, respectively. Data are presented as the mean Â± SEM (***<i>P</i> < 0.001, ns = not significant, <i>n</i> > 6 mice per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Compound <b>31</b> Ameliorates Pathologic Neovascularization in the CNV Mouse Model</h3><div class="NLM_p">To evaluate the antiangiogenic efficacy of <b>31</b>, a mouse laser-induced CNV model was employed. The efficacy of <b>31</b> was determined by eye drop formulation. Fundus fluorescein angiography (FFA) was photographed 10 days after CNV induction. In the CNV lesion size observed on FFA, a statistically significant decrease was observed in the test group-administered 1% <b>31</b> compared with that in the vehicle group (<i>P</i> < 0.05). Additionally, the effects were similar to those of the test group-administered aflibercept (Eylea) (<i>P</i> < 0.05) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative FFA images and corrected total fluorescence (CTF) at 10 days after CNV induction. (A) The CTF of the wounded area was analyzed by ImageJ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 33); G2 (Eylea, IVT, <i>n</i> = 32); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 34). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle). (B) White arrows indicate CNV lesions. The volume of the lesions was measured using ImageJ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 33); G2 (Eylea, IVT, <i>n</i> = 32); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 34). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle). (C) Amplitude of each eye was analyzed using âLabScribeERG Softwareâ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 10); G2 (Eylea, IVT, <i>n</i> = 8); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 8). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle) (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ****<i>P</i> < 0.0001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The cross-sectional view of the retina was photographed using optical coherence tomography angiography (OCTA) 10 days after CNV induction. However, comparing the volume of the lesion on OCTA with that of the vehicle group, the lesion volume was significantly reduced in the test group-administered 1% <b>31</b> (<i>P</i> < 0.05). However, efficacy was not superior to that of the test group-administered aflibercept (Eylea) (<i>P</i> < 0.0001) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B). The scotopic retinal potential test (ERG) response was measured at a light intensity of 0.9 log cds/m<sup>2</sup> 11 days after CNV induction. The highest retinal potential was observed in the aflibercept (Eylea) administration group (<i>P</i> < 0.0001), and the 1% <b>31</b> administration group showed more significant increases than the vehicle administration group (<i>P</i> < 0.05) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C).</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">VEGF is a major proangiogenic mediator that plays an important role in the development of neovascularized pathogenic processes. Therefore, anti-VEGF biologics are currently used in the clinic to treat diabetic retinopathy to inhibit abnormal vessel growth caused by high glucose blood levels in the eye environment. However, current anti-VEGF biologic drugs have limitations, including the lack of long-lasting effects, frequent intravitreal injections, and the generation of side effects. Therefore, the development of novel, safe, and potent antiangiogenic small molecules may provide a crucial benefit to complement biologic therapy. Additionally, ANGPT2 is involved in neovascularization and ANGPT2 overexpression occurs in retinal pathogenic processes. In particular, high glucose potentially upregulates ANGPT2 expression and subsequently increases vascular permeability in the retina. ANGPT2 is also upregulated by VEGF, suggesting crosstalk between ANGPT2 and VEGF in the progression of diabetic retinopathy. In this study, we designed and synthesized structurally simplified wondonin analogues starting from previously developed <b>3</b> with an epimerizable chiral center. The initial structural modification of parent compound <b>3</b> was performed by eliminating the stereocenter by replacing the carbon atom with the nitrogen atom. The next structural change was the replacement of the triazole ring with the simple alkyl chain. This modification yielded a compound that had improved potency in tube formation inhibition and less cytotoxicity compared to the parent triazole compound. In general, the decrease in alkyl chain length resulted in increased potency and decreased cytotoxicity. No clear relationship was drawn between the types of pendant amino groups and activities. The modification of the dimethoxyphenyl moiety was not tolerated. Through SAR studies, we identified analogue <b>31</b>, which exhibits potent antiangiogenic activity with minimized cytotoxicity in HUVEC. The selectivity index value of <b>31</b> was higher than that of <b>3</b> or sunitinib, and the aqueous solubility of <b>31</b> was higher than that of <b>3</b>. Compound <b>31</b> effectively suppressed the activation of VEGF-induced VEGFR2 expression (<i>p</i>-VEGFR2) and high glucose-induced ANGPT2 expression. Further molecular mechanism studies revealed that ANGPT2 suppression by <b>31</b> is associated with the modulation of the c-Abl/STAT5/PI3K pathway in ocular cells. The <i>in vivo</i> antiangiogenic activity of <b>31</b> was also demonstrated in CNV and OIR mouse models. Our data collectively suggest that compound <b>31</b> is prioritized as a promising lead or candidate to develop small-molecule therapeutic agents to treat diabetic retinopathy.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div class="NLM_p last">The details of the synthesis procedures, including all the intermediates and analogues <b>4â34</b>, are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Supporting Information</a>. All the chemicals used were purchased in reagent grade from commercial suppliers, and all the reactions were executed under an inert atmosphere comprising dry nitrogen using distilled dry solvents. The reactions were monitored by thin-layer chromatography (TLC) performed on silica gel 60 F<sub>254</sub> TLC plates. The synthesized products were purified by flash column chromatography on silica gel 60 (40â63 Î¼m, 230â400 mesh, Merck). NMR spectra were recorded using a JNM-ECZ400S/L1 spectrometer (Jeol, Akishima, Tokyo, Japan). <sup>1</sup>H NMR (400 MHz) and <sup>13</sup>C NMR (100 MHz) spectra were obtained in Î´ units using residual CDCl<sub>3</sub> (<sup>1</sup>H NMR Î´ = 7.26 ppm and <sup>13</sup>C NMR Î´ = 77.16 ppm) and CD<sub>2</sub>Cl<sub>2</sub> (<sup>1</sup>H NMR Î´ = 5.32 ppm and <sup>13</sup>C NMR Î´ = 53.84 ppm) as the internal standards. IR spectra were obtained using an Agilent 5500a FTIR system (Agilent, USA). High-resolution mass spectroscopy (HRMS) spectra were obtained using fast atom bombardment (FAB) and electrospray ionization (ESI). The purity of all the final target compounds was confirmed to be at least >95% pure by analytical HPLC (Agilent 1200 Series; Agilent Technologies, Palo Alto, CA, USA). The purity of all the final target compounds, HPLC methods, and spectra are shown in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-((1-(2-(piperidin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>4</b>)</h3><div class="NLM_p">To a solution of <b>47</b> (100 mg, 0.20 mmol) in DMF/MeCN (1:1, 2 mL, 0.1 M) was added K<sub>2</sub>CO<sub>3</sub> (110 mg, 0.80 mmol) and piperidine (200 Î¼L, 1.99 mmol). The reaction mixture was stirred at 50 Â°C for 19 h and then diluted with H<sub>2</sub>O and extracted with ethyl acetate (EtOAc). The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude product was separated by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 30:1, <i>R</i><sub>f</sub> = 0.2) to produce the desired product <b>4</b> (96.0 mg, 95%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.96 (s, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.11â7.08 (m, 1H), 7.01 (d, <i>J</i> = 2.0 Hz, 1H), 6.96â6.93 (m, 1H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.74â6.73 (m, 1H), 4.74 (s, 2H), 4.46 (t, <i>J</i> = 6.2 Hz, 2H), 3.92 (s, 3H), 3.86 (s, 3H), 2.75 (t, <i>J</i> = 6.2 Hz, 2H), 2.50â2.41 (m, 6H), 1.60â1.54 (m, 4H), 1.45â1.40 (m, 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.5, 141.6, 136.4, 134.9, 128.7, 127.6, 126.7, 126.6, 124.1, 122.4, 117.2, 115.5, 112.0, 58.3, 56.3, 56.1, 54.7 (2C), 49.5, 48.1, 28.6, 26.1 (2C), 24.3, 15.4; IR (neat) Ï<sub>max</sub>: 2933, 2214, 1584, 1503, 1440, 1253, 1230, 1135, 1022, 807, 762 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 507.2542; found, 507.2539.</div><div class="NLM_p last">All <b>5</b>â<b>7</b> compounds were synthesized using a similar procedure to that for compound <b>4</b>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-((1-(2-(Cyclopentylamino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)-<i>N</i>-(3,4-dimethoxyphenyl)-6-ethylbenzo[<i>d</i>]thiazol-2-amine (<b>5</b>)</h3><div class="NLM_p last">(90.0 mg, 89%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.86 (s, 1H), 7.16 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.06 (m, 1H), 6.99 (d, <i>J</i> = 2.1 Hz, 1H), 6.95â6.92 (m, 1H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.73â6.72 (m, 1H), 4.72 (s, 2H), 4.45 (t, <i>J</i> = 5.9 Hz, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.09â3.03 (m, 3H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 1.81â1.75 (m, 2H), 1.66â1.58 (m, 2H), 1.52â1.46 (m, 3H), 1.29â1.21 (m, 2H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.5, 141.6, 136.3, 134.8, 128.7, 127.6, 126.62, 126.56, 124.0, 122.3, 117.1, 115.3, 112.0, 59.6, 56.2, 56.1, 51.1, 49.3, 47.8, 33.2 (2C), 28.5, 24.0 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 2954, 2852, 2214, 1584, 1503, 1398, 1253, 1230, 1022, 762 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 507.2542; found, 507.2552.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-((1-(2-(propylamino)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>6</b>)</h3><div class="NLM_p last">(70.0 mg, 73%, white solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.86 (s, 1H), 7.16 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.99 (d, <i>J</i> = 2.0 Hz, 1H), 6.94 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 6.88 (d, <i>J</i> = 8.4 Hz, 1H), 6.72â6.71 (m, 1H), 4.72 (s, 2H), 4.45 (t, <i>J</i> = 5.9 Hz, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.09 (t, <i>J</i> = 5.9 Hz, 2H), 2.56 (t, <i>J</i> = 7.2 Hz, 2H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 1.49â1.40 (m, 3H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H), 0.87 (t, <i>J</i> = 7.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.5, 141.6, 136.3, 134.8, 128.6, 127.6, 126.63, 126.55, 124.0, 122.3, 117.1, 115.3, 112.0, 56.2, 56.1, 51.4, 50.7, 49.3, 49.0, 28.5, 23.2, 15.4, 11.8; IR (neat) Ï<sub>max</sub>: 2927, 2214, 1584, 1503, 1440, 1253, 1230, 1138, 1022, 763 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>33</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 481.2380; found, 481.2387.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-((1-(2-(pyrrolidin-1-yl)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)benzo[<i>d</i>]thiazol-2-amine (<b>7</b>)</h3><div class="NLM_p last">(62.0 mg, 63%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.89 (s, 1H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.10â7.07 (m, 1H), 7.00 (d, <i>J</i> = 2.0 Hz, 1H), 6.95â6.93 (m, 1H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.73â6.72 (m, 1H), 4.73 (s, 2H), 4.49 (t, <i>J</i> = 6.4 Hz, 2H), 3.91 (s, 3H), 3.85 (s, 3H), 2.95 (t, <i>J</i> = 6.4 Hz, 2H), 2.56â2.52 (m, 4H), 2.47 (q, <i>J</i> = 7.6 Hz, 2H), 1.81â1.74 (m, 4H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.5, 141.7, 136.3, 134.8, 128.7, 127.6, 126.7, 126.6, 123.9, 122.4, 117.1, 115.5, 112.0, 56.2, 56.1, 55.5, 54.2 (2C), 49.7, 49.4, 28.5, 23.7 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 2962, 2798, 2214, 1584, 1503, 1398, 1253, 1230, 1137, 1022, 763 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>26</sub>H<sub>33</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 493.2386; found, 493.2382.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(2-(piperidin-1-yl)ethyl)benzo[<i>d</i>]thiazol-2-amine (<b>8</b>)</h3><div class="NLM_p">To a solution of <b>49</b> (150 mg, 0.36 mmol) in DMF/MeCN (1:1, 3.56 mL, 0.1 M) was added K<sub>2</sub>CO<sub>3</sub> (197 mg, 1.42 mmol) and piperidine (352 Î¼L, 3.56 mmol). The reaction mixture was stirred at 50 Â°C for 13 h and then diluted with H<sub>2</sub>O and extracted with EtOAc. The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude product was separated by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 20:1, <i>R</i><sub>f</sub> = 0.2) to produce the desired product <b>8</b> (90.0 mg, 59%, white solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.07 (m, 1H), 7.00â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.71â6.72 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.55 (t, <i>J</i> = 6.8 Hz, 2H), 2.61 (t, <i>J</i> = 6.8 Hz, 2H), 2.51â2.41 (m, 6H), 1.60â1.54 (m, 4H), 1.45â1.41 (m, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.1, 136.4, 135.2, 128.4, 127.6, 127.1, 126.3, 122.5, 117.2, 116.0, 112.0, 56.24, 56.21, 56.1, 54.7 (2C), 51.0, 28.5, 26.0 (2C), 24.4, 15.5; IR (neat) Ï<sub>max</sub>: 2934, 2214, 1584, 1503, 1398, 1253, 1231, 1135, 1023, 762 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 426.2210; found, 426.2204.</div><div class="NLM_p last">All <b>9</b>â<b>11</b> and <b>15</b>â<b>34</b> compounds were synthesized using a similar procedure to that for compound <b>8</b>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(3-(piperidin-1-yl)propyl)benzo[<i>d</i>]thiazol-2-amine (<b>9</b>)</h3><div class="NLM_p last">(102 mg, 68%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.23 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.00â6.97 (m, 2H), 6.90 (d, <i>J</i> = 8.4 Hz, 1H), 6.71â6.70 (m, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.49 (t, <i>J</i> = 7.3 Hz, 2H), 2.50â2.39 (m, 8H), 2.00â1.92 (m, 2H), 1.60â1.54 (m, 4H), 1.45â1.42 (m, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.2, 136.6, 135.2, 128.5, 127.7, 126.4 (2C), 122.4, 117.2, 115.8, 112.0, 56.2, 56.1, 55.8, 54.6 (2C), 52.4, 28.6, 26.0 (2C), 25.3, 24.5, 15.5; IR (neat) Ï<sub>max</sub>: 2933, 2213, 1584, 1503, 1400, 1252, 1230, 1136, 1023, 851, 762 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 440.2366; found, 440.2370.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(4-(piperidin-1-yl)butyl)benzo[<i>d</i>]thiazol-2-amine (<b>10</b>)</h3><div class="NLM_p last">(87.0 mg, 66%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.98â6.95 (m, 2H), 6.88 (d, <i>J</i> = 8.4 Hz, 1H), 6.69â6.68 (m, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.43 (t, <i>J</i> = 7.1 Hz, 2H), 2.49â2.39 (m, 8H), 1.81â1.60 (m, 8H), 1.46â1.43 (m, 2H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.5, 135.1, 128.4, 127.7, 126.4, 126.3, 122.2, 117.2, 115.7, 112.0, 58.6, 56.2, 56.0, 54.4 (2C), 53.8, 28.5, 26.0, 25.5 (2C), 24.1, 23.4, 15.4; IR (neat) Ï<sub>max</sub>: 2935, 2213, 1584, 1503, 1441, 1253, 1230, 1136, 1023, 728 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 454.2523; found, 454.2527.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(5-(piperidin-1-yl)pentyl)benzo[<i>d</i>]thiazol-2-amine (<b>11</b>)</h3><div class="NLM_p last">(109 mg, 83%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 6.99â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.70 (d, <i>J</i> = 2.0 Hz, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.41 (t, <i>J</i> = 7.4 Hz, 2H), 2.50â2.36 (m, 8H), 1.82â1.75 (m, 2H), 1.67â1.56 (m, 6H), 1.48â1.40 (m, 4H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.2, 136.6, 135.1, 128.4, 127.7, 126.41, 126.36, 122.3, 117.3, 115.8, 112.0, 59.0, 56.2, 56.1, 54.5 (2C), 53.9, 28.5, 27.8, 26.1, 25.5 (2C), 24.6, 24.2, 15.5; IR (neat) Ï<sub>max</sub>: 2934, 2213, 1584, 1503, 1321, 1253, 1231, 1136, 1022, 762 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 468.2685; found, 468.2690.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(2-(pyrrolidin-1-yl)ethyl)benzo[<i>d</i>]thiazol-2-amine (<b>15</b>)</h3><div class="NLM_p last">(87.0 mg, 89%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.29 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.00â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.71â6.70 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.57 (t, <i>J</i> = 7.2 Hz, 2H), 2.82 (t, <i>J</i> = 7.2 Hz, 2H), 2.57â2.56 (m, 4H), 2.48 (q, <i>J</i> = 7.6 Hz, 2H), 1.80â1.77 (m, 4H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.6, 135.0, 128.4, 127.7, 126.9, 126.4, 122.4, 117.3, 115.9, 112.0, 56.2, 56.1, 54.2 (2C), 53.4, 52.5, 28.5, 23.7 (2C) 15.5; IR (neat) Ï<sub>max</sub>: 2963, 2214, 1584, 1503, 1440, 1252, 1230, 1135, 1022, 806 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>23</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 412.2053; found, 412.2048.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(3-(pyrrolidin-1-yl)propyl)benzo[<i>d</i>]thiazol-2-amine (<b>16</b>)</h3><div class="NLM_p last">(74.0 mg, 50%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.07 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.99â6.96 (m, 2H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 6.70â6.69 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.51 (t, <i>J</i> = 7.2 Hz, 2H), 2.68 (t, <i>J</i> = 7.3 Hz, 2H), 2.62â2.58 (m, 4H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 2.06â1.99 (m, 2H), 1.82â1.78 (m, 4H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.5, 135.0, 128.5, 127.7, 126.42, 126.35, 122.2, 117.2, 115.6, 112.0, 56.2, 56.1, 54.1 (2C), 53.1, 52.3, 28.5, 27.0, 23.5 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 2985, 2214, 1585, 1503, 1442, 1253, 1231, 1137, 1023, 728 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 426.2215; found, 426.2220.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(4-(pyrrolidin-1-yl)butyl)benzo[<i>d</i>]thiazol-2-amine (<b>17</b>)</h3><div class="NLM_p last">(101 mg, 74%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.07 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.98â6.96 (m, 2H), 6.88 (d, <i>J</i> = 8.4 Hz, 1H), 6.69â6.68 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.44 (t, <i>J</i> = 6.9 Hz, 2H), 2.69â2.61 (m, 6H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 1.87â1.74 (m, 8H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.3, 136.5, 135.0, 128.4, 127.7, 126.4, 126.3, 122.1, 117.2, 115.6, 112.0, 56.2, 56.1, 55.7, 54.1 (2C), 53.7, 28.5, 25.9, 25.1, 23.5 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 2963, 2213, 1584, 1503, 1441, 1253, 1230, 1136, 1022, 728 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 440.2366; found, 440.2364.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(5-(pyrrolidin-1-yl)pentyl)benzo[<i>d</i>]thiazol-2-amine (<b>18</b>)</h3><div class="NLM_p last">(87.0 mg, 60%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 6.99â6.97 (m, 2H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.70â6.69 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.43 (t, <i>J</i> = 7.3 Hz, 2H), 2.90â2.77 (m, 4H), 2.70 (t, <i>J</i> = 7.9 Hz, 2H), 2.47 (q, <i>J</i> = 7.6 Hz, 2H), 1.94â1.89 (m, 4H), 1.84â1.70 (m, 4H), 1.55â1.47 (m, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.3, 136.6, 135.0, 128.4, 127.8, 126.44, 126.38, 122.2, 117.3, 115.7, 112.1, 56.3, 56.1, 55.9, 54.0 (2C), 53.7, 28.5, 27.6, 27.2, 24.3, 23.5 (2C), 15.5; IR (neat) Ï<sub>max</sub>: 2934, 2213, 1736, 1584, 1503, 1441, 1251, 1231, 1136, 1023, 806 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 454.2528; found, 454.2520.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(2-morpholinoethyl)benzo[<i>d</i>]thiazol-2-amine (<b>19</b>)</h3><div class="NLM_p last">(18.0 mg, 84%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.33 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.07 (m, 1H), 7.00â6.97 (m, 2H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.70â6.99 (m, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.73â3.71 (m, 4H), 3.58 (t, <i>J</i> = 6.3 Hz, 2H), 2.67 (t, <i>J</i> = 6.1 Hz, 2H), 2.51â2.45 (m, 6H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.3, 136.5, 135.0, 128.4, 127.7, 127.0, 126.3, 122.2, 117.2, 115.9, 112.0, 66.9 (2C), 56.2, 56.1, 55.9, 53.6 (2C), 50.2, 28.5, 15.5; IR (neat) Ï<sub>max</sub>: 2934, 2214, 1584, 1503, 1440, 1252, 1230, 1115, 1022, 729 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>23</sub>H<sub>30</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 428.2002; found, 428.1996.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(3-morpholinopropyl)benzo[<i>d</i>]thiazol-2-amine (<b>20</b>)</h3><div class="NLM_p last">(100 mg, 98%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.06 (m, 1H), 6.99â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.71â6.70 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.68â3.66 (m, 4H), 3.51 (t, <i>J</i> = 7.2 Hz, 2H), 2.50â2.41 (m, 8H), 1.97â1.90 (m, 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.1, 149.8, 145.3, 136.6, 135.1, 128.4, 127.8, 126.4, 126.3, 122.2, 117.2, 115.7, 112.0, 66.9 (2C), 56.2, 56.1, 55.4, 53.6, 52.1, 29.8, 28.6, 24.8, 15.5; IR (neat) Ï<sub>max</sub>: 2935, 2213, 1584, 1503, 1441, 1252, 1230, 1115, 1022, 728 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 442.2159; found, 442.2162.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(4-morpholinobutyl)benzo[<i>d</i>]thiazol-2-amine (<b>21</b>)</h3><div class="NLM_p last">(125 mg, 92%, white solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.06 (m, 1H), 6.99â6.97 (m, 2H), 6.89 (d, <i>J</i> = 8.4 Hz, 1H), 6.70â6.69 (m, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.71â3.68 (m, 4H), 3.45 (t, <i>J</i> = 7.3 Hz, 2H), 2.50â2.36 (m, 8H), 1.85â1.77 (m, 2H), 1.68â1.61 (m, 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.2, 136.6, 135.2, 128.4, 127.7, 126.4, 126.3, 122.2, 117.2, 115.7, 112.0, 67.0 (2C), 58.4, 56.2, 56.1, 53.9, 53.7 (2C), 28.5, 25.9, 23.4, 15.5; IR (neat) Ï<sub>max</sub>: 2934, 2213, 1677, 1584, 1503, 1253, 1231, 1116, 1022, 733 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>25</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 456.2321; found, 456.2313.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(3,4-Dimethoxyphenyl)-6-ethyl-<i>N</i>-(5-morpholinopentyl)benzo[<i>d</i>]thiazol-2-amine (<b>22</b>)</h3><div class="NLM_p last">(110 mg, 72%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.99â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.4 Hz, 1H), 6.70â6.69 (m, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.70â3.68 (m, 4H), 3.41 (t, <i>J</i> = 7.4 Hz, 2H), 2.50â2.41 (m, 6H), 2.33 (t, <i>J</i> = 7.4 Hz, 2H), 1.83â1.75 (m, 2H), 1.56â1.43 (m, 4H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.6, 135.2, 128.4, 127.7, 126.4, 126.3, 122.2, 117.3, 115.7, 112.0, 67.0 (2C), 58.8, 56.2, 56.1, 53.9, 53.8 (2C), 28.5, 27.9, 26.2, 24.4, 15.5; IR (neat) Ï<sub>max</sub>: 2936, 2213, 1584, 1503, 1398, 1253, 1231, 1116, 1022, 731 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 470.2472; found, 470.2464.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i><sup>1</sup>-(3,4-Dimethoxyphenyl)-<i>N</i><sup><i>2</i></sup>,<i>N</i><sup><i>2</i></sup>-diethyl-<i>N</i><sup>1</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)ethane-1,2-diamine (<b>23</b>)</h3><div class="NLM_p last">(68 mg, 69%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.30 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.06 (m, 1H), 6.99â6.97 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.73â6.72 (m, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.52 (t, <i>J</i> = 7.1 Hz, 2H), 2.79 (t, <i>J</i> = 7.1 Hz, 2H), 2.58 (q, <i>J</i> = 7.1 Hz, 4H), 2.48 (q, <i>J</i> = 7.6 Hz, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H), 1.02 (t, <i>J</i> = 7.1 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 149.9, 149.7, 145.1, 136.2, 135.4, 128.5, 127.6, 126.8, 126.4, 122.4, 117.1, 115.9, 112.0, 56.2, 56.1, 51.8, 50.8, 47.3 (2C), 28.5, 15.5, 11.7 (2C); IR (neat) Ï<sub>max</sub>: 2966, 2213, 1584, 1503, 1440, 1252, 1230, 1136, 1022, 729 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>23</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 414.2210; found, 414.2204.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i><sup>1</sup>-(3,4-Dimethoxyphenyl)-<i>N</i><sup>3</sup>,<i>N</i><sup>3</sup>-diethyl-<i>N</i><sup>1</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)propane-1,3-diamine (<b>24</b>)</h3><div class="NLM_p last">(80.0 mg, 81%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.00â6.97 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.71â6.70 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.49 (t, <i>J</i> = 7.3 Hz, 2H), 2.59â2.44 (m, 8H), 1.96â1.88 (m, 2H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H), 1.01 (t, <i>J</i> = 7.1 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl3): Î´ 150.0, 149.8, 145.3, 136.6, 135.1, 128.4, 127.8, 126.4, 126.3, 122.2, 117.3, 115.6, 112.0, 56.2, 56.1, 52.4, 49.8, 46.8 (2C), 29.8, 28.6, 25.3, 15.5, 11.3; IR (neat) Ï<sub>max</sub>: 2987, 2213, 1584, 1503, 1441, 1253, 1231, 1136, 1023, 806, 734 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>24</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 428.2366; found, 428.2369.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i><sup>1</sup>-(3,4-Dimethoxyphenyl)-<i>N</i><sup>4</sup>,<i>N</i><sup>4</sup>-diethyl-<i>N</i><sup>1</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)butane-1,4-diamine (<b>25</b>)</h3><div class="NLM_p last">(108 mg, 82%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.99â6.97 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.70â6.69 (m, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.45 (t, <i>J</i> = 7.4 Hz, 2H), 2.55 (q, <i>J</i> = 7.2 Hz, 4H), 2.51â2.44 (m, 4H), 1.82â1.74 (m, 2H), 1.65â1.58 (m, 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H), 1.03 (t, <i>J</i> = 7.2 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.2, 136.6, 135.1, 128.4, 127.8, 126.42, 126.36, 122.3, 117.3, 115.7, 112.0, 56.2, 56.1, 54.0, 52.4, 46.9 (2C), 28.5, 26.1, 23.9, 15.5, 11.6 (2C); IR (neat) Ï<sub>max</sub>: 2966, 2213, 1584, 1503, 1441, 1398, 1253, 1231, 1138, 1023, 762 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 442.2523; found, 442.2519.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i><sup>1</sup>-(3,4-Dimethoxyphenyl)-<i>N</i><sup>5</sup>,<i>N</i><sup>5</sup>-diethyl-<i>N</i><sup>1</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)pentane-1,5-diamine (<b>26</b>)</h3><div class="NLM_p last">(119 mg, 80%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.00â6.97 (m, 2H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.71 (d, <i>J</i> = 2.0 Hz, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.43 (t, <i>J</i> = 7.4 Hz, 2H), 2.62â2.57 (m, 4H), 2.51â2.45 (m, 4H), 1.85â1.77 (m, 2H), 1.60â1.52 (m, 2H), 1.49â1.41 (m, 2H), 1.11â1.04 (m, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.8, 145.3, 136.6, 135.1, 128.3, 127.8, 126.4 (2C), 122.2, 117.3, 115.7, 112.1, 56.2, 56.1, 53.8, 52.4, 46.8 (2C), 28.5, 27.8, 25.7, 24.4, 15.5, 10.7 (2C); IR (neat) Ï<sub>max</sub>: 2967, 2213, 1738, 1584, 1503, 1253, 1231, 1137, 1023, 762 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>26</sub>H<sub>38</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 456.2679; found, 456.2675.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i><sup>1</sup>-Cyclohexyl-<i>N</i><sup>2</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>2</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)ethane-1,2-diamine (<b>27</b>)</h3><div class="NLM_p last">(99.0 mg, 95%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 7.07â7.04 (m, 1H), 6.99â6.96 (m, 2H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 6.68â6.67 (m, 1H), 4.10â3.95 (m, 3H), 3.88 (s, 3H), 3.82 (s, 3H), 3.70â3.69 (m, 2H), 3.45 (t, <i>J</i> = 7.7 Hz, 2H), 2.46 (q, <i>J</i> = 7.6 Hz, 2H), 1.89â1.87 (m, 2H), 1.79â1.76 (m, 2H), 1.66â1.63 (m, 1H), 1.52â1.30 (m, 4H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 158.5, 149.9, 149.6, 145.4, 139.7, 133.2, 128.3, 127.9, 127.4, 126.4, 122.1, 117.4, 111.9, 56.2, 56.0, 53.1 (2C), 47.4, 40.6, 29.8, 28.6, 25.7, 25.4 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 3315, 2931, 1655, 1549, 1503, 1253, 1230, 1136, 1020, 729 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 440.2366; found, 440.2362.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i><sup>1</sup>-Cyclohexyl-<i>N</i><sup>3</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>3</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)propane-1,3-diamine (<b>28</b>)</h3><div class="NLM_p last">(83 mg, 54%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.12â7.09 (m, 2H), 7.03â7.00 (m, 2H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 6.60â6.59 (m, 1H), 4.52 (tt, <i>J</i> = 11.6, 3.5 Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.68â3.62 (m, 1H), 3.55â3.41 (m, 3H), 2.48 (q, <i>J</i> = 7.6 Hz, 2H), 2.28â2.14 (m, 2H), 1.96â1.69 (m, 8H), 1.54â1.43 (m, 2H), 1.10 (t, <i>J</i> = 7.5 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 152.4, 150.7, 150.0, 147.7, 139.5, 132.1, 129.1, 128.6, 127.3, 126.9, 119.2, 118.1, 112.3, 58.1, 56.5, 56.1, 48.0, 39.7, 30.14, 30.09, 28.8, 25.4, 24.9, 24.8, 21.8, 15.4; IR (neat) Ï<sub>max</sub>: 3453, 2932, 1583, 1503, 1321, 1253, 1231, 1137, 1020, 725 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 454.2523; found, 454.2517.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i><sup>1</sup>-Cyclohexyl-<i>N</i><sup>4</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>4</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)butane-1,4-diamine (<b>29</b>)</h3><div class="NLM_p last">(91.0 mg, 58%, white solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.21 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 6.99â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.70â6.69 (m, 1H), 3.91 (s, 3H), 3.84 (s, 3H), 3.43 (t, <i>J</i> = 7.4 Hz, 2H), 2.69 (t, <i>J</i> = 7.3 Hz, 2H), 2.50â2.44 (m, 3H), 1.90â1.57 (m, 10H), 1.28â1.05 (m, 8H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.6, 135.1, 128.3, 127.8, 126.41, 126.35, 122.2, 117.3, 115.7, 112.0, 57.0, 56.2, 56.0, 53.9 (2C), 46.2, 33.1, 28.5, 26.9, 26.1, 25.9, 25.1 (2C), 15.5; IR (neat) Ï<sub>max</sub>: 2929, 2213, 1585, 1503, 1442, 1253, 1230, 1136, 1023, 728 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 468.2679; found, 468.2675.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i><sup>1</sup>-Cyclohexyl-<i>N</i><sup>5</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>5</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)pentane-1,5-diamine (<b>30</b>)</h3><div class="NLM_p last">(112 mg, 72%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.07 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.99â6.95 (m, 2H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 6.69â6.68 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.41 (t, <i>J</i> = 7.4 Hz, 2H), 2.69 (t, <i>J</i> = 7.5 Hz, 2H), 2.53â2.43 (m, 3H), 1.94â1.90 (m, 2H), 1.82â1.70 (m, 4H), 1.66â1.58 (m, 3H), 1.51â1.45 (m, 2H), 1.25â1.11 (m, 5H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.2, 136.6, 135.1, 128.3, 127.8, 126.4, 126.3, 122.2, 117.3, 115.7, 112.0, 57.0, 56.2, 56.1, 53.9 (2C), 46.1, 32.6, 29.0, 28.5, 27.8, 25.9, 25.0 (2C), 24.3, 15.4; IR (neat) Ï<sub>max</sub>: 2929, 2213, 1584, 1503, 1321, 1253, 1231, 1023, 729 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>28</sub>H<sub>40</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 482.2836; found, 482.2833.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i><sup>1</sup>-Cyclopentyl-<i>N</i><sup>2</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>2</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)ethane-1,2-diamine (<b>31</b>)</h3><div class="NLM_p last">(767 mg, 76%, white solid). <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>): Î´ 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.02â7.00 (m, 2H), 6.90 (d, <i>J</i> = 8.3 Hz, 1H), 6.75â6.74 (m, 1H), 4.38â4.31 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.72â3.61 (m, 3H), 3.36 (t, <i>J</i> = 7.2 Hz, 2H), 2.49 (q, <i>J</i> = 7.6 Hz, 2H), 1.90â1.84 (m, 2H), 1.74â1.54 (m, 6H), 1.10 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.0, 149.7, 145.1, 136.4, 135.2, 128.4, 127.6, 127.1, 126.3, 122.5, 117.2, 116.0, 112.0, 56.24, 56.21, 56.1, 54.7 (2C), 51.0, 28.5, 26.0 (2C), 24.4, 15.5; IR (neat) Ï<sub>max</sub>: 3173, 2961, 1658, 1547, 1498, 1253, 1228, 1136, 1019, 804 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 426.2215; found, 426.2214.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i><sup>1</sup>-Cyclopentyl-<i>N</i><sup>3</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>3</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)propane-1,3-diamine (<b>32</b>)</h3><div class="NLM_p last">(91.0 mg, 61%, ivory solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.13â7.08 (m, 2H), 7.02â6.99 (m, 2H), 6.94 (d, <i>J</i> = 8.4 Hz, 1H), 6.60â6.59 (m, 1H), 5.02â4.94 (m, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.70â3.64 (m, 1H), 3.54â3.48 (m, 1H), 3.43 (t, <i>J</i> = 5.8 Hz, 2H), 2.48 (q, <i>J</i> = 7.6 Hz, 2H), 2.32â2.13 (m, 4H), 1.86â1.50 (m, 7H), 1.09 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 152.9, 150.7, 150.0, 147.7, 139.6, 132.2, 129.1, 128.6, 127.2, 126.8, 119.3, 118.1, 112.3, 60.0, 56.4, 56.1, 47.9, 40.0, 29.2, 28.8, 28.7, 24.3, 24.2, 21.9, 15.4; IR (neat) Ï<sub>max</sub>: 3320, 2921, 1639, 1583, 1503, 1442, 1253, 1231, 1021, 729 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>25</sub>H<sub>34</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 440.2366; found, 440.2373.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i><sup>1</sup>-Cyclopentyl-<i>N</i><sup>4</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>4</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)butane-1,4-diamine (<b>33</b>)</h3><div class="NLM_p last">(140 mg, 37%, colorless oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.06 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 6.99â6.95 (m, 2H), 6.88 (d, <i>J</i> = 8.3 Hz, 1H), 6.67â6.66 (m, 1H), 3.90 (s, 3H), 3.83 (s, 3H), 3.43 (t, <i>J</i> = 7.3 Hz, 2H), 3.38â3.31 (m, 1H), 2.92 (t, <i>J</i> = 8.0 Hz, 2H), 2.45 (q, <i>J</i> = 7.6 Hz, 2H), 2.05â1.97 (m, 4H), 1.92 (s, 1H), 1.87â1.79 (m, 6H), 1.58â1.49 (m, 2H), 1.06 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 150.1, 149.8, 145.5, 136.7, 134.6, 128.3, 127.9, 126.54, 126.49, 121.9, 117.3, 115.5, 112.1, 59.3, 56.3, 56.1, 53.2, 46.4, 29.8 (2C), 28.5, 25.5, 23.9 (2C), 23.0, 15.5; IR (neat) Ï<sub>max</sub>: 3401, 2958, 2212, 1583, 1502, 1440, 1252, 1230, 1135, 1021, 762 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>26</sub>H<sub>36</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 454.2528; found, 454.2527.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i><sup>1</sup>-Cyclopentyl-<i>N</i><sup>5</sup>-(3,4-dimethoxyphenyl)-<i>N</i><sup>5</sup>-(6-ethylbenzo[<i>d</i>]thiazol-2-yl)pentane-1,5-diamine (<b>34</b>)</h3><div class="NLM_p last">(136 mg, 89%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 7.09â7.06 (m, 1H), 6.99â6.96 (m, 2H), 6.89 (d, <i>J</i> = 8.3 Hz, 1H), 6.69â6.68 (m, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.41 (t, <i>J</i> = 7.4 Hz, 2H), 3.10â3.03 (m, 1H), 2.61 (t, <i>J</i> = 7.2 Hz, 2H), 2.47 (q, <i>J</i> = 7.6 Hz, 2H), 1.90â1.74 (m, 4H), 1.72â1.62 (m, 2H), 1.61â1.43 (m, 6H), 1.39â1.31 (m, 2H), 1.08 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 149.9, 149.7, 145.1, 136.6, 135.1, 128.3, 127.7, 126.33, 126.27 122.2, 117.2, 115.7, 112.0, 59.9, 56.1, 56.0, 53.9, 48.3, 32.8 (2C), 29.5, 28.4, 27.8, 24.3, 24.1 (2C), 15.4; IR (neat) Ï<sub>max</sub>: 2937, 2213, 1585, 1503, 1321, 1253, 1231, 1023, 728 (cm<sup>â1</sup>); HRMS (ESI): calcd for C<sub>27</sub>H<sub>38</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 468.2679; found, 468.2697.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 6-Ethyl-<i>N</i>-(3-methoxyphenyl)-<i>N</i>-(3-(piperidin-1-yl)propyl)benzo[<i>d</i>]thiazol-2-amine (<b>12</b>)</h3><div class="NLM_p">To a solution of <b>53</b> (200 mg, 0.49 mmol) in DMF/MeCN (1:1, 5 mL, 0.1 M) was added K<sub>2</sub>CO<sub>3</sub> (273 mg, 1.97 mmol) and piperidine (484 Î¼L, 4.90 mmol). The reaction mixture was stirred at 50 Â°C for 14 h and then diluted with H<sub>2</sub>O and extracted with EtOAc. The organic layer was dried over MgSO<sub>4</sub>, filtered, and evaporated <i>in vacuo</i>. The crude product was separated by silica gel column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 20:1, <i>R</i><sub>f</sub> = 0.2) to produce the desired product <b>12</b> (84.0 mg, 42%, colorless oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.28 (d, <i>J</i> = 8.0 Hz, 1H), 7.26â7.22 (m, 1H), 7.09 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.04â7.03 (m, 1H), 6.92â6.89 (m, 1H), 6.89â6.88 (m, 1H), 6.83 (ddd, <i>J</i> = 8.2, 2.5, 0.7 Hz, 1H), 3.77 (s, 3H), 3.46 (t, <i>J</i> = 7.3 Hz, 2H), 2.54 (q, <i>J</i> = 7.6 Hz, 2H), 2.38â2.32 (m, 6H), 1.88 (td, <i>J</i> = 14.6, 7.3 Hz, 2H), 1.57â1.51 (m, 4H), 1.43â1.39 (m, 2H) 1.14 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 160.3, 145.1, 137.5, 135.2, 133.0, 132.2, 130.3, 128.1, 126.4, 123.8, 116.6, 115.6, 113.8, 55.7, 55.5, 54.5 (2C), 52.5, 28.4, 25.9 (2C), 25.2, 24.4, 15.4; IR (neat) Ï<sub>max</sub>: 2933, 2772, 2213, 1589, 1480, 1426, 1230, 1038, 857, 774, 687 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>24</sub>H<sub>32</sub>N<sub>3</sub>OS [M + H]<sup>+</sup>, 410.2266; found, 410.2260.</div><div class="NLM_p last">All <b>13</b> and <b>14</b> compounds were synthesized using a similar procedure to that for compound <b>12</b>.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(3,4-Difluorophenyl)-6-ethyl-<i>N</i>-(3-(piperidin-1-yl)propyl)benzo[<i>d</i>]thiazol-2-amine (<b>13</b>)</h3><div class="NLM_p last">(30.0 mg, 56%, white solid). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.29 (d, <i>J</i> = 8.1 Hz, 1H), 7.18â7.07 (m, 4H), 7.00â6.99 (m, 1H), 3.46 (t, <i>J</i> = 7.6 Hz, 2H), 2.56 (q, <i>J</i> = 7.6 Hz, 2H), 2.38â2.32 (m, 6H), 1.88 (td, <i>J</i> = 14.5, 7.2 Hz, 2H), 1.56â1.50 (m, 4H), 1.43â1.39 (m, 2H), 1.15 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 151.70 (dd, <i>J</i> = 12.9, 45.7 Hz, 1C), 149.20 (dd, <i>J</i> = 12.7, 44.1 Hz, 1C), 145.3, 137.7, 132.4, 132.1, 130.52 (t, <i>J</i> = 5.0 Hz, 1C), 128.6, 128.04 (q, <i>J</i> = 3.3 Hz, 1C), 126.5, 120.65 (d, <i>J</i> = 18.2 Hz, 1C), 118.34 (d, <i>J</i> = 17.7 Hz, 1C), 115.4, 55.7, 54.6 (2C), 52.6, 28.4, 26.1 (2C), 25.3, 24.5, 15.4; IR (neat) Ï<sub>max</sub>: 2934, 2214, 1600, 1501, 1486, 1403, 1272, 1200, 1116, 903, 771 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>23</sub>H<sub>28</sub>F<sub>2</sub>N<sub>3</sub>S [M + H]<sup>+</sup>, 416.1972; found, 416.1964.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 6-Ethyl-<i>N</i>-(3-(piperidin-1-yl)propyl)-<i>N</i>-(4-(trifluoromethyl)phenyl)benzo[<i>d</i>]thiazol-2-amine (<b>14</b>)</h3><div class="NLM_p last">(45.0 mg, 56%, yellow oil). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): Î´ 7.49 (d, <i>J</i> = 8.3 Hz, 2H), 7.34â7.31 (m, 1H), 7.26â7.23 (m, 2H), 7.20â7.19 (m, 2H), 3.43 (t, <i>J</i> = 7.3 Hz, 2H), 2.57 (q, <i>J</i> = 7.6 Hz, 2H), 2.31â2.28 (m, 6H), 1.81 (td, <i>J</i> = 14.4, 7.2 Hz, 2H), 1.52â1.46 (m, 4H), 1.38â1.37 (m, 2H), 1.16 (t, <i>J</i> = 7.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): Î´ 145.4, 141.0, 139.5, 134.9, 129.8, 129.6, 129.0 (2C), 128.83 (q, <i>J</i> = 32.4 Hz, 1C), 126.5, 126.19 (q, <i>J</i> = 3.7 Hz, 2C), 124.1 (q, <i>J</i> = 269.6 Hz, 1C), 115.3, 55.6, 54.6 (2C), 52.7, 28.3, 26.0 (2C), 25.2, 24.4, 15.4; IR (neat) Ï<sub>max</sub>: 2935, 2214, 1605, 1486, 1323, 1163, 1122, 1089, 1062, 1013, 827 (cm<sup>â1</sup>); HRMS (FAB): calcd for C<sub>24</sub>H<sub>29</sub>F<sub>3</sub>N<sub>3</sub>S [M + H]<sup>+</sup>, 448.2034; found, 448.2024.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Chemicals and Reagents</h3><div class="NLM_p last">3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), DMSO, and gelatin were purchased from Sigma-Aldrich (St. Louis, MO, USA). All the tested compounds were dissolved in 100% DMSO, and the final concentration of DMSO was 0.1% for all the <i>in vitro</i> experiments. Recombinant human VEGF (VEGF<sub>165</sub>) was obtained from PeproTech (Rocky Hill, NJ, USA). Growth factor-reduced Matrigel was purchased from BD Biosciences (San Jose, CA, USA). Antibodies against IL-1Î² (sc-32294), NFÎºB p50 (sc-8414), NFÎºB p65 (sc-372), and Î²-actin (sc-47778) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). <i>p</i>-VEGFR2 (#2478), VEGFR2 (#2479), p-PI3K (#4228), PI3K (#4249), c-Abl (#2862), and STAT5 (#25656) were purchased from Cell Signaling Technology (Danvers, MA, USA). p-STAT5 (#71-6900) was purchased from Invitrogen (Invitrogen, Carlsbad, CA, USA). ANGPT2 (24613-1-AP) was purchased from Proteintech (Rosemont, IL, USA). Secondary antibodies were purchased from Younginfrontier (Seoul, Korea).</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Cell Culture</h3><div class="NLM_p last">HUVEC and ARPE-19 cells were obtained from the ATCC (Rockville, MD, USA). HRMECs were obtained from Cell Systems (Kirkland, MA, USA). HUVECs and HRMECs were cultured using EGM-2 Bulletkit (Lonza, Walkersville, MD, USA) supplemented with 10% FBS and 1% antibiotics-antimycotics (AA) (PSF; 100 units/mL of penicillin G sodium, 100 Î¼g/mL of streptomycin, and 250 ng/mL of amphotericin B), and ARPE-19 cells were cultured in Dulbeccoâs modified Eagleâs medium/nutrient mixture F-12 (DMEM/F-12) (Gibco, Grand Island, NY, USA) supplemented with 10% FBS and 1% AA. All the cells were maintained at 37 Â°C in a 5% CO<sub>2</sub> atmosphere.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Tube Formation and Cell Viability Test</h3><div class="NLM_p last">HUVECs or HRMECs (1.5 Ã 10<sup>4</sup> cells/well) were mixed with various compound concentrations and seeded onto each well of a Matrigel-coated 96-well plate. The cells were then incubated for 6 h at 37 Â°C in a 5% CO<sub>2</sub> atmosphere and photographed using an inverted microscope. In our previous study, the number of branches for each image was counted by the eye. To obtain more accurate data, we modified the method to calculate the total segment lengths per image using the angiogenesis analyzer for ImageJ. Consequently, the IC<sub>50</sub> values of the previous and present studies are not directly comparable. The following formula was used for quantification: 100 Ã (avg. of tot. seg.<sub>lengthÂ compound</sub> â avg. of tot. seg.<sub>lengthÂ VEGF(â)control</sub>)/(avg. of tot. seg.<sub>lengthÂ VEGF(+)control</sub> â avg. of tot. seg.<sub>lengthÂ VEGF(â)control</sub>). For cell viability, HUVECs were seeded in 96-well plates (8 Ã 10<sup>3</sup> cells/well). On the next day, the cells were serum-starved overnight and treated with various concentrations of compounds in EBM-2 media with 2% FBS for 24 h in the presence of VEGF (50 ng/mL). Cell viability was assayed by the MTT method. The IC<sub>50</sub> values were calculated via log (inhibitor) versus normalized response (variable slope) analysis using GraphPad Prism (GraphPad Software, San Diego, CA).</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> VEGFR-2 Tyrosine Kinase Assay</h3><div class="NLM_p last">VEGFR-2 tyrosine kinase activities of the compounds were measured with the VEGFR-2 tyrosine kinase assay kit (BPS Bioscience, San Diego, CA, USA) and the Kinase-Glo MAX luminescence kinase assay kit (Promega, Madison, WI, USA). The kinase assay kits determine kinase activity with the inhibitor by quantitating the number of ATP molecules in the solution. Kinase activity of the reaction lowers the amount of ATP remaining in the solution; therefore, the luminescence intensity is conversely correlated with the kinase activity. The compounds were dissolved in 10% DMSO in the assay to make 1% DMSO concentration in every reaction mixtures. The final reaction mixture was made of 10 mM MgCl<sub>2</sub>, 10 Î¼M ATP, 40 mM Tris (pH 7.4), 0.1 mg/mL BSA, kinase substrate, and the enzyme. All of the enzymatic reactions were incubated at 30 Â°C for 45 min. After the incubating time, 50â¯Î¼L of Kinase-Glo Max luminescence solution (Promega, Madison, WI, USA) was added to each well. The plate was covered with aluminum foil and incubated at room temperature for 15 min. Luminescence intensity of each well was determined using a Centro LB 960 microplate luminometer. Inhibition activity was calculated using the following equation: 100 â [100 Ã (test compound signal â blank signal)/(negative control signal â blank signal)].</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Migration Assay</h3><div class="NLM_p last">HUVECs were seeded onto six-well plates in full media. When the cells were fully grown, they were scratched with a 10 Î¼L tip. The media were removed and replaced with 2% FBS/EGM-2 and treated with DMSO or the indicated concentrations of the test compound. After 24 h, the cells were visualized and photographed using an inverted microscope.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> High Glucose-Induced Model</h3><div class="NLM_p last">Cells were seeded onto 60 mm dishes. When the cells reached 80% confluency, the media were removed and replaced with media supplemented with 2% FBS. The cells were treated with DMSO or the indicated concentrations of the test compound for 30 min, and a final concentration of 5.5 mM or 30 mM <span class="smallcaps smallerCapital">d</span>-glucose was added to the media. The cells were further incubated for 48 h at 37 Â°C in a 5% CO<sub>2</sub> atmosphere.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Western Blotting Analysis</h3><div class="NLM_p last">The cells were lysed in 2Ã sample loading buffer (250 mM TrisâHCl (pH 6.8), 4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% Î²-mercaptoethanol, 50 mM sodium fluoride, and 5 mM sodium orthovanadate). The collected samples were subjected to 6â12% SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h at room temperature and then incubated with primary antibodies in 2.5% BSA in TBST overnight at 4 Â°C on a shaker. The membranes were washed three times with TBST and incubated with secondary antibodies (HRP) (Younginfrontier, Seoul, Korea) diluted in TBST for 2 h at room temperature. After washing with TBST, the membranes were exposed to enhanced chemiluminescence solution (Intron, Daejeon, Korea). The chemiluminescence signals were captured using the LAS-4000 system (Fuji Film Corp., Tokyo, Japan).</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Real-Time PCR Analysis</h3><div class="NLM_p last">The total RNA of the cells was isolated using NucleoZOL (Macherey-Nagel GmbH & Co., KG, Duren, Germany). The isolated RNA (1 Î¼g) was reverse transcribed using ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan) according to the manufacturerâs instructions. Using synthesized cDNA, real-time PCR was conducted using iQTM SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) according to the manufacturerâs instructions. The sequences of the primers used were <i>ANGPT2</i> (F) 5â²-ATTCAGCGACGTGAGGATGGCA-3â² (R) 5â²-GCACATAGCGTTGCTGATTAGTC-3â² and <i>HPRT1</i> (F) 5â²-TGCAGACTTTGCTTTCCTTGGTCAGG-3â² (R) 5â²-CCAACACTTCGTGGGGTCCTTTTCA-3â²</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Laser-Induced CNV in Mice</h3><div class="NLM_p last">C57BL/6 mice (Orientbio Inc, Korea) were treated in accordance with the Guide of the Care and Use of Laboratory Animals and Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and approved by the Institutional Animal Care and Use Committee at KPC Labs. For the induction of CNV, mice were anesthetized by the ketamine (ketamine 100 mg + xylazine 10 mg/10 mL/kg). Anesthesia one eye drops (0.5% proparacaine) were applied to pupils for further local anesthesia. The laser (Meridian Merilas 532 green laser photocoagulator) burn induced according to the CNV induction condition (wavelength 532 nm, diameter 50 Î¼m, duration 80 mS, and power level 200 mW) to break the Bruchâs membrane. One drop of antibiotic mucus (0.3% tobramycin) was applied to the eye with the CNV induction completed. Mice were administered with drugs 1 day after CNV induction for 11 days. Eylea was injected into the scleral puncture with a 34G needle connected to the IO kit and then administered to both eyes (3 mg/mL concentration, 1 Î¼L/eye) once a day. Vehicle and 1% <b>31</b> eye drops were applied to mouse eyes (1 Î¼L/eye) four times a day. When the administration was completed, an antibiotic ophthalmic solution was instilled in the eye of the mouse to prevent infection.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Fundus Fluorescent Angiography/Optical Coherence Tomography Angiography</h3><div class="NLM_p last">On the 10th day after CNV induction, mice were anesthetized with ketamine, and then, a fluorescent contrast agent (10% fluorescite 1 mL/kg) was injected intraperitoneally. Anesthesia eye drops were instilled into the eye, followed by additional local anesthesia. The mouse was placed on the sacrifice table, and the image was adjusted to the fundus with the Micron-IV imaging camera (Phoenix, CA, USA), and the lubricating gel was instilled on the eye. The lens of the OCTA was brought into contact with the cornea of the mouse. After FFA/OCTA imaging was performed, a drop of antibiotic ophthalmic solution was instilled on the mouse eye. FFA and OCTA images were analyzed using the ImageJ program (National Institutes of health, Bethesda, MD).</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> ERG Recording</h3><div class="NLM_p last">Each mouse was subjected to induced dark adaptation in the dark from 12 h before ERG evaluation. On the day of evaluation (11 days after CNV induction), after general anesthesia with rompun and ketamine, an alkaline solution was instilled into the eye to induce additional local anesthesia. The mouse was placed on an ERG staging table, and the ERG probe was made to contact the tail, head, and cornea. ERG was measured as the change in the retinal potential for a single flash stimulation [0.9 log cds/m<sup>2</sup> (10 responses/intensity)]. When the ERG evaluation was completed, a drop of Tobrex was instilled into the mouse eye. ERG analysis was performed using the Lab Scribe ERG program (iWorx Data Acquisition Software).</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Mouse Model of OIR</h3><div class="NLM_p last">The animals were cared for in accordance with the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health. The protocols were also approved by the Institutional Animal Care and Use Committee of Chung-Ang University. Pregnant C57BL/6 mice were purchased from Orientbio Inc. (Seoul, Korea). The mice were housed in microisolator cages on individually ventilated cage racks with access to an autoclaved standard rodent diet ad libitum (LabDiet 5008, Purina, St. Louis, MO, USA) and were kept under a 12:12 h lightâdark cycle. For the surgical procedures, the mice were anesthetized with an intraperitoneal injection of ketamine hydrochloride (100 mg/kg of body weight) and xylazine hydrochloride (6 mg/kg of body weight). The pupils of the anesthetized mice were dilated with topical drops of 1% tropicamide (Santen, Osaka, Japan). The litters of newborn mice and their nursing mothers were placed in a hyperoxic (75% oxygen) chamber connected to an oxygen controller (ProOx P110; BioSpherix, Parish, NY, USA) from postnatal day (P)7 to P12 (Phase I: vaso-obliteration). At P12, the mice were returned to room air with a normal oxygen content and received a single intravitreal injection of <b>31</b> (3 Î¼g/Î¼L in DMSO) or an equivalent volume of DMSO. Uninjected contralateral eyes were served as controls. At P17, after 5 days of exposure to room air, the mice were sacrificed, and both eyes were harvested for the analysis of the retinal vasculature (Phase II; neovascularization). Underdeveloped neonatal mice with weights less than 6 g at P17 were excluded. In Phase I, hyperoxia inhibits central vessel growth in the retina and causes significant vessel regression; in Phase II, hypoxia enhances the expression of angiogenic factors, such as VEGF, triggering pathological neovascularization, which reaches a maximum at P17.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Quantification of Retinal Neovascularization</h3><div class="NLM_p last">The eyes were enucleated and fixed overnight in 4% paraformaldehyde. The retinas were then dissected and stained overnight at 4 Â°C with Alexa Fluor 594-conjugated Griffonia Bandeiraea Simplicifolia isolectin B4 (IB4, 1:100 dilution; Invitrogen, Carlsbad, CA, USA). The retinas were rinsed three times with PBS, flat-mounted on microscope slides, and imaged using a fluorescence microscope (Olympus, Tokyo, Japan); the exposure and gain were kept constant for all samples. In each image, the number of pixels of preretinal neovascular tufts was determined using ImageJ software (National Institutes of Health, Bethesda, MD, USA) and compared with the total number of pixels in the entire retinal area.</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Solubility Analysis</h3><div class="NLM_p last">The solubility of compound <b>31</b> was measured using the pH-metric CheqSol technique<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> (Sirius Analytical Instruments Ltd.). Experiments were performed in 0.15 M KCl solution under a nitrogen atmosphere at 25 Â°C and titrated using standardized 0.5 M HCl and 0.5 M KOH solutions.</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> KINOMEscan</h3><div class="NLM_p last">The kinase profile of <b>31</b> was evaluated using DiscoverX KINOMEscan as previously described.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Binding affinity of compound <b>31</b> at 10 Î¼M was evaluated against 468 kinase panels. The binding interactions were calculated using the following equation. % Ctrl calculation = 100 Ã (test compound signal â positive control signal)/(negative control signal â positive control signal), where negative control is DMSO and positive control is the control compound.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Metabolic Stability</h3><div class="NLM_p last">To the mix buffer [0.1 M phosphate buffer (182 Î¼L, pH 7.4)] was added NADPH-regenerating system solution A followed by NADPH-regenerating system solution B. A stock solution of <b>31</b> (1 Î¼L, 200 Î¼M) was added, and the mixture was prewarmed to 37 Â°C for 10 min. Pooled liver microsomes (5 Î¼L, prewarmed in a 37 Â°C water bath before use) were added. At selected time points (0 and 30 min), aliquots (30 Î¼L) were withdrawn from the tube, and cold acetonitrile (120 Î¼L) containing an internal standard (chlorpromazine) was added to stop the reaction. The samples were centrifuged at 14,000 rpm for 10 min at 4 Â°C. The supernatant (30 Î¼L) was withdrawn and transferred to a sample vial containing an insert. LCâMS/MS analysis was performed using an Agilent 1290 infinity II and AB SCIEX Triple Quad 6500 plus system. Chromatographic separation was performed by injecting 5 Î¼L of the sample onto a Phenomenex Luna C18 column (2 Ã 50 mm, 3 Î¼m). The flow conditions were 50% solvent A (water containing 0.1% formic acid) and 50% solvent B (acetonitrile containing 0.1% formic acid). The flow rate was 0.3 mL/min.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Plasma Stability</h3><div class="NLM_p last">The buffered plasma was prepared by mixing 0.1 M PBS and plasma in a ratio of 1:9. Buffed plasma (195 Î¼L) was prewarmed to 37 Â°C for 10 min, and stock solution of <b>31</b> (5 Î¼L, 40 Î¼M) was added. At selected time points (0, 120 min), aliquots (30 Î¼L) were withdrawn from the tube and cold acetonitrile (120 Î¼L) containing an internal standard (chlorpromazine) was added to stop reaction. The samples were centrifuged at 14,000 rpm for 10 min at 4 Â°C. The supernatant (30 Î¼L) was withdrawn and transferred to a sample vial with the insert. LCâMS/MS analysis was performed on an Agilent 1290 infinity II and AB SCIEX Triple Quad 6500 plus system. Chromatographic separation was performed by injecting 5 Î¼L of the sample onto a Phenomenex Luna C18 (2 Ã 50 mm, 3 Î¼m) column. The flow conditions were 50% solvent A (water containing 0.1% formic acid) and 50% solvent B (acetonitrile containing 0.1% formic acid). The flow rate was 0.3 mL/min.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Statistics</h3><div class="NLM_p last">For the CNV animal model, the experimental results obtained in the experiment were expressed as means Â± SD and were tested using GraphPad Prism. The ShapiroâWilk normality test was performed for all the data. When the normal distribution was followed, one-way analysis of variance (ANOVA) was performed. Additionally, Tukeyâs multiple comparison test was performed to determine the test group with a significant difference from the control group (excipient group). If not, the KruskalâWallis test was performed, and a post hoc test was performed with Dunnâs multiple comparisons test (significance level: 5 and 1% on both sides). For the OIR animal model, data were presented as the mean Â± SEM, and statistical significance was calculated using unpaired Studentâs <i>t</i>-test. All the other data were presented as means Â± SD for at least two independently performed experiments. Statistical significance was determined by ANOVA using Dunnettâs test (two-sided).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01965" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01965?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01965</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Selective index of all the final target compounds, IC<sub>50</sub> graphs for tube formation and cell viability of <b>31</b>, VEGFR-2 kinase activity of <b>31</b>, DiscoverX KINOMEscan profiling of <b>31</b>, experimental procedures and spectroscopic data for all new compounds, and HRMS and HPLC analysis of the biologically tested compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">DiscoverX KINOMEscan profiling of <b>31</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf">jm0c01965_si_001.pdf (12.2 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_002.csv">jm0c01965_si_002.csv (2.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_003.csv">jm0c01965_si_003.csv (8.68 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01965" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sang Kook Lee</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4306-7024" title="Orcid link">http://orcid.org/0000-0002-4306-7024</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#93e0f8fff6f6a5a2d3e0fde6bdf2f0bdf8e1"><span class="__cf_email__" data-cfemail="b9cad2d5dcdc8f88f9cad7cc97d8da97d2cb">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanghee Kim</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9125-9541" title="Orcid link">http://orcid.org/0000-0001-9125-9541</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#58283d3636333135182b362d76393b76332a"><span class="__cf_email__" data-cfemail="19697c7777727074596a776c37787a37726b">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donghwa Kim</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1425-213X" title="Orcid link">http://orcid.org/0000-0003-1425-213X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sang Won Choi</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jihee Cho</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1814-7794" title="Orcid link">http://orcid.org/0000-0002-1814-7794</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jae-Hui Been</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyoungsun Choi</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhe Jiang</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaeho Han</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy, Seoul National University, Seoul 08826, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jedo Oh</span> - <span class="hlFld-Affiliation affiliation">Hana
Pharmaceutical Co., Pangyo 13486, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changmin Park</span> - <span class="hlFld-Affiliation affiliation">Hana
Pharmaceutical Co., Pangyo 13486, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soongyu Choi</span> - <span class="hlFld-Affiliation affiliation">Hana
Pharmaceutical Co., Pangyo 13486, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Songyi Seo</span> - <span class="hlFld-Affiliation affiliation">Department
of Global Innovative Drug, Graduate School of Chung-Ang University,
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Koung Li Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Global Innovative Drug, Graduate School of Chung-Ang University,
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wonhee Suh</span> - <span class="hlFld-Affiliation affiliation">Department
of Global Innovative Drug, Graduate School of Chung-Ang University,
College of Pharmacy, Chung-Ang University, Seoul 06974, Korea</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5811-0833" title="Orcid link">http://orcid.org/0000-0001-5811-0833</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.K. and S.W.C. contributed equally to this work. All the authors have approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87056" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87056" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI18C1371).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AMD</td><td class="NLM_def"><p class="first last">age-related macular degeneration</p></td></tr><tr><td class="NLM_term">ANGPT2</td><td class="NLM_def"><p class="first last">angiopoietin-2</p></td></tr><tr><td class="NLM_term">ARPE-19</td><td class="NLM_def"><p class="first last">adult retinal pigment epithelial cell line-19</p></td></tr><tr><td class="NLM_term">CNV</td><td class="NLM_def"><p class="first last">choroidal neovascularization</p></td></tr><tr><td class="NLM_term">CTF</td><td class="NLM_def"><p class="first last">corrected total fluorescence</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">diabetic macular edema</p></td></tr><tr><td class="NLM_term">DMEM/F-12</td><td class="NLM_def"><p class="first last">Dulbeccoâs modified Eagleâs medium/nutrient mixture F-12</p></td></tr><tr><td class="NLM_term">EBM</td><td class="NLM_def"><p class="first last">endothelial basal medium</p></td></tr><tr><td class="NLM_term">EGM-2</td><td class="NLM_def"><p class="first last">endothelial cell growth medium-2</p></td></tr><tr><td class="NLM_term">ERG</td><td class="NLM_def"><p class="first last">electroretinogram</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FES</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase Fes/Fps</p></td></tr><tr><td class="NLM_term">FTIR</td><td class="NLM_def"><p class="first last">Fourier-transform infrared</p></td></tr><tr><td class="NLM_term">FYN</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase Fyn</p></td></tr><tr><td class="NLM_term">HRMECs</td><td class="NLM_def"><p class="first last">human retinal microvascular endothelial cells</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">HUVECs</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">IL-1Î²</td><td class="NLM_def"><p class="first last">interleukin 1 beta</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">OIR</td><td class="NLM_def"><p class="first last">oxygen-induced retinopathy</p></td></tr><tr><td class="NLM_term">DR</td><td class="NLM_def"><p class="first last">proliferative diabetic retinopathy</p></td></tr><tr><td class="NLM_term">PI3KCA</td><td class="NLM_def"><p class="first last">phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</p></td></tr><tr><td class="NLM_term">PI3KR1</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3-kinase regulatory subunit alpha</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">polyvinylidene difluoride</p></td></tr><tr><td class="NLM_term">ROP</td><td class="NLM_def"><p class="first last">retinopathy of prematurity</p></td></tr><tr><td class="NLM_term">STAT5A</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 5A</p></td></tr><tr><td class="NLM_term">STAT5B</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 5B</p></td></tr><tr><td class="NLM_term"><i>t</i>-BuOH</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl alcohol</p></td></tr><tr><td class="NLM_term">TBST</td><td class="NLM_def"><p class="first last">tris-buffered saline containing 0.1% Tween-20</p></td></tr><tr><td class="NLM_term">TEK</td><td class="NLM_def"><p class="first last">TEK receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TGFÎ²1</td><td class="NLM_def"><p class="first last">transforming growth factor beta 1</p></td></tr><tr><td class="NLM_term">Tie2</td><td class="NLM_def"><p class="first last">tunica interna endothelial cell kinase 2</p></td></tr><tr><td class="NLM_term">TIMPs</td><td class="NLM_def"><p class="first last">tissue inhibitors of metalloproteinases</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fallah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghinia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahroba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidari, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molavi, O.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Angiogenesis Molecular Pathways in Angiogenesis-Dependent Diseases</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">775</span>â <span class="NLM_lpage">785</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.biopha.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30554116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaqur3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=775-785&author=A.+Fallahauthor=A.+Sadeghiniaauthor=H.+Kahrobaauthor=A.+Samadiauthor=H.+R.+Heidariauthor=B.+Bradaranauthor=S.+Zeinaliauthor=O.+Molavi&title=Therapeutic+Targeting+of+Angiogenesis+Molecular+Pathways+in+Angiogenesis-Dependent+Diseases&doi=10.1016%2Fj.biopha.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases</span></div><div class="casAuthors">Fallah, Asghar; Sadeghinia, Ali; Kahroba, Houman; Samadi, Amin; Heidari, Hamid Reza; Bradaran, Behzad; Zeinali, Sirous; Molavi, Ommoleila</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a crit. step in the progression of almost all human malignancies and some other life-threatening diseases.  Anti-angiogenic therapy is a novel and effective approach for treatment of angiogenesis-dependent diseases such as cancer, diabetic retinopathy, and age-related macular degeneration.  In this article, we will review the main strategies developed for anti-angiogenic therapies beside their clin. applications, the major challenges, and the latest advances in the development of anti-angiogenesis-based targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVyEzLjxY5rVg90H21EOLACvtfcHk0linRuLWz8KTBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaqur3M&md5=2ea25608fbf980eca0d5a39dcfe1d4be</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFallah%26aufirst%3DA.%26aulast%3DSadeghinia%26aufirst%3DA.%26aulast%3DKahroba%26aufirst%3DH.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DHeidari%26aufirst%3DH.%2BR.%26aulast%3DBradaran%26aufirst%3DB.%26aulast%3DZeinali%26aufirst%3DS.%26aulast%3DMolavi%26aufirst%3DO.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Angiogenesis%2520Molecular%2520Pathways%2520in%2520Angiogenesis-Dependent%2520Diseases%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D110%26spage%3D775%26epage%3D785%26doi%3D10.1016%2Fj.biopha.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breier, G.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis in Embryonic Development-A Review</span>. <i>Placenta</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">S11</span>â <span class="NLM_lpage">S15</span>, <span class="refDoi">Â DOI: 10.1053/plac.1999.0525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1053%2Fplac.1999.0525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10831116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=S11-S15&author=G.+Breier&title=Angiogenesis+in+Embryonic+Development-A+Review&doi=10.1053%2Fplac.1999.0525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fplac.1999.0525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fplac.1999.0525%26sid%3Dliteratum%253Aachs%26aulast%3DBreier%26aufirst%3DG.%26atitle%3DAngiogenesis%2520in%2520Embryonic%2520Development-A%2520Review%26jtitle%3DPlacenta%26date%3D2000%26volume%3D21%26spage%3DS11%26epage%3DS15%26doi%3D10.1053%2Fplac.1999.0525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felmeden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blann, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis: Basic Pathophysiology and Implications for Disease</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">586</span>â <span class="NLM_lpage">603</span>, <span class="refDoi">Â DOI: 10.1016/s0195-668x(02)00635-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2FS0195-668X%2802%2900635-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=12657217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlWgsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=586-603&author=D.+Felmedenauthor=A.+D.+Blannauthor=G.+Y.+H.+Lip&title=Angiogenesis%3A+Basic+Pathophysiology+and+Implications+for+Disease&doi=10.1016%2Fs0195-668x%2802%2900635-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: basic pathophysiology and implications for disease</span></div><div class="casAuthors">Felmeden, D. C.; Blann, A. D.; Lip, G. Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">586-603</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review on the basic mechanisms of blood vessel formation and the potential implications of angiogenesis in disease states.  Angiogenic growth factors such as vascular endothelial growth factor, fibroblast growth factor and angiopoietin are essential to angiogenesis.  The pathophysiol. consequences of the interactions between these growth factors and their receptors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbFnI9GZGMrVg90H21EOLACvtfcHk0linRuLWz8KTBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlWgsrc%253D&md5=db79253eb7359a436a4be2c8e5b15c40</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0195-668X%2802%2900635-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0195-668X%252802%252900635-8%26sid%3Dliteratum%253Aachs%26aulast%3DFelmeden%26aufirst%3DD.%26aulast%3DBlann%26aufirst%3DA.%2BD.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DAngiogenesis%253A%2520Basic%2520Pathophysiology%2520and%2520Implications%2520for%2520Disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2003%26volume%3D24%26spage%3D586%26epage%3D603%26doi%3D10.1016%2Fs0195-668x%2802%2900635-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, K. C.</span></span> <span> </span><span class="NLM_article-title">COX-2, VEGF and Tumor Angiogenesis</span>. <i>Surgeon</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1016/s1479-666x(09)80042-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2FS1479-666X%2809%2980042-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19580182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD1MvmvVSiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=174-180&author=D.+P.+Toomeyauthor=J.+F.+Murphyauthor=K.+C.+Conlon&title=COX-2%2C+VEGF+and+Tumor+Angiogenesis&doi=10.1016%2Fs1479-666x%2809%2980042-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">COX-2, VEGF and tumour angiogenesis</span></div><div class="casAuthors">Toomey D P; Murphy J F; Conlon K C</div><div class="citationInfo"><span class="NLM_cas:title">The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">174-80</span>
        ISSN:<span class="NLM_cas:issn">1479-666X</span>.
    </div><div class="casAbstract">Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer.  Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis.  Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target.  Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells.  While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7pKC8rIEEEudfST00W0BcfW6udTcc2eafwl9C3QAoGrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvmvVSiug%253D%253D&md5=5a4b0b68e3d3dc298f6c37d885152483</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1479-666X%2809%2980042-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1479-666X%252809%252980042-5%26sid%3Dliteratum%253Aachs%26aulast%3DToomey%26aufirst%3DD.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BF.%26aulast%3DConlon%26aufirst%3DK.%2BC.%26atitle%3DCOX-2%252C%2520VEGF%2520and%2520Tumor%2520Angiogenesis%26jtitle%3DSurgeon%26date%3D2009%26volume%3D7%26spage%3D174%26epage%3D180%26doi%3D10.1016%2Fs1479-666x%2809%2980042-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loukovaara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robciuc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holopainen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liinamaa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukkonen, K.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jauhiainen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keski-Oja, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immonen, I.</span></span> <span> </span><span class="NLM_article-title">Ang-2 Upregulation Correlates with Increased Levels of MMP-9, VEGF, EPI, and TGFÎ²1 in Diabetic Eyes Undergoing Vitrectomy</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1111/j.1755-3768.2012.02473.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.1755-3768.2012.02473.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23106921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSnsr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=531-539&author=S.+Loukovaaraauthor=A.+Robciucauthor=J.+M.+Holopainenauthor=K.+Lehtiauthor=T.+Pessiauthor=J.+Liinamaaauthor=K.-T.+Kukkonenauthor=M.+Jauhiainenauthor=K.+Koliauthor=J.+Keski-Ojaauthor=I.+Immonen&title=Ang-2+Upregulation+Correlates+with+Increased+Levels+of+MMP-9%2C+VEGF%2C+EPI%2C+and+TGF%CE%B21+in+Diabetic+Eyes+Undergoing+Vitrectomy&doi=10.1111%2Fj.1755-3768.2012.02473.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFÎ²1 in diabetic eyes undergoing vitrectomy</span></div><div class="casAuthors">Loukovaara, Sirpa; Robeiuc, Alexandra; Holopainen, Juha M.; Lehti, Kaisa; Pessi, Timo; Liinamaa, Johanna; Kukkonen, Kirsti-Tiina; Jauhiainen, Matti; Koli, Katri; Keski-Oja, Jorma; Immonen, Ilkka</div><div class="citationInfo"><span class="NLM_cas:title">Acta Ophthalmologica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-539</span>CODEN:
                <span class="NLM_cas:coden">AOOUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1755-375X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Purpose: Angiogenesis in diabetic retinopathy (DR) is a multifactorial process regulated by hypoxia-induced growth factors and inflammatory cytokines.  In addn. to the angiogenic switch, the proteolytic processing and altered synthesis of the extracellular matrix are crit. steps in this disease.  This study was performed to evaluate the levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 (MMP-2 and MMP-9), angiopoietin-1 and angiopoietin-2 (Ang-1 and Ang-2), vascular endothelial growth factor (VEGF), erythropoietin (EPO) and transforming growth factor-Î²1 (totalTGFÎ²1) in the vitreous of diabetic eyes undergoing vitrectomy compared with control eyes operated because of macular hole or pucker.  Methods: Prospective consecutive controlled observational study performed in the unit of vitreoretinal surgery in Finland during the years 2006-2008.  Vitreous samples were collected before the start of the conventional 3-ppp vitrectomy.  Vitreous MMP-2 and MMP-9, Ang-1 and Ang-2, VEGF, EPO and TGFÎ²1 concns. were measured from 69 patients with Type 1 or 2 diabetes and 40 controls.  Results: Comparison of eyes with DR with controls revealed that the mean vitreous concns. of proMMP-2(p = 0.0015), totalMMP-2 (p = 0.0011), proMMP-9(p = 0.00001), total-MMP-9 (p < 0.00001), Ang-2 (p < 0.00001), VEGF (p < 0.00001), EPO (p < 0.00001) and totalTGFÎ²1 (p = 0.000026) were significantly higher in the former group.  A multivariate logistic regression anal. suggested intravitreal Ang-2 concn. being the key marker of PDR (p = 0.00025) (OR = 1507.9).  Conclusion: The main new finding is that the intravitreal concns. of Ang-2 correlated significantly with MMP-9, VEGF, EPO and TGFÎ²1 levels in diabetic eyes undergoing vitrectomy.  Thus, these factors could promote retinal angiogenesis synergistically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKdKt0TSujbVg90H21EOLACvtfcHk0lhIUJs2teExQw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSnsr%252FN&md5=68b4eb5a8a09de9943fe13f0161daa77</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2012.02473.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2012.02473.x%26sid%3Dliteratum%253Aachs%26aulast%3DLoukovaara%26aufirst%3DS.%26aulast%3DRobciuc%26aufirst%3DA.%26aulast%3DHolopainen%26aufirst%3DJ.%2BM.%26aulast%3DLehti%26aufirst%3DK.%26aulast%3DPessi%26aufirst%3DT.%26aulast%3DLiinamaa%26aufirst%3DJ.%26aulast%3DKukkonen%26aufirst%3DK.-T.%26aulast%3DJauhiainen%26aufirst%3DM.%26aulast%3DKoli%26aufirst%3DK.%26aulast%3DKeski-Oja%26aufirst%3DJ.%26aulast%3DImmonen%26aufirst%3DI.%26atitle%3DAng-2%2520Upregulation%2520Correlates%2520with%2520Increased%2520Levels%2520of%2520MMP-9%252C%2520VEGF%252C%2520EPI%252C%2520and%2520TGF%25CE%25B21%2520in%2520Diabetic%2520Eyes%2520Undergoing%2520Vitrectomy%26jtitle%3DActa%2520Ophthalmol.%26date%3D2013%26volume%3D91%26spage%3D531%26epage%3D539%26doi%3D10.1111%2Fj.1755-3768.2012.02473.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duh, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, A. W.</span></span> <span> </span><span class="NLM_article-title">Diabetic Retinopathy: Current Understanding, Mechanisms, and Treatment Strategies</span>. <i>JCI insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e93751</span> <span class="refDoi">Â DOI: 10.1172/jci.insight.93751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1172%2Fjci.insight.93751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28724805" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=E.+J.+Duhauthor=J.+K.+Sunauthor=A.+W.+Stitt&title=Diabetic+Retinopathy%3A+Current+Understanding%2C+Mechanisms%2C+and+Treatment+Strategies&doi=10.1172%2Fjci.insight.93751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.93751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.93751%26sid%3Dliteratum%253Aachs%26aulast%3DDuh%26aufirst%3DE.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%2BK.%26aulast%3DStitt%26aufirst%3DA.%2BW.%26atitle%3DDiabetic%2520Retinopathy%253A%2520Current%2520Understanding%252C%2520Mechanisms%252C%2520and%2520Treatment%2520Strategies%26jtitle%3DJCI%2520insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.93751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yau, J. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamoureux, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauslund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikram, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayurasakorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHare, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tielsch, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Global Prevalence and Major Risk Factors of Diabetic Retinopathy</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.2337/dc11-1909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdc11-1909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=22301125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC38rgt1ajtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=556-564&author=J.+W.+Y.+Yauauthor=S.+L.+Rogersauthor=R.+Kawasakiauthor=E.+L.+Lamoureuxauthor=J.+W.+Kowalskiauthor=T.+Bekauthor=S.-J.+Chenauthor=J.+M.+Dekkerauthor=A.+Fletcherauthor=J.+Grauslundauthor=S.+Haffnerauthor=R.+F.+Hammanauthor=M.+K.+Ikramauthor=T.+Kayamaauthor=B.+E.+K.+Kleinauthor=R.+Kleinauthor=S.+Krishnaiahauthor=K.+Mayurasakornauthor=J.+P.+O%E2%80%99Hareauthor=T.+J.+Orchardauthor=M.+Portaauthor=M.+Remaauthor=M.+S.+Royauthor=T.+Sharmaauthor=J.+Shawauthor=H.+Taylorauthor=J.+M.+Tielschauthor=R.+Varmaauthor=J.+J.+Wangauthor=N.+Wangauthor=S.+Westauthor=L.+Xuauthor=M.+Yasudaauthor=X.+Zhangauthor=P.+Mitchellauthor=T.+Y.+Wong&title=Global+Prevalence+and+Major+Risk+Factors+of+Diabetic+Retinopathy&doi=10.2337%2Fdc11-1909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Global prevalence and major risk factors of diabetic retinopathy</span></div><div class="casAuthors">Yau Joanne W Y; Rogers Sophie L; Kawasaki Ryo; Lamoureux Ecosse L; Kowalski Jonathan W; Bek Toke; Chen Shih-Jen; Dekker Jacqueline M; Fletcher Astrid; Grauslund Jakob; Haffner Steven; Hamman Richard F; Ikram M Kamran; Kayama Takamasa; Klein Barbara E K; Klein Ronald; Krishnaiah Sannapaneni; Mayurasakorn Korapat; O'Hare Joseph P; Orchard Trevor J; Porta Massimo; Rema Mohan; Roy Monique S; Sharma Tarun; Shaw Jonathan; Taylor Hugh; Tielsch James M; Varma Rohit; Wang Jie Jin; Wang Ningli; West Sheila; Xu Liang; Yasuda Miho; Zhang Xinzhi; Mitchell Paul; Wong Tien Y</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">556-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes.  RESEARCH DESIGN AND METHODS:  A pooled analysis using individual participant data from population-based studies around the world was performed.  A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs.  Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors.  Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20-79 years.  RESULTS:  A total of 35 studies (1980-2008) provided data from 22,896 individuals with diabetes.  The overall prevalence was 34.6% (95% CI 34.5-34.8) for any DR, 6.96% (6.87-7.04) for proliferative DR, 6.81% (6.74-6.89) for diabetic macular edema, and 10.2% (10.1-10.3) for VTDR.  All DR prevalence end points increased with diabetes duration, hemoglobin A(1c), and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes.  CONCLUSIONS:  There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide.  Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR.  These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence.  This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROE9nlduqLo0loaUqgkFHkfW6udTcc2eY8nCfgQ7p0Ibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgt1ajtQ%253D%253D&md5=91c2be562a7b55dee1fde96a13f7ddcd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2337%2Fdc11-1909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-1909%26sid%3Dliteratum%253Aachs%26aulast%3DYau%26aufirst%3DJ.%2BW.%2BY.%26aulast%3DRogers%26aufirst%3DS.%2BL.%26aulast%3DKawasaki%26aufirst%3DR.%26aulast%3DLamoureux%26aufirst%3DE.%2BL.%26aulast%3DKowalski%26aufirst%3DJ.%2BW.%26aulast%3DBek%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DDekker%26aufirst%3DJ.%2BM.%26aulast%3DFletcher%26aufirst%3DA.%26aulast%3DGrauslund%26aufirst%3DJ.%26aulast%3DHaffner%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DR.%2BF.%26aulast%3DIkram%26aufirst%3DM.%2BK.%26aulast%3DKayama%26aufirst%3DT.%26aulast%3DKlein%26aufirst%3DB.%2BE.%2BK.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DKrishnaiah%26aufirst%3DS.%26aulast%3DMayurasakorn%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DJ.%2BP.%26aulast%3DOrchard%26aufirst%3DT.%2BJ.%26aulast%3DPorta%26aufirst%3DM.%26aulast%3DRema%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DM.%2BS.%26aulast%3DSharma%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DH.%26aulast%3DTielsch%26aufirst%3DJ.%2BM.%26aulast%3DVarma%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DGlobal%2520Prevalence%2520and%2520Major%2520Risk%2520Factors%2520of%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%2520Care%26date%3D2012%26volume%3D35%26spage%3D556%26epage%3D564%26doi%3D10.2337%2Fdc11-1909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolanska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, R.</span></span> <span> </span><span class="NLM_article-title">Retinopathy in Diabetes</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>771</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1007/978-1-4614-5441-0_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1007%2F978-1-4614-5441-0_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23393674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC3szmsleltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=771&publication_year=2012&pages=88-106&author=J.+M.+Tarrauthor=K.+Kaulauthor=K.+Wolanskaauthor=E.+M.+Kohnerauthor=R.+Chibber&title=Retinopathy+in+Diabetes&doi=10.1007%2F978-1-4614-5441-0_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Retinopathy in diabetes</span></div><div class="casAuthors">Tarr Joanna M; Kaul Kirti; Wolanska Katarzyna; Kohner Eva M; Chibber Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Advances in experimental medicine and biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">771</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88-106</span>
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    </div><div class="casAbstract">With the incidence, and prevalence of diabetes mellitus increasing worldwide, diabetic retinopathy is expected to reach epidemic proportions.  The aim of this chapter is to introduce diabetic retinopathy, a leading cause of blindness in people of the working age.  The clinical course of retinopathy, anatomical changes, its pathogenesis and current treatment are described, followed by an overview of the emerging drug therapies for the potential treatment of this sight-threatening complication of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeDurHW-hMkxKDYG3bNImrfW6udTcc2eY8nCfgQ7p0Ibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmsleltQ%253D%253D&md5=95dcbf8e2b8ad9bb132c7c573b1a4f75</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-5441-0_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-5441-0_10%26sid%3Dliteratum%253Aachs%26aulast%3DTarr%26aufirst%3DJ.%2BM.%26aulast%3DKaul%26aufirst%3DK.%26aulast%3DWolanska%26aufirst%3DK.%26aulast%3DKohner%26aufirst%3DE.%2BM.%26aulast%3DChibber%26aufirst%3DR.%26atitle%3DRetinopathy%2520in%2520Diabetes%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D771%26spage%3D88%26epage%3D106%26doi%3D10.1007%2F978-1-4614-5441-0_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris
Nwanyanwu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. D.</span></span> <span> </span><span class="NLM_article-title">Predicting Development of Proliferative Diabetic Retinopathy</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1562</span>â <span class="NLM_lpage">1568</span>, <span class="refDoi">Â DOI: 10.2337/dc12-0790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdc12-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23275374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC3s3lsVSmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=1562-1568&author=K.+Harris%0ANwanyanwuauthor=N.+Talwarauthor=T.+W.+Gardnerauthor=J.+S.+Wrobelauthor=W.+H.+Hermanauthor=J.+D.+Stein&title=Predicting+Development+of+Proliferative+Diabetic+Retinopathy&doi=10.2337%2Fdc12-0790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting development of proliferative diabetic retinopathy</span></div><div class="casAuthors">Harris Nwanyanwu Kristen; Talwar Nidhi; Gardner Thomas W; Wrobel James S; Herman William H; Stein Joshua D</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Identifying individuals most at risk for diabetic retinopathy progression and intervening early can limit vision loss and reduce the costs associated with managing more advanced disease.  The purpose of this study was to identify factors associated with progression from nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR).  RESEARCH DESIGN AND METHODS:  This was a retrospective cohort analysis using a claims database of all eye care recipients age â¥ 30 years enrolled in a large managed-care network from 2001 to 2009.  Individuals with newly diagnosed NPDR were followed longitudinally.  Multivariable Cox regression analyses identified factors associated with progression to PDR.  Three- and five-year probabilities of retinopathy progression were determined.  RESULTS:  Among the 4,617 enrollees with incident NPDR, 307 (6.6%) developed PDR.  After adjustment for confounders, every 1-point increase in HbA1c was associated with a 14% (adjusted hazard ratio 1.14 [95% CI 1.07-1.21]) increased hazard of developing PDR.  Those with nonhealing ulcers had a 54% (1.54 [1.15-2.07]) increased hazard of progressing to PDR, and enrollees with nephropathy had a marginally significant increased hazard of progressing to PDR (1.29 [0.99-1.67]) relative to those without these conditions.  The 5-year probability of progression for low-risk individuals with NPDR was 5% (range 2-8) and for high-risk patients was 38% (14-55).  CONCLUSIONS:  Along with glycemic control, nonophthalmologic manifestations of diabetes mellitus (e.g., nephropathy and nonhealing ulcers) are associated with an increased risk of diabetic retinopathy progression.  Our retinopathy progression risk score can help clinicians stratify patients who are most at risk for disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxCnbyOtQBVuQ4Pl9hzjQhfW6udTcc2eY8nCfgQ7p0Ibntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3lsVSmsA%253D%253D&md5=65e383883cd0f5264f0ad4a054508cd1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2337%2Fdc12-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-0790%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%2BNwanyanwu%26aufirst%3DK.%26aulast%3DTalwar%26aufirst%3DN.%26aulast%3DGardner%26aufirst%3DT.%2BW.%26aulast%3DWrobel%26aufirst%3DJ.%2BS.%26aulast%3DHerman%26aufirst%3DW.%2BH.%26aulast%3DStein%26aufirst%3DJ.%2BD.%26atitle%3DPredicting%2520Development%2520of%2520Proliferative%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D1562%26epage%3D1568%26doi%3D10.2337%2Fdc12-0790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blodi, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellarin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampol, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, And Ranibizumab</span>. <i>JAMA Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">558</span>â <span class="NLM_lpage">568</span>, <span class="refDoi">Â DOI: 10.1001/jamaophthalmol.2017.0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1001%2Fjamaophthalmol.2017.0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28448655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC1crhslejtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=558-568&author=S.+B.+Bresslerauthor=D.+Liuauthor=A.+R.+Glassmanauthor=B.+A.+Blodiauthor=A.+A.+Castellarinauthor=L.+M.+Jampolauthor=P.+L.+Kaufmanauthor=M.+Meliaauthor=H.+Singhauthor=J.+A.+Wells&title=Change+in+Diabetic+Retinopathy+Through+2+Years%3A+Secondary+Analysis+of+a+Randomized+Clinical+Trial+Comparing+Aflibercept%2C+Bevacizumab%2C+And+Ranibizumab&doi=10.1001%2Fjamaophthalmol.2017.0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab</span></div><div class="casAuthors">Bressler Susan B; Liu Danni; Glassman Adam R; Melia Michele; Blodi Barbara A; Castellarin Alessandro A; Jampol Lee M; Kaufman Paul L; Singh Harinderjit; Wells John A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA ophthalmology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">558-568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening.  It is unknown whether these effects differ across anti-VEGF agents.  Objective:  To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME.  Design, Setting, and Participants:  Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab.  Retinopathy improvement and worsening were determined during 2 years of treatment.  Participants were randomized in 2012 through 2013, and the trial concluded on September 23, 2015.  Interventions:  Random assignment to aflibercept, 2.0 mg; bevacizumab, 1.25 mg; ranibizumab, 0.3 mg, up to every 4 weeks through 2 years following a retreatment protocol.  Main Outcomes and Measures:  Percentages with retinopathy improvement at 1 and 2 years and cumulative probabilities for retinopathy worsening through 2-year without adjustment for multiple outcomes.  Results:  A total of 650 participants (495 [76.2%] nonproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were women and mean (SD) age was 61 (10) years; 425 (65.4%) were white.  At 1 year, among 423 NPDR eyes, 44 of 141 (31.2%) treated with aflibercept, 29 of 131 (22.1%) with bevacizumab, and 57 of 151 (37.7%) with ranibizumab had improvement of DR severity (adjusted difference: 11.7%; 95% CI, 2.9% to 20.6%; P = .004 for aflibercept vs bevacizumab; 8.9%; 95% CI, 1.7% to 16.1%; P = .01 for ranibizumab vs bevacizumab; and 2.9%; 95% CI, -5.7% to 11.4%; P = .51 for aflibercept vs ranibizumab).  At 2 years, 33 eyes (24.8%) in the aflibercept group, 25 eyes (22.1%) in the bevacizumab group, and 40 eyes (31.0%) in the ranibizumab group had DR improvement; no treatment group differences were identified.  For 93 eyes with PDR at baseline, 1-year improvement rates were 75.9% for aflibercept, 31.4% for bevacizumab, and 55.2% for ranibizumab (adjusted difference: 50.4%; 95% CI, 26.8% to 74.0%; P < .001 for aflibercept vs bevacizumab; 20.4%; 95% CI, -3.1% to 44.0%; P = .09 for ranibizumab vs bevacizumab; and 30.0%; 95% CI, 4.4% to 55.6%; P = .02 for aflibercept vs ranibizumab).  These rates and treatment group differences appeared to be maintained at 2 years.  Despite the reduced numbers of injections in the second year, 66 (59.5%) of NPDR and 28 (70.0%) of PDR eyes that manifested improvement at 1 year maintained improvement at 2 years.  Two-year cumulative rates for retinopathy worsening ranged from 7.1% to 10.2% and 17.2% to 26.4% among anti-VEGF groups for NPDR and PDR eyes, respectively.  No statistically significant treatment differences were noted.  Conclusions and Relevance:  At 1 and 2 years, eyes with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR severity.  Less improvement was demonstrated with bevacizumab at 1 year than with aflibercept or ranibizumab.  Aflibercept was associated with more improvement at 1 and 2 years in the smaller subgroup of participants with PDR at baseline.  All 3 anti-VEGF treatments were associated with low rates of DR worsening.  These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRylYUBtyUvJpotVjB3IRIyfW6udTcc2ea1OwW1NCjlIbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhslejtQ%253D%253D&md5=78ba6d358e9e0f94e1f14fa0e4aab1bc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1001%2Fjamaophthalmol.2017.0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaophthalmol.2017.0821%26sid%3Dliteratum%253Aachs%26aulast%3DBressler%26aufirst%3DS.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DGlassman%26aufirst%3DA.%2BR.%26aulast%3DBlodi%26aufirst%3DB.%2BA.%26aulast%3DCastellarin%26aufirst%3DA.%2BA.%26aulast%3DJampol%26aufirst%3DL.%2BM.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26aulast%3DMelia%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DChange%2520in%2520Diabetic%2520Retinopathy%2520Through%25202%2520Years%253A%2520Secondary%2520Analysis%2520of%2520a%2520Randomized%2520Clinical%2520Trial%2520Comparing%2520Aflibercept%252C%2520Bevacizumab%252C%2520And%2520Ranibizumab%26jtitle%3DJAMA%2520Ophthalmol.%26date%3D2017%26volume%3D135%26spage%3D558%26epage%3D568%26doi%3D10.1001%2Fjamaophthalmol.2017.0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span> <span> </span><span class="NLM_article-title">New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1066</span>â <span class="NLM_lpage">1071</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00281</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00281" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOrsb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1066-1071&author=S.+Yuauthor=J.+Ohauthor=F.+Liauthor=Y.+Kwonauthor=H.+Choauthor=J.+Shinauthor=S.+K.+Leeauthor=S.+Kim&title=New+Scaffold+for+Angiogenesis+Inhibitors+Discovered+by+Targeted+Chemical+Transformations+of+Wondonin+Natural+Products&doi=10.1021%2Facsmedchemlett.7b00281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products</span></div><div class="casAuthors">Yu, Shuai; Oh, Jedo; Li, Feng; Kwon, Yongseok; Cho, Hyunkyung; Shin, Jongheon; Lee, Sang Kook; Kim, Sanghee</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure of wondonin marine natural products was renovated to attain new drug-like scaffolds.  Wondonins have novel antiangiogenic properties without overt cytotoxicity.  However, the chem. instability and synthetic complexity of wondonins have hindered their development as a new type of antiangiogenesis agent.  Using a structure-based bioisosterism, the benzodioxole moiety was changed to benzothiazole, and the imidazole moiety was replaced by 1,2,3-triazole.  The authors' efforts resulted in a new scaffold with enhanced antiangiogenic activity and minimized cytotoxicity.  One compd. with this scaffold effectively inhibited hyaloid vessel formation in diabetic retinopathy mimic zebrafish model.  The biol. findings together suggested the potential of the scaffold as a lead structure for development of antiangiogenic drugs with novel functions and as a probe to elucidate new biol. mechanisms assocd. with angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpje8l61l36ELVg90H21EOLACvtfcHk0lit34J44PgRqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOrsb%252FF&md5=7ae303dfa823b91a4cb37b07a8968b65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00281%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DOh%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DS.%26atitle%3DNew%2520Scaffold%2520for%2520Angiogenesis%2520Inhibitors%2520Discovered%2520by%2520Targeted%2520Chemical%2520Transformations%2520of%2520Wondonin%2520Natural%2520Products%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1066%26epage%3D1071%26doi%3D10.1021%2Facsmedchemlett.7b00281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cifuentes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayupi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis-Barros, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata-Torres, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros-Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abarca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullian, C.</span></span> <span> </span><span class="NLM_article-title">Spectroscopic Studies of the Interaction of 3-(2-Thienyl)-[1,2,3]Triazolo[1,5-<i>a</i>] Pyridine with 2,6-Dimethyl-Î²-Cyclodextrin and <i>ct</i>DNA</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9760</span>â <span class="NLM_lpage">9767</span>, <span class="refDoi">Â DOI: 10.1039/c6ob01573e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1039%2FC6OB01573E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27714322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhs7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=9760-9767&author=T.+Cifuentesauthor=J.+Cayupiauthor=C.+Celis-Barrosauthor=G.+Zapata-Torresauthor=R.+Ballesterosauthor=R.+Ballesteros-Garridoauthor=B.+Abarcaauthor=C.+Jullian&title=Spectroscopic+Studies+of+the+Interaction+of+3-%282-Thienyl%29-%5B1%2C2%2C3%5DTriazolo%5B1%2C5-a%5D+Pyridine+with+2%2C6-Dimethyl-%CE%B2-Cyclodextrin+and+ctDNA&doi=10.1039%2Fc6ob01573e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Spectroscopic studies of the interaction of 3-(2-thienyl)-[1,2,3]triazolo[1,5-a]pyridine with 2,6-dimethyl-Î²-cyclodextrin and ctDNA</span></div><div class="casAuthors">Cifuentes, T.; Cayupi, J.; Celis-Barros, C.; Zapata-Torres, G.; Ballesteros, Rafael; Ballesteros-Garrido, Rafael; Abarca, B.; Jullian, C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9760-9767</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The inclusion complexation behavior of 3-(2-thienyl)-[1,2,3]triazolo[1,5-a] pyridine (TTP) with native Î²-cyclodextrin and derivatized cyclodextrins was investigated.  Stability consts. for complexes with 1 : 1 molar ratios were calcd. from phase soly. diagrams.  The solubilizing efficiency of the TTP inclusion complex is enhanced in the order of DMÎ²CD > HPÎ²CD > Î²CD.  The TTP-DMÎ²CD inclusion complex was further characterized in soln. by means of absorption, fluorescence, 2D NMR and mol. modeling methods.  The thermodn. studies indicate that the inclusion of TTP into the cyclodextrin cavity is mainly an enthalpy-driven process.  The 2D NMR studies revealed that the thienyl moiety of TTP is inserted into the CD cavity while the triazolopyridine protrudes the primary rim of the DMÎ²CD, which are in good agreement with docking results.  The fluorescence titrn. of TTP by ctDNA suggested that the quenching mechanism is a dynamic quenching procedure resulting from the temp. dependence of the TTP-ctDNA complex.  Thermodn. of the interaction revealed that the pos. values of ÎH and ÎS announced that the binding process was primarily driven by hydrophobic forces indicating that TTP interacts with ctDNA by means of the minor groove.  These results are in good agreement with docking expts. and iodide expts. which reinforce TTP's interactions in the minor groove.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcjmnylHoEt7Vg90H21EOLACvtfcHk0lit34J44PgRqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhs7vF&md5=7fdfba16bb6501d07b3fa77338ae62ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1039%2FC6OB01573E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB01573E%26sid%3Dliteratum%253Aachs%26aulast%3DCifuentes%26aufirst%3DT.%26aulast%3DCayupi%26aufirst%3DJ.%26aulast%3DCelis-Barros%26aufirst%3DC.%26aulast%3DZapata-Torres%26aufirst%3DG.%26aulast%3DBallesteros%26aufirst%3DR.%26aulast%3DBallesteros-Garrido%26aufirst%3DR.%26aulast%3DAbarca%26aufirst%3DB.%26aulast%3DJullian%26aufirst%3DC.%26atitle%3DSpectroscopic%2520Studies%2520of%2520the%2520Interaction%2520of%25203-%25282-Thienyl%2529-%255B1%252C2%252C3%255DTriazolo%255B1%252C5-a%255D%2520Pyridine%2520with%25202%252C6-Dimethyl-%25CE%25B2-Cyclodextrin%2520and%2520ctDNA%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D9760%26epage%3D9767%26doi%3D10.1039%2Fc6ob01573e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, A.</span></span> <span> </span><span class="NLM_article-title">Fluorescence Properties of 5-(5,6-Dimethoxybenzothiazol-2-yl)-2â²-deoxyuridine (d<sup>bt</sup>U) and Oligodeoxyribonucleotides Containing d<sup>bt</sup>U</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">6206</span>â <span class="NLM_lpage">6217</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.201100818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1002%2Fejoc.201100818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2gsbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=6206-6217&author=W.+Hiroseauthor=K.+Satoauthor=A.+Matsuda&title=Fluorescence+Properties+of+5-%285%2C6-Dimethoxybenzothiazol-2-yl%29-2%E2%80%B2-deoxyuridine+%28dbtU%29+and+Oligodeoxyribonucleotides+Containing+dbtU&doi=10.1002%2Fejoc.201100818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence Properties of 5-(5,6-Dimethoxybenzothiazol-2-yl)-2'-deoxyuridine (dbtU) and Oligodeoxyribonucleotides Containing dbtU</span></div><div class="casAuthors">Hirose, Wataru; Sato, Kousuke; Matsuda, Akira</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6206-6217, S6206/1-S6206/43</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We describe the synthesis and photo-phys. properties of 11 substituted 5-(benzothiazol-2-yl)-2'-deoxyuridine derivs. and oligodeoxyribonucleotides (ODNs) contg. 5-(5,6-dimethoxybenzothiazol-2-yl)-2'-deoxyuridine (dbtU), which was the strongest fluorescent deriv. among those prepd.  The fluorescence properties of dbtU itself and ODNs contg. dbtU show the same tendency of being weaker in both neutral and acidic soln. and stronger in basic soln.  The ODNs (15mer) contg. 16 combinations of 5'-XbtU-3' and 5'-btUY-3', where X, Y = A, T, G, or C, were synthesized, and their fluorescence intensity and quantum yield in basic soln. were compared.  On av., only the ODN with the 5'-GbtU-3' sequence shows a 7.9-fold lower fluorescence intensity than the other sequences.  Ab initio calcns. of 5'-GbtU-3' and 5'-btUG-3' as models under basic conditions suggest that the lower fluorescence of the ODN contg. the 5'-GbtU-3' sequence is caused by a wider overlap between stacked guanine (Gua) and btUra than that of the 5'-btUG-3' sequence and that the HOMO is delocalized not only on btUra but also on Gua.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6KEFkAz7xELVg90H21EOLACvtfcHk0lgSUp8HW09JLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2gsbvE&md5=fb8079bf06d7c4372e19ad6f344b0ea6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201100818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201100818%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DW.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DA.%26atitle%3DFluorescence%2520Properties%2520of%25205-%25285%252C6-Dimethoxybenzothiazol-2-yl%2529-2%25E2%2580%25B2-deoxyuridine%2520%2528dbtU%2529%2520and%2520Oligodeoxyribonucleotides%2520Containing%2520dbtU%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D6206%26epage%3D6217%26doi%3D10.1002%2Fejoc.201100818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaendler, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimar, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Racemic Ethanolamine Plasmalogen</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1996</i></span>,  <span class="NLM_fpage">1345</span>â <span class="NLM_lpage">1349</span>, <span class="refDoi">Â DOI: 10.1055/s-1996-4390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1055%2Fs-1996-4390" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1996&publication_year=1996&pages=1345-1349&author=H.+R.+Pfaendlerauthor=V.+Weimar&title=Synthesis+of+Racemic+Ethanolamine+Plasmalogen&doi=10.1055%2Fs-1996-4390"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1055%2Fs-1996-4390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1996-4390%26sid%3Dliteratum%253Aachs%26aulast%3DPfaendler%26aufirst%3DH.%2BR.%26aulast%3DWeimar%26aufirst%3DV.%26atitle%3DSynthesis%2520of%2520Racemic%2520Ethanolamine%2520Plasmalogen%26jtitle%3DSynthesis%26date%3D1996%26volume%3D1996%26spage%3D1345%26epage%3D1349%26doi%3D10.1055%2Fs-1996-4390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abhinand, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumya, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arya, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakaran, P. R.</span></span> <span> </span><span class="NLM_article-title">VEGF-A/VEGFR2 Signaling Network in Endothelial Cells Relevant to Angiogenesis</span>. <i>J. Cell Comm. Signal.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1007/s12079-016-0352-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1007%2Fs12079-016-0352-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27619687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC2szpslaqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=347-354&author=C.+S.+Abhinandauthor=R.+Rajuauthor=S.+J.+Soumyaauthor=P.+S.+Aryaauthor=P.+R.+Sudhakaran&title=VEGF-A%2FVEGFR2+Signaling+Network+in+Endothelial+Cells+Relevant+to+Angiogenesis&doi=10.1007%2Fs12079-016-0352-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis</span></div><div class="casAuthors">Abhinand Chandran S; Arya Prabha S; Sudhakaran Perumana R; Raju Rajesh; Soumya Sasikumar J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cell communication and signaling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-354</span>
        ISSN:<span class="NLM_cas:issn">1873-9601</span>.
    </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF-A) is essential for endothelial cell functions associated with angiogenesis.  Signal transduction networks initiated by VEGFA/VEGFR2, the most prominent ligand-receptor complex in the VEGF system, leads to endothelial cell proliferation, migration, survival and new vessel formation involved in angiogenesis.  Considering its biomedical importance, we have developed the first comprehensive map of endothelial cell-specific signaling events of VEGFA/VEGFR2 system pertaining to angiogenesis.  Screening over 20,000 published research articles and following the post-translational modification (PTM) and site specificity of VEGFR2, we have documented 240 proteins and their diverse PTM-dependent reactions involved in VEGFA/VEGFR2 signal transduction.  From the ligand-receptor complex, this map has been extended to the level of major transcriptionally regulated genes for which the signaling cascades leading to their transcription factors are reported.  We believe that this map would serve as a novel platform for reference, integration, and representation and more significantly, the progressive analysis of dynamic features of VEGF signaling in endothelial cells including their cross-talks with other ligand-receptor systems involved in angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa74p-KSP5he_Q9URG6Dx8fW6udTcc2ebNuNicb4H-Hrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szpslaqtg%253D%253D&md5=d00c7849b4004ab93903460e383ab846</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12079-016-0352-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12079-016-0352-8%26sid%3Dliteratum%253Aachs%26aulast%3DAbhinand%26aufirst%3DC.%2BS.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DSoumya%26aufirst%3DS.%2BJ.%26aulast%3DArya%26aufirst%3DP.%2BS.%26aulast%3DSudhakaran%26aufirst%3DP.%2BR.%26atitle%3DVEGF-A%252FVEGFR2%2520Signaling%2520Network%2520in%2520Endothelial%2520Cells%2520Relevant%2520to%2520Angiogenesis%26jtitle%3DJ.%2520Cell%2520Comm.%2520Signal.%26date%3D2016%26volume%3D10%26spage%3D347%26epage%3D354%26doi%3D10.1007%2Fs12079-016-0352-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamalice, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Boeuf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, J.</span></span> <span> </span><span class="NLM_article-title">Endothelial Cell Migration during Angiogenesis</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">782</span>â <span class="NLM_lpage">794</span>, <span class="refDoi">Â DOI: 10.1161/01.res.0000259593.07661.1e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1161%2F01.RES.0000259593.07661.1e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=17395884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlWmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=782-794&author=L.+Lamaliceauthor=F.+Le+Boeufauthor=J.+Huot&title=Endothelial+Cell+Migration+during+Angiogenesis&doi=10.1161%2F01.res.0000259593.07661.1e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial Cell Migration During Angiogenesis</span></div><div class="casAuthors">Lamalice, Laurent; Le Boeuf, Fabrice; Huot, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">782-794</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Endothelial cell migration is essential to angiogenesis.  This motile process is directionally regulated by chemotactic, haptotactic, and mechanotactic stimuli and further involves degrdn. of the extracellular matrix to enable progression of the migrating cells.  It requires the activation of several signaling pathways that converge on cytoskeletal remodeling.  Then, it follows a series of events in which the endothelial cells extend, contract, and throw their rear toward the front and progress forward.  The aim of this review is to give an integrative view of the signaling mechanisms that govern endothelial cell migration in the context of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB2etwgW2fV7Vg90H21EOLACvtfcHk0lgSUp8HW09JLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlWmsr4%253D&md5=0bfb1f8f86194eb66a8fc729fdaa43d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000259593.07661.1e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000259593.07661.1e%26sid%3Dliteratum%253Aachs%26aulast%3DLamalice%26aufirst%3DL.%26aulast%3DLe%2BBoeuf%26aufirst%3DF.%26aulast%3DHuot%26aufirst%3DJ.%26atitle%3DEndothelial%2520Cell%2520Migration%2520during%2520Angiogenesis%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D782%26epage%3D794%26doi%3D10.1161%2F01.res.0000259593.07661.1e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hykin, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I. A.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin Concentrations in Diabetic Retinopathy</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">480</span>â <span class="NLM_lpage">483</span>, <span class="refDoi">Â DOI: 10.1136/bjo.2004.049940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1136%2Fbjo.2004.049940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15774928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD2M7kt1SmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2005&pages=480-483&author=J.+I.+Patelauthor=P.+G.+Hykinauthor=Z.+J.+Gregorauthor=M.+Boultonauthor=I.+A.+Cree&title=Angiopoietin+Concentrations+in+Diabetic+Retinopathy&doi=10.1136%2Fbjo.2004.049940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin concentrations in diabetic retinopathy</span></div><div class="casAuthors">Patel J I; Hykin P G; Gregor Z J; Boulton M; Cree I A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">480-3</span>
        ISSN:<span class="NLM_cas:issn">0007-1161</span>.
    </div><div class="casAbstract">BACKGROUND/AIM:  Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models.  Although VEGF concentrations are elevated, there is little information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy.  METHODS:  Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy.  RESULTS:  Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml).  Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14 329 pg/ml).  For both macular hole and PDR patients angiopoietin 2 was below the limit of detection.  CONCLUSIONS:  Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO.  Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent.  The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO.  The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuk3hiGspp5Aqdek-gHSrIfW6udTcc2eYj75IQFh8wf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7kt1SmtA%253D%253D&md5=d82cff7ffcfdb2fdc3311b1ba5ec4990</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1136%2Fbjo.2004.049940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjo.2004.049940%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DJ.%2BI.%26aulast%3DHykin%26aufirst%3DP.%2BG.%26aulast%3DGregor%26aufirst%3DZ.%2BJ.%26aulast%3DBoulton%26aufirst%3DM.%26aulast%3DCree%26aufirst%3DI.%2BA.%26atitle%3DAngiopoietin%2520Concentrations%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2005%26volume%3D89%26spage%3D480%26epage%3D483%26doi%3D10.1136%2Fbjo.2004.049940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">vom Hagen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzizok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownlee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, U.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin-2 Causes Pericyte Dropout in the Normal Retina: Evidence for Involvement in Diabetic Retinopathy</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1104</span>â <span class="NLM_lpage">1110</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.53.4.1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdiabetes.53.4.1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15047628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFyqtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=1104-1110&author=H.-P.+Hammesauthor=J.+Linauthor=P.+Wagnerauthor=Y.+Fengauthor=F.+vom+Hagenauthor=T.+Krzizokauthor=O.+Rennerauthor=G.+Breierauthor=M.+Brownleeauthor=U.+Deutsch&title=Angiopoietin-2+Causes+Pericyte+Dropout+in+the+Normal+Retina%3A+Evidence+for+Involvement+in+Diabetic+Retinopathy&doi=10.2337%2Fdiabetes.53.4.1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy</span></div><div class="casAuthors">Hammes, Hans-Peter; Lin, Jihong; Wagner, Patrick; Feng, Yuxi; vom Hagen, Franziska; Krzizok, Thomas; Renner, Oliver; Breier, Georg; Brownlee, Michael; Deutsch, Urban</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1104-1110</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Pericyte loss is an early pathol. feature of diabetic retinopathy, consistently present in retinae of diabetic humans and animals.  Because pericyte recruitment and endothelial cell survival are controlled, in part, by the angiopoietin/Tie2 ligand/receptor system, we studied the expression of angiopoietin-2 and -1 in relation to the evolution of pericyte loss in diabetic rat retinae, using quant. retinal morphometry, and in retinae from mice with heterozygous angiopoietin deficiency (Ang-2 LacZ knock-in mice).  Finally, recombinant angiopoietin-2 was injected into eyes of nondiabetic rats, and pericyte nos. were quantitated in retinal capillaries.  Angiopoietin-1 protein was present in the normal maturing retina and was upregulated 2.5-fold in diabetic retinae over 3 mo of diabetes.  In contrast, angiopoietin-2 protein was consistently upregulated more than 30-fold in the retinae of diabetic rats, preceding the onset of pericyte loss.  Heterozygous angiopoietin-2 deficiency completely prevented diabetes-induced pericyte loss and reduced the no. of acellular capillary segments.  Injection of angiopoietin-2 into the eyes of normal rats induced a dose-dependent pericyte loss.  These data show that upregulation of angiopoietin-2 plays a crit. role in the loss of pericytes in the diabetic retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMwn67TgRG4bVg90H21EOLACvtfcHk0lioeqq7074HNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFyqtrw%253D&md5=8b834d296e92a303f313da368d6bfe67</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.53.4.1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.53.4.1104%26sid%3Dliteratum%253Aachs%26aulast%3DHammes%26aufirst%3DH.-P.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3Dvom%2BHagen%26aufirst%3DF.%26aulast%3DKrzizok%26aufirst%3DT.%26aulast%3DRenner%26aufirst%3DO.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DBrownlee%26aufirst%3DM.%26aulast%3DDeutsch%26aufirst%3DU.%26atitle%3DAngiopoietin-2%2520Causes%2520Pericyte%2520Dropout%2520in%2520the%2520Normal%2520Retina%253A%2520Evidence%2520for%2520Involvement%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%26date%3D2004%26volume%3D53%26spage%3D1104%26epage%3D1110%26doi%3D10.2337%2Fdiabetes.53.4.1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Y.</span></span> <span> </span><span class="NLM_article-title">Potential Role of the Angiopoietin/Tie2 System in Ischemia-Induced Retinal Neovascularization</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">393</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1167/iovs.02-0276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1167%2Fiovs.02-0276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=12506101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD38jktFOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=393-402&author=H.+Takagiauthor=S.+Koyamaauthor=H.+Seikeauthor=H.+Ohauthor=A.+Otaniauthor=M.+Matsumuraauthor=Y.+Honda&title=Potential+Role+of+the+Angiopoietin%2FTie2+System+in+Ischemia-Induced+Retinal+Neovascularization&doi=10.1167%2Fiovs.02-0276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization</span></div><div class="casAuthors">Takagi Hitoshi; Koyama Shinji; Seike Hisayuki; Oh Hideyasu; Otani Atsushi; Matsumura Miyo; Honda Yoshihito</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-402</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Ischemia-induced neovascularization can cause catastrophic loss of vision in retinal disorders such as diabetic retinopathy.  Recent studies have shown that the angiopoietin-Tie2 system is a major regulator of vascular integrity and is involved in pathologic angiogenesis.  In the study described herein, the role of these molecules in ischemic retinal disorders was investigated.  METHODS:  Human epiretinal membranes were examined by immunohistochemistry, In situ hybridization, and reverse transcription-polymerase chain reaction (RT-PCR) analysis.  Effects of angiopoietins on tube formation were studied in vitro in bovine retinal capillary endothelial cells (BRECs) and in a murine model of ischemia-induced retinal neovascularization.  RESULTS:  In human epiretinal membranes surgically obtained from eyes with ischemic retinal disorders, substantial upregulation of angiopoietin 2 (Ang2) and the receptor Tie2 was recorded than in those from eyes with nonischemic diseases, whereas expression of Ang1 was constant in all membranes.  Both Ang1 and Ang2 promoted tube-forming activity and enhanced the effects of vascular endothelial growth factor (VEGF) in cultured BRECs.  Soluble Tie2 fusion protein (sTie2-Fc), which precluded modulation of VEGF-dependent tube formation by the angiopoietins, suppressed both VEGF and hypoxia-conditioned, medium-induced tube-forming activity in BRECs.  Intravitreal injection of sTie2-Fc, soluble Flt-1 fusion protein (sFlt-1-Fc), and both chimeric proteins suppressed retinal angiogenesis in a murine model of retinal ischemia in the order of sTie2-Fc < sFlt-1-Fc < sTie2-Fc+sFlt-1-Fc.  CONCLUSIONS:  These results reinforce the substantial role of the angiopoietins/Tie2 system in ischemia-induced angiogenesis as well as the VEGF system and suggest that combined inhibition of Tie2 and VEGF signaling may be more effective in halting or preventing pathologic angiogenesis in ischemic retinal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBZdWOugH4ZPSAs_PE1QvifW6udTcc2eYj75IQFh8wf7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jktFOmtw%253D%253D&md5=38fb52a411995c49a43c6ac00c67bd5d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1167%2Fiovs.02-0276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.02-0276%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DH.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DSeike%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DH.%26aulast%3DOtani%26aufirst%3DA.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DHonda%26aufirst%3DY.%26atitle%3DPotential%2520Role%2520of%2520the%2520Angiopoietin%252FTie2%2520System%2520in%2520Ischemia-Induced%2520Retinal%2520Neovascularization%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2003%26volume%3D44%26spage%3D393%26epage%3D402%26doi%3D10.1167%2Fiovs.02-0276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ockrim, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joussen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziemssen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hykin, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. E.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin Modulation of Vascular Endothelial Growth Factor: Effects on Retinal Endothelial Cell Permeability</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2007.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.cyto.2007.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=17959386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyhsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=144-150&author=S.+Petersauthor=I.+A.+Creeauthor=R.+Alexanderauthor=P.+Turowskiauthor=Z.+Ockrimauthor=J.+Patelauthor=S.+R.+Boydauthor=A.+M.+Joussenauthor=F.+Ziemssenauthor=P.+G.+Hykinauthor=S.+E.+Moss&title=Angiopoietin+Modulation+of+Vascular+Endothelial+Growth+Factor%3A+Effects+on+Retinal+Endothelial+Cell+Permeability&doi=10.1016%2Fj.cyto.2007.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability</span></div><div class="casAuthors">Peters, Swaantje; Cree, Ian A.; Alexander, Robert; Turowski, Patric; Ockrim, Zoe; Patel, Jignesh; Boyd, Shelley R.; Joussen, Antonia M.; Ziemssen, Focke; Hykin, Philip G.; Moss, Stephen E.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vascular permeability is important at many sites, but particularly so in diabetic retinopathy where macular edema is the major cause of blindness.  Angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) are important factors involved in neovascularization and vascular leakage, but there is little data on their interaction to promote increased vascular permeability.  Porcine retinal endothelial cells (PREC) were seeded into permeable inserts and cultured in 24-well plates that permit measurement of permeability using fluorescent dextrans.  Cell purity was assessed immunohistochem.  At confluency, PREC were treated with increasing concns. of VEGF (20-100 ng/mL) and Ang-2 (15-75 ng/mL).  The effect on tight junctions was assessed by visualization with an anti-ZO-1 antibody.  Immunohistochem. showed high purity of isolated PREC.  Permeability of untreated PREC monolayers was low.  The increase in permeability in Ang-2 treated cells (25-30% compared with non-treated cells) was less than that for cells treated with VEGF only (20-100% compared with untreated cells).  Highest permeability was seen with a combination of Ang-2 and VEGF (100-400% compared with untreated cells).  Permeability increased with time after growth factor application.  Preliminary ZO-1 immunohistochem. appeared to demonstrate the presence of tight junctions between untreated PREC, and loss of tight junctions after treatment with VEGF and Ang-2.  VEGF alone is twice as potent in interrupting tight junctions in an endothelial cell monolayer as Ang-2.  However, both growth factors acting together increase permeability three times as much as VEGF alone.  Treatments designed to reduce vascular permeability in diabetic macular edema should consider that crosstalk between growth factors including VEGF and the Ang-2/Tie-2 system can multiply their effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU8BcbgwlhFbVg90H21EOLACvtfcHk0lgOjJoJFpsdfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyhsr7E&md5=d35e60446fb7fc90d3b2fa998ca42e98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2007.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2007.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCree%26aufirst%3DI.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DTurowski%26aufirst%3DP.%26aulast%3DOckrim%26aufirst%3DZ.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DBoyd%26aufirst%3DS.%2BR.%26aulast%3DJoussen%26aufirst%3DA.%2BM.%26aulast%3DZiemssen%26aufirst%3DF.%26aulast%3DHykin%26aufirst%3DP.%2BG.%26aulast%3DMoss%26aufirst%3DS.%2BE.%26atitle%3DAngiopoietin%2520Modulation%2520of%2520Vascular%2520Endothelial%2520Growth%2520Factor%253A%2520Effects%2520on%2520Retinal%2520Endothelial%2520Cell%2520Permeability%26jtitle%3DCytokine%26date%3D2007%26volume%3D40%26spage%3D144%26epage%3D150%26doi%3D10.1016%2Fj.cyto.2007.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiweem, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulla, T. A.</span></span> <span> </span><span class="NLM_article-title">Tie-2/Angiopoietin Pathway Modulation as a Therapeutic Strategy for Retinal Disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">861</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1080/13543784.2019.1667333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1080%2F13543784.2019.1667333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=31513439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGntL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=861-869&author=R.+M.+Hussainauthor=A.+E.+Neiweemauthor=V.+Kansaraauthor=A.+Harrisauthor=T.+A.+Ciulla&title=Tie-2%2FAngiopoietin+Pathway+Modulation+as+a+Therapeutic+Strategy+for+Retinal+Disease&doi=10.1080%2F13543784.2019.1667333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease</span></div><div class="casAuthors">Hussain, Rehan M.; Neiweem, Ashley E.; Kansara, Viral; Harris, Alon; Ciulla, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">861-869</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).  Activation of Tie-2 receptor via Ang-1 maintains vascular stability to limit exudation.  Ang-2, a competitive antagonist to Ang-1, and VE-PTP, an endothelial-specific phosphatase, interfere with the Tie-2-Ang-1 axis, resulting in vascular leakage.: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.  Nesvacumab is an Ang-2 inhibitor; when coformulated with aflibercept, it failed to show benefit over aflibercept monotherapy in achieving visual gains in phase 2 studies of nAMD and DME.  ARP-1536 is an intravitreally administered VE-PTP inhibitor undergoing preclin. studies.  AKB-9778 is a s.c. administered VE-PTP inhibitor that, when combined with monthly ranibizumab, reduced DME more effectively than ranibizumab monotherapy in a phase 2 study.  AKB-9778 monotherapy did not reduce diabetic retinopathy severity score compared to placebo.  AXT107, currently in the preclin. phase, promotes conversion of Ang-2 into a Tie-2 agonist and blocks signaling through VEGFR2 and other receptor tyrosine-kinases.: Tie-2/Angiopoietin pathway modulators show promise to reduce treatment burden and improve visual outcomes in nAMD and DME, with potential to treat cases refractory to current treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjxY1pL8K5abVg90H21EOLACvtfcHk0lgOjJoJFpsdfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGntL%252FP&md5=d782ac40c606cbb612a5fa29e8c2caf9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1667333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1667333%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DR.%2BM.%26aulast%3DNeiweem%26aufirst%3DA.%2BE.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCiulla%26aufirst%3DT.%2BA.%26atitle%3DTie-2%252FAngiopoietin%2520Pathway%2520Modulation%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Retinal%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26spage%3D861%26epage%3D869%26doi%3D10.1080%2F13543784.2019.1667333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10533</span>â <span class="NLM_lpage">10593</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVCksbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10533-10593&author=K.-J.+Chengauthor=C.-M.+Hsiehauthor=K.+Nepaliauthor=J.-P.+Liou&title=Ocular+Disease+Therapeutics%3A+Design+and+Delivery+of+Drugs+for+Diseases+of+the+Eye&doi=10.1021%2Facs.jmedchem.9b01033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye</span></div><div class="casAuthors">Cheng, Kuei-Ju; Hsieh, Chien-Ming; Nepali, Kunal; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10533-10593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ocular drug discovery field has evidenced significant advancement in the past decade.  The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone intracanalicular insert) for ocular inflammation, ReSure sealant to seal corneal incisions, and Lifitegrast for dry eye represent some of the major developments in the field of ocular therapeutics.  A literature survey also indicates that gene therapy, stem cell therapy, and target discovery through genomic research represent significant promise as potential strategies to achieve tissue repair or regeneration and to attain therapeutic benefits in ocular diseases.  Overall, the emergence of new technologies coupled with first-in-class entries in ophthalmol. are highly anticipated to restructure and boost the future trends in the field of ophthalmic drug discovery.  This perspective focuses on various aspects of ocular drug discovery and the recent advances therein.  Recent medicinal chem. campaigns along with a brief overview of the structure-activity relationships of the diverse chem. classes and developments in ocular drug delivery (ODD) are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv-gUombQ8yrVg90H21EOLACvtfcHk0liGvfgnT7ppbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVCksbvF&md5=79da37197a60945cac9e3ff4f0c9da6f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01033%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.-J.%26aulast%3DHsieh%26aufirst%3DC.-M.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DOcular%2520Disease%2520Therapeutics%253A%2520Design%2520and%2520Delivery%2520of%2520Drugs%2520for%2520Diseases%2520of%2520the%2520Eye%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10533%26epage%3D10593%26doi%3D10.1021%2Facs.jmedchem.9b01033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van
Loon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adriaens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownstein, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCioccio, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1348</span>â <span class="NLM_lpage">1355</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-15-1221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F1078-0432.CCR-15-1221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=26490310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28Xktlajs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1348-1355&author=K.+P.+Papadopoulosauthor=R.+K.+Kelleyauthor=A.+W.+Tolcherauthor=A.+R.+A.+Razakauthor=K.+Van%0ALoonauthor=A.+Patnaikauthor=P.+L.+Bedardauthor=A.+A.+Alfaroauthor=M.+Beeramauthor=L.+Adriaensauthor=C.+M.+Brownsteinauthor=I.+Lowyauthor=A.+Kosticauthor=P.+A.+Trailauthor=B.+Gaoauthor=A.+T.+DiCioccioauthor=L.+L.+Siu&title=A+Phase+I+First-in-Human+Study+of+Nesvacumab+%28REGN910%29%2C+a+Fully+Human+Anti-Angiopoietin-2+%28Ang2%29+Monoclonal+Antibody%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.ccr-15-1221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Papadopoulos, Kyriakos P.; Kelley, Robin Kate; Tolcher, Anthony W.; Abdul Razak, Albiruni R.; Van Loon, Katherine; Patnaik, Amita; Bedard, Philippe L.; Alfaro, Ariceli A.; Beeram, Muralidhar; Adriaens, Lieve; Brownstein, Carrie M.; Lowy, Israel; Kostic, Ana; Trail, Pamela A.; Gao, Bo; DiCioccio, A. Thomas; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1348-1355</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Nesvacumab (REGN910) is a fully human IgG1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1.  The main objectives of this trial were to det. the safety, tolerability, dose-limiting toxicities (DLT), and recommended phase II dose (RP2D) of nesvacumab.  Exptl. Design: Nesvacumab was administered i.v. every two weeks with dose escalations from 1 to 20 mg/kg in patients with advanced solid tumors.  Results: A total of 47 patients were treated with nesvacumab.  No patients in the dose escalation phase experienced DLTs, therefore a max. tolerated dose (MTD) was not reached.  The most common nesvacumab-related adverse events were fatigue (23.4%), peripheral edema (21.3%), decreased appetite, and diarrhea (each 10.6%; all grade â¤ 2).  Nesvacumab was characterized by linear kinetics and had a terminal half-life of 6.35 to 9.66 days in a dose-independent manner.  Best response by RECIST 1.1 in 43 evaluable patients included 1 partial response (adrenocortical carcinoma) of 24 wk duration.  Two patients with hepatocellular carcinoma had stable disease (SD) > 16 wk, with tumor regression and >50% decrease in Î±-fetoprotein.  Analyses of putative angiogenesis biomarkers in serum and tumor biopsies were uninformative for treatment duration.  Conclusions: Nesvacumab safety profile was acceptable at all dose levels tested.  Preliminary antitumor activity was obsd. in patients with treatment-refractory advanced solid tumors.  On the basis of cumulative safety, antitumor activity, pharmacokinetic and pharmacodynamic data, the 20 mg/kg dose was detd. to be the RP2D.  Clin Cancer Res; 22(6); 1348-55. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8IKdHdjydLVg90H21EOLACvtfcHk0liGvfgnT7ppbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xktlajs7w%253D&md5=43f1fc21b79c12b9dd5054acf089af23</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1221%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DKelley%26aufirst%3DR.%2BK.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRazak%26aufirst%3DA.%2BR.%2BA.%26aulast%3DVan%2BLoon%26aufirst%3DK.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26aulast%3DAlfaro%26aufirst%3DA.%2BA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DAdriaens%26aufirst%3DL.%26aulast%3DBrownstein%26aufirst%3DC.%2BM.%26aulast%3DLowy%26aufirst%3DI.%26aulast%3DKostic%26aufirst%3DA.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DDiCioccio%26aufirst%3DA.%2BT.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DA%2520Phase%2520I%2520First-in-Human%2520Study%2520of%2520Nesvacumab%2520%2528REGN910%2529%252C%2520a%2520Fully%2520Human%2520Anti-Angiopoietin-2%2520%2528Ang2%2529%2520Monoclonal%2520Antibody%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1348%26epage%3D1355%26doi%3D10.1158%2F1078-0432.ccr-15-1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini-Tenzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¼ssmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¼newald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Novel TIE-2 Inhibitor BAY-826 Displays <i>in vivo</i> Efficacy in Experimental Syngeneic Murine Glioma Models</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1111/jnc.13877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fjnc.13877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27787897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGmt7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=170-182&author=H.+Schneiderauthor=E.+Szaboauthor=R.+A.+C.+Machadoauthor=A.+Broggini-Tenzerauthor=A.+Walterauthor=M.+Lobellauthor=D.+Heldmannauthor=F.+S%C3%BCssmeierauthor=S.+Gr%C3%BCnewaldauthor=M.+Weller&title=Novel+TIE-2+Inhibitor+BAY-826+Displays+in+vivo+Efficacy+in+Experimental+Syngeneic+Murine+Glioma+Models&doi=10.1111%2Fjnc.13877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models</span></div><div class="casAuthors">Schneider, Hannah; Szabo, Emese; Machado, Raquel A. C.; Broggini-Tenzer, Angela; Walter, Alexander; Lobell, Mario; Heldmann, Dieter; Suessmeier, Frank; Gruenewald, Sylvia; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-182</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Targeting the vascular endothelial growth factor signaling axis in glioblastoma inevitably leads to tumor recurrence and a more aggressive phenotype.  Therefore, other angiogenic pathways, like the angiopoietin/tunica interna endothelial cell kinase (TIE) signaling axis, have become addnl. targets for therapeutic intervention.  Here, we explored whether targeting the receptor tyrosine kinase TIE-2 using a novel, highly potent, orally available small mol. TIE-2 inhibitor (BAY-826) improves tumor control in syngeneic mouse glioma models.  BAY-826 inhibits TIE-2 phosphorylation in vitro and in vivo as demonstrated by suppression of Angiopoietin-1- or Na3VO4-induced TIE-2 phosphorylation in glioma cells or exts. of lungs from BAY-826-treated mice.  There was a trend toward prolonged survival upon single-agent treatment in two of four models (SMA-497 and SMA-540) and there was a significant survival benefit in one model (SMA-560).  Co-treatment with BAY-826 and irradn. was ineffective in one model (SMA-497), but provided synergistic prolongation of survival in another (SMA-560).  Decreased vessel densities and increased leukocyte infiltration were obsd., but might be independent processes as the effect was also obsd. in single treatment modalities.  These data demonstrate that TIE-2 inhibition may improve tumor response to treatment in highly vascularized tumors such as glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSM7CpumxyGLVg90H21EOLACvtfcHk0liGvfgnT7ppbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGmt7%252FK&md5=bd7b5a44b6c3c51f56e90f1e4f89f47d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13877%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DH.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DMachado%26aufirst%3DR.%2BA.%2BC.%26aulast%3DBroggini-Tenzer%26aufirst%3DA.%26aulast%3DWalter%26aufirst%3DA.%26aulast%3DLobell%26aufirst%3DM.%26aulast%3DHeldmann%26aufirst%3DD.%26aulast%3DS%25C3%25BCssmeier%26aufirst%3DF.%26aulast%3DGr%25C3%25BCnewald%26aufirst%3DS.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DNovel%2520TIE-2%2520Inhibitor%2520BAY-826%2520Displays%2520in%2520vivo%2520Efficacy%2520in%2520Experimental%2520Syngeneic%2520Murine%2520Glioma%2520Models%26jtitle%3DJ.%2520Neurochem.%26date%3D2017%26volume%3D140%26spage%3D170%26epage%3D182%26doi%3D10.1111%2Fjnc.13877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harney, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignatelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadioglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oktay, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Palma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J. S.</span></span> <span> </span><span class="NLM_article-title">The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2<sup>Hi</sup> Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2486</span>â <span class="NLM_lpage">2501</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-17-0241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F1535-7163.MCT-17-0241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28838996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2486-2501&author=A.+S.+Harneyauthor=G.+S.+Karagiannisauthor=J.+Pignatelliauthor=B.+D.+Smithauthor=E.+Kadiogluauthor=S.+C.+Wiseauthor=M.+M.+Hoodauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=W.-P.+Luauthor=G.+Al-Aniauthor=X.+Chenauthor=D.+Entenbergauthor=M.+H.+Oktayauthor=Y.+Wangauthor=L.+Chunauthor=M.+De+Palmaauthor=J.+G.+Jonesauthor=D.+L.+Flynnauthor=J.+S.+Condeelis&title=The+Selective+Tie2+Inhibitor+Rebastinib+Blocks+Recruitment+and+Function+of+Tie2Hi+Macrophages+in+Breast+Cancer+and+Pancreatic+Neuroendocrine+Tumors&doi=10.1158%2F1535-7163.mct-17-0241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors</span></div><div class="casAuthors">Harney, Allison S.; Karagiannis, George S.; Pignatelli, Jeanine; Smith, Bryan D.; Kadioglu, Ece; Wise, Scott C.; Hood, Molly M.; Kaufman, Michael D.; Leary, Cynthia B.; Lu, Wei-Ping; Al-Ani, Gada; Chen, Xiaoming; Entenberg, David; Oktay, Maja H.; Wang, Yarong; Chun, Lawrence; De Palma, Michele; Jones, Joan G.; Flynn, Daniel L.; Condeelis, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2486-2501</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy.  Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer.  Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through redn. of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM).  The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor vol., metastasis, and improving overall survival.  Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis.  Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.  Mol Cancer Ther; 16(11); 2486-501. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwpn_ZOd8hLVg90H21EOLACvtfcHk0lhFs7MRLK_tdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrjI&md5=7dfc9791d4afab12f0c94467e9d29069</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0241%26sid%3Dliteratum%253Aachs%26aulast%3DHarney%26aufirst%3DA.%2BS.%26aulast%3DKaragiannis%26aufirst%3DG.%2BS.%26aulast%3DPignatelli%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKadioglu%26aufirst%3DE.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DAl-Ani%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DEntenberg%26aufirst%3DD.%26aulast%3DOktay%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DJ.%2BG.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DCondeelis%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Selective%2520Tie2%2520Inhibitor%2520Rebastinib%2520Blocks%2520Recruitment%2520and%2520Function%2520of%2520Tie2Hi%2520Macrophages%2520in%2520Breast%2520Cancer%2520and%2520Pancreatic%2520Neuroendocrine%2520Tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2486%26epage%3D2501%26doi%3D10.1158%2F1535-7163.mct-17-0241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugel, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanani, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wykoff, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauly-Evers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadikhov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogoceke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauser, S.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1155</span>â <span class="NLM_lpage">1170</span>, <span class="refDoi">Â DOI: 10.1016/j.ophtha.2019.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.ophtha.2019.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30905643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BB3cbnsFCmuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2019&pages=1155-1170&author=J.+Sahniauthor=S.+S.+Patelauthor=P.+U.+Dugelauthor=A.+M.+Khananiauthor=C.+D.+Jhaveriauthor=C.+C.+Wykoffauthor=V.+S.+Hershbergerauthor=M.+Pauly-Eversauthor=S.+Sadikhovauthor=P.+Szczesnyauthor=D.+Schwabauthor=E.+Nogocekeauthor=A.+Osborneauthor=R.+Weikertauthor=S.+Fauser&title=Simultaneous+Inhibition+of+Angiopoietin-2+and+Vascular+Endothelial+Growth+Factor-A+with+Faricimab+in+Diabetic+Macular+Edema%3A+BOULEVARD+Phase+2+Randomized+Trial&doi=10.1016%2Fj.ophtha.2019.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial</span></div><div class="casAuthors">Sahni Jayashree; Patel Sunil S; Dugel Pravin U; Khanani Arshad M; Jhaveri Chirag D; Wykoff Charles C; Hershberger Vrinda S; Pauly-Evers Meike; Szczesny Piotr; Schwab Dietmar; Nogoceke Everson; Weikert Robert; Fauser Sascha; Sadikhov Shamil; Osborne Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1155-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME).  DESIGN:  The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States.  PARTICIPANTS:  The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 Î¼m or more.  METHODS:  Anti-VEGF treatment-naive patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to 6.0 mg faricimab or 0.3 mg ranibizumab.  Patients were dosed monthly for 20 weeks, followed by an observation period up to week 36 to assess durability.  MAIN OUTCOME MEASURES:  The prespecified primary outcome measure was mean change in BCVA from baseline at week 24 for faricimab versus ranibizumab in treatment-naive patients.  Key secondary and exploratory outcome measures included CST, Diabetic Retinopathy Severity Scale (DRSS) score, and durability as assessed by time to re-treatment.  RESULTS:  The trial enrolled 229 patients (168 treatment-naive and 61 previously treated with anti-VEGF).  In treatment-naive patients, 6.0 mg faricimab, 1.5 mg faricimab, and 0.3 mg ranibizumab resulted in mean improvements of 13.9, 11.7, and 10.3 ETDRS letters from baseline, respectively.  The 6.0-mg faricimab dose demonstrated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03).  In both patient populations, faricimab resulted in dose-dependent reductions in CST, improvements in DRSS score, and longer time to re-treatment during the observation period compared with ranibizumab.  Faricimab showed no new or unexpected safety signals.  CONCLUSIONS:  The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naive patients.  Central subfield thickness reduction, DRSS score improvement, and extended durability outcomes support the primary outcome.  These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ15QcwhY7IOIHSmpohpd0fW6udTcc2ebPuktko6blBrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbnsFCmuw%253D%253D&md5=21447179f36dc5307a36f43d8dbcb53a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2019.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2019.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSahni%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%2BS.%26aulast%3DDugel%26aufirst%3DP.%2BU.%26aulast%3DKhanani%26aufirst%3DA.%2BM.%26aulast%3DJhaveri%26aufirst%3DC.%2BD.%26aulast%3DWykoff%26aufirst%3DC.%2BC.%26aulast%3DHershberger%26aufirst%3DV.%2BS.%26aulast%3DPauly-Evers%26aufirst%3DM.%26aulast%3DSadikhov%26aufirst%3DS.%26aulast%3DSzczesny%26aufirst%3DP.%26aulast%3DSchwab%26aufirst%3DD.%26aulast%3DNogoceke%26aufirst%3DE.%26aulast%3DOsborne%26aufirst%3DA.%26aulast%3DWeikert%26aufirst%3DR.%26aulast%3DFauser%26aufirst%3DS.%26atitle%3DSimultaneous%2520Inhibition%2520of%2520Angiopoietin-2%2520and%2520Vascular%2520Endothelial%2520Growth%2520Factor-A%2520with%2520Faricimab%2520in%2520Diabetic%2520Macular%2520Edema%253A%2520BOULEVARD%2520Phase%25202%2520Randomized%2520Trial%26jtitle%3DOphthalmology%26date%3D2019%26volume%3D126%26spage%3D1155%26epage%3D1170%26doi%3D10.1016%2Fj.ophtha.2019.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szklarczyk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gable, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta-Cepas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doncheva, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bork, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mering, C. V.</span></span> <span> </span><span class="NLM_article-title">STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D607</span>â <span class="NLM_lpage">D613</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1093%2Fnar%2Fgky1131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30476243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Gqtr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D607-D613&author=D.+Szklarczykauthor=A.+L.+Gableauthor=D.+Lyonauthor=A.+Jungeauthor=S.+Wyderauthor=J.+Huerta-Cepasauthor=M.+Simonovicauthor=N.+T.+Donchevaauthor=J.+H.+Morrisauthor=P.+Borkauthor=L.+J.+Jensenauthor=C.+V.+Mering&title=STRING+V11%3A+Protein-Protein+Association+Networks+with+Increased+Coverage%2C+Supporting+Functional+Discovery+in+Genome-Wide+Experimental+Datasets&doi=10.1093%2Fnar%2Fgky1131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">STRING v11: protein-protein association networks with increased coverage supporting functional discovery in genome-wide experimental datasets</span></div><div class="casAuthors">Szklarczyk, Damian; Gable, Annika L.; Lyon, David; Junge, Alexander; Wyder, Stefan; Huerta-Cepas, Jaime; Simonovic, Milan; Doncheva, Nadezhda T.; Morris, John H.; Bork, Peer; Jensen, Lars J.; von Mering, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D607-D613</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Proteins and their functional interactions form the backbone of the cellular machinery.  Their connectivity network needs to be considered for the full understanding of biol. phenomena, but the available information on protein-protein assocns. is incomplete and exhibits varying levels of annotation granularity and reliability.  The STRING database aims to collect, score and integrate all publicly available sources of protein-protein interaction information, and to complement these with computational predictions.  Its goal is to achieve a comprehensive and objective global network, including direct (phys.) as well as indirect (functional) interactions.  The latest version of STRING (11.0) more than doubles the no. of organisms it covers, to 5090.  The most important new feature is an option to upload entire, genome-wide datasets as input, allowing users to visualize subsets as interaction networks and to perform gene-set enrichment anal. on the entire input.  For the enrichment anal., STRING implements well-known classification systems such as Gene Ontol. and KEGG, but also offers addnl., new classification systems based on high-throughput text-mining as well as on a hierarchical clustering of the assocn. network itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UX25KcxhhbVg90H21EOLACvtfcHk0lhFs7MRLK_tdg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Gqtr%252FM&md5=43df05a2de505f1df210fb4aaa200f58</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1131%26sid%3Dliteratum%253Aachs%26aulast%3DSzklarczyk%26aufirst%3DD.%26aulast%3DGable%26aufirst%3DA.%2BL.%26aulast%3DLyon%26aufirst%3DD.%26aulast%3DJunge%26aufirst%3DA.%26aulast%3DWyder%26aufirst%3DS.%26aulast%3DHuerta-Cepas%26aufirst%3DJ.%26aulast%3DSimonovic%26aufirst%3DM.%26aulast%3DDoncheva%26aufirst%3DN.%2BT.%26aulast%3DMorris%26aufirst%3DJ.%2BH.%26aulast%3DBork%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DL.%2BJ.%26aulast%3DMering%26aufirst%3DC.%2BV.%26atitle%3DSTRING%2520V11%253A%2520Protein-Protein%2520Association%2520Networks%2520with%2520Increased%2520Coverage%252C%2520Supporting%2520Functional%2520Discovery%2520in%2520Genome-Wide%2520Experimental%2520Datasets%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD607%26epage%3DD613%26doi%3D10.1093%2Fnar%2Fgky1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, A.</span></span> <span> </span><span class="NLM_article-title">Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor-Induced Vascular Endothelial Morphogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1668</span>â <span class="NLM_lpage">1677</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-07-6385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F0008-5472.CAN-07-6385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19176400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslyntr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1668-1677&author=X.+Yangauthor=D.+Qiaoauthor=K.+Meyerauthor=A.+Friedl&title=Signal+Transducers+and+Activators+of+Transcription+Mediate+Fibroblast+Growth+Factor-Induced+Vascular+Endothelial+Morphogenesis&doi=10.1158%2F0008-5472.can-07-6385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis</span></div><div class="casAuthors">Yang, Xinhai; Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1668-1677</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factors (FGF) play diverse roles in development, wound healing, and angiogenesis.  The intracellular signal transduction pathways, which mediate these pleiotropic activities, remain incompletely understood.  We show here that the proangiogenic factors FGF2 and FGF8b can activate signal transducers and activators of transcription (STAT) in mouse microvascular endothelial cells (EC).  Both FGF2 and FGF8b activate STAT5 and to a lesser extent STAT1, but not STAT3.  The FGF2-dependent activation of endothelial STAT5 was confirmed in vivo with the Matrigel plug angiogenesis assay.  In tissue samples of human gliomas, a tumor type wherein FGF-induced angiogenesis is important, STAT5 is detected in tumor vessel EC nuclei, consistent with STAT5 activation.  By forced expression of constitutively active or dominant-neg. mutant STAT5A in mouse brain ECs, we further show that STAT5 activation is both necessary and sufficient for FGF-induced cell migration, invasion, and tube formation, which are key events in vascular endothelial morphogenesis and angiogenesis.  In contrast, STAT5 is not required for brain EC mitogenesis.  The cytoplasmic tyrosine kinases Src and Janus kinase 2 (Jak2) both seem to be involved in the activation of STAT5, as their inhibition reduces FGF2- and FGF8b-induced STAT5 phosphorylation and EC tube formation.  Constitutively active STAT5A partially restores tube formation in the presence of Src or Jak2 inhibitors.  These observations show that FGFs use distinct signaling pathways to induce angiogenic phenotypes.  Together, our findings implicate the FGF-Jak2/Src-STAT5 cascade as a crit. angiogenic FGF signaling pathway. [Cancer Res 2009;69(4):1668-77].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprD1Oim8vZobVg90H21EOLACvtfcHk0ljHJg_3T1F4Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslyntr0%253D&md5=dc4e4e34a75bb08177327b966314ee8c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6385%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DQiao%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DFriedl%26aufirst%3DA.%26atitle%3DSignal%2520Transducers%2520and%2520Activators%2520of%2520Transcription%2520Mediate%2520Fibroblast%2520Growth%2520Factor-Induced%2520Vascular%2520Endothelial%2520Morphogenesis%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1668%26epage%3D1677%26doi%3D10.1158%2F0008-5472.can-07-6385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, A.</span></span> <span> </span><span class="NLM_article-title">STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">21184</span>â <span class="NLM_lpage">21196</span>, <span class="refDoi">Â DOI: 10.1074/jbc.m113.481119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1074%2Fjbc.M113.481119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23729680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeksL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=21184-21196&author=X.+Yangauthor=K.+Meyerauthor=A.+Friedl&title=STAT5+and+Prolactin+Participate+in+a+Positive+Autocrine+Feedback+Loop+That+Promotes+Angiogenesis&doi=10.1074%2Fjbc.m113.481119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis</span></div><div class="casAuthors">Yang, Xinhai; Meyer, Kristy; Friedl, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">21184-21196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal role in angiogenesis induced by the FGF2/STAT5 signaling cascade.  To delineate the signaling pathway downstream of STAT5 in the human system, where proliferin does not exist, we expressed constitutively active (CA) or dominant-neg. (DN) mutant STAT5A in hCMEC/D3 human brain endothelial cells.  We found that conditioned medium from CA-STAT5A- but not from DN-STAT5A-overexpressing endothelial cells (EC) is sufficient to induce EC migration and tube formation but not proliferation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors.  We identified prolactin (PRL) as a candidate autocrine factor.  CA-STAT5A expression stimulates PRL prodn. at the RNA and protein level, and STAT5A binds to the PRL promoter region, suggesting direct transcriptional regulation.  Medium conditioned by CA-STAT5A-overexpressing EC induces phosphorylation of the PRL receptor and activates MAPK.  Knockdown of PRL expression by shRNA or blocking of PRL activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC.  The addn. of recombinant PRL restores this activity.  STAT5A-induced PRL in the conditioned medium can activate STAT5, STAT1, and to a lesser extent STAT3 in hCMEC/D3 cells, suggesting the existence of a pos. feedback loop between STAT5 and PRL that promotes angiogenesis.  Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A, and VEGF induction depends on PRL expression.  These observations demonstrate a STAT5/PRL/VEGF signaling cascade in human brain EC and implicate PRL and VEGF as autocrine regulators of EC migration, invasion, and tube formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYh_1y9l4_2bVg90H21EOLACvtfcHk0ljHJg_3T1F4Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeksL3L&md5=b205eef56dd2d0516b63ffacbaec3a70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.481119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.481119%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DFriedl%26aufirst%3DA.%26atitle%3DSTAT5%2520and%2520Prolactin%2520Participate%2520in%2520a%2520Positive%2520Autocrine%2520Feedback%2520Loop%2520That%2520Promotes%2520Angiogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D21184%26epage%3D21196%26doi%3D10.1074%2Fjbc.m113.481119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. D.</span></span> <span> </span><span class="NLM_article-title">Enalapril Alters Expression of Key Growth Factors in Experimental Diabetic Retinopathy</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">976</span>â <span class="NLM_lpage">987</span>, <span class="refDoi">Â DOI: 10.3109/02713680903249913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.3109%2F02713680903249913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19958114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSqsb3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=976-987&author=H.+W.+Kimauthor=J.+L.+Kimauthor=H.+K.+Leeauthor=D.+Y.+Hurauthor=I.+H.+Yunauthor=S.+D.+Kim&title=Enalapril+Alters+Expression+of+Key+Growth+Factors+in+Experimental+Diabetic+Retinopathy&doi=10.3109%2F02713680903249913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Enalapril Alters Expression of Key Growth Factors in Experimental Diabetic Retinopathy</span></div><div class="casAuthors">Kim, Hyun Woong; Kim, Jung Lim; Lee, Han Kee; Hur, Dae Young; Yun, Il Han; Kim, Sin Dong</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">976-987</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Purpose: Angiogenic factors such as vascular endothelial growth factor (VEGF), erythropoietin, and angiopoietin play important roles in the development of diabetic retinopathy.  However, the suppression of a single factor does not inhibit angiogenesis completely.  This study simultaneously evaluated the expression of several angiogenic factors in the retinas of diabetes-induced rats and detd. the effects of an angiotensin-converting enzyme inhibitor (enalapril) on the expression of angiogenic factors.  Methods: Diabetes was chem. induced by injecting 14 of 21 Sprague-Dawley rats with streptozotocin.  After induction of diabetes, enalapril (10 mg/kg) was administered orally to seven rats.  The rats were divided into normal, diabetes mellitus (DM), and enalapril-treated groups (each group, n = 7).  The eyeballs were removed at 8 wk after the induction of diabetes, and the retinal expression of VEGF, the signal transducer and activator of transcription (STAT)3/5, erythropoietin, and angiopoietin were examd. using immunohistochem., RT-PCR, and Western blotting.  Results: RT-PCR revealed that the expression of VEGF, VEGF receptors, STAT3, erythropoietin, erythropoietin receptor, STAT5, angiopoietin 2, and Tie2 mRNA increased in the DM group, whereas angiopoietin 1 expression decreased.  The enalapril-treated group showed no increase in mRNA expression of angiogenic factors.  Immunohistochem. staining and Western blotting showed that the expression of VEGF, STAT3, and erythropoietin receptor proteins increased in the DM group but not in the enalapril-treated group.  Erythropoietin and angiopoietin proteins were not detected by immunohistochem. staining or Western blotting.  STAT5 protein expression was detected only in the DM group using immunohistochem. staining and Western blotting.  The mRNA expression of the angiogenic factors VEGF, erythropoietin, and angiopoietin 2 increased in the DM group but not in the enalapril-treated group.  In contrast, angiopoietin 1 mRNA expression decreased in the DM group.  Conclusions: Enalapril treatment prevented increased angiogenic factor levels in the retinas of exptl. induced diabetic rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBvKF91BI3k7Vg90H21EOLACvtfcHk0ljHJg_3T1F4Nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSqsb3K&md5=4deedf399ef7f324fe55d981b501a1c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F02713680903249913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713680903249913%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DHur%26aufirst%3DD.%2BY.%26aulast%3DYun%26aufirst%3DI.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BD.%26atitle%3DEnalapril%2520Alters%2520Expression%2520of%2520Key%2520Growth%2520Factors%2520in%2520Experimental%2520Diabetic%2520Retinopathy%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2009%26volume%3D34%26spage%3D976%26epage%3D987%26doi%3D10.3109%2F02713680903249913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez-Mendez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinyard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraehling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudvig, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakides, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, W. C.</span></span> <span> </span><span class="NLM_article-title">Endothelial Cell Autonomous Role of Akt1</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">870</span>â <span class="NLM_lpage">879</span>, <span class="refDoi">Â DOI: 10.1161/atvbaha.118.310748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1161%2FATVBAHA.118.310748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=29449333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFentL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=870-879&author=M.+Y.+Leeauthor=A.+Gamez-Mendezauthor=J.+Zhangauthor=Z.+Zhuangauthor=D.+J.+Vinyardauthor=J.+Kraehlingauthor=H.+Velazquezauthor=G.+W.+Brudvigauthor=T.+R.+Kyriakidesauthor=M.+Simonsauthor=W.+C.+Sessa&title=Endothelial+Cell+Autonomous+Role+of+Akt1&doi=10.1161%2Fatvbaha.118.310748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis</span></div><div class="casAuthors">Lee, Monica Y.; Gamez-Mendez, Ana; Zhang, Jiasheng; Zhuang, Zhenwu; Vinyard, David J.; Kraehling, Jan; Velazquez, Heino; Brudvig, Gary W.; Kyriakides, Themis R.; Simons, Michael; Sessa, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">870-879</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: The importance of PI3K/Akt signaling in the vasculature has been demonstrated in several models, as global loss of Akt1 results in impaired postnatal ischemia- and VEGF-induced angiogenesis.  The ubiquitous expression of Akt1, however, raises the possibility of cell-type-dependent Akt1-driven actions, thereby necessitating tissue-specific characterization.  APPROACH AND RESULTS-: Herein, we used an inducible, endothelial-specific Akt1-deleted adult mouse model (Akt1iECKO) to characterize the endothelial cell autonomous functions of Akt1 in the vascular system.  Endothelial-targeted ablation of Akt1 reduces eNOS (endothelial nitric oxide synthase) phosphorylation and promotes both increased vascular contractility in isolated vessels and elevated diastolic blood pressures throughout the diurnal cycle in vivo.  Furthermore, Akt1iECKO mice subject to the hindlimb ischemia model display impaired blood flow and decreased arteriogenesis.  CONCLUSIONS-: Endothelial Akt1 signaling is necessary for ischemic resoln. post-injury and likely reflects the consequence of NO insufficiency crit. for vascular repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPJgIaj-WiobVg90H21EOLACvtfcHk0lhRfAQjQcGj8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFentL4%253D&md5=c4583567e21b66218ee3baec2c6521d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.118.310748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.118.310748%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DGamez-Mendez%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DVinyard%26aufirst%3DD.%2BJ.%26aulast%3DKraehling%26aufirst%3DJ.%26aulast%3DVelazquez%26aufirst%3DH.%26aulast%3DBrudvig%26aufirst%3DG.%2BW.%26aulast%3DKyriakides%26aufirst%3DT.%2BR.%26aulast%3DSimons%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DW.%2BC.%26atitle%3DEndothelial%2520Cell%2520Autonomous%2520Role%2520of%2520Akt1%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2018%26volume%3D38%26spage%3D870%26epage%3D879%26doi%3D10.1161%2Fatvbaha.118.310748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graupera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillermet-Guibert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foukas, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phng, L.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cain, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutillas, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhrberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis Selectively Requires the P110Î± Isoform of PI3K to Control Endothelial Cell Migration</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">662</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1038/nature06892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1038%2Fnature06892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=18449193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVKqtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=662-666&author=M.+Grauperaauthor=J.+Guillermet-Guibertauthor=L.+C.+Foukasauthor=L.-K.+Phngauthor=R.+J.+Cainauthor=A.+Salpekarauthor=W.+Pearceauthor=S.+Meekauthor=J.+Millanauthor=P.+R.+Cutillasauthor=A.+J.+H.+Smithauthor=A.+J.+Ridleyauthor=C.+Ruhrbergauthor=H.+Gerhardtauthor=B.+Vanhaesebroeck&title=Angiogenesis+Selectively+Requires+the+P110%CE%B1+Isoform+of+PI3K+to+Control+Endothelial+Cell+Migration&doi=10.1038%2Fnature06892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis selectively requires the p110Î± isoform of PI3K to control endothelial cell migration</span></div><div class="casAuthors">Graupera, Mariona; Guillermet-Guibert, Julie; Foukas, Lazaros C.; Phng, Li-Kun; Cain, Robert J.; Salpekar, Ashreena; Pearce, Wayne; Meek, Stephen; Millan, Jaime; Cutillas, Pedro R.; Smith, Andrew J. H.; Ridley, Anne J.; Ruhrberg, Christiana; Gerhardt, Holger; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">453</span>
        (<span class="NLM_cas:issue">7195</span>),
    <span class="NLM_cas:pages">662-666</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) signal downstream of multiple cell-surface receptor types.  Class IA PI3K isoforms couple to tyrosine kinases and consist of a p110 catalytic subunit (p110Î±, p110Î² or p110Î´), constitutively bound to one of five distinct p85 regulatory subunits.  PI3Ks have been implicated in angiogenesis, but little is known about potential selectivity among the PI3K isoforms and their mechanism of action in endothelial cells during angiogenesis in vivo.  Here we show that only p110Î± activity is essential for vascular development.  Ubiquitous or endothelial cell-specific inactivation of p110Î± led to embryonic lethality at mid-gestation because of severe defects in angiogenic sprouting and vascular remodelling. p110Î± exerts this crit. endothelial cell-autonomous function by regulating endothelial cell migration through the small GTPase RhoA. p110Î± activity is particularly high in endothelial cells and preferentially induced by tyrosine kinase ligands (such as vascular endothelial growth factor (VEGF)-A).  In contrast, p110Î² in endothelial cells signals downstream of G-protein-coupled receptor (GPCR) ligands such as SDF-1Î±, whereas p110Î´ is expressed at low level and contributes only minimally to PI3K activity in endothelial cells.  These results provide the first in vivo evidence for p110-isoform selectivity in endothelial PI3K signalling during angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9rOrqV5M9bVg90H21EOLACvtfcHk0lhRfAQjQcGj8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVKqtb4%253D&md5=27a919eea8bd0688b1c2e530012bb569</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature06892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06892%26sid%3Dliteratum%253Aachs%26aulast%3DGraupera%26aufirst%3DM.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26aulast%3DFoukas%26aufirst%3DL.%2BC.%26aulast%3DPhng%26aufirst%3DL.-K.%26aulast%3DCain%26aufirst%3DR.%2BJ.%26aulast%3DSalpekar%26aufirst%3DA.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DMeek%26aufirst%3DS.%26aulast%3DMillan%26aufirst%3DJ.%26aulast%3DCutillas%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DRidley%26aufirst%3DA.%2BJ.%26aulast%3DRuhrberg%26aufirst%3DC.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DAngiogenesis%2520Selectively%2520Requires%2520the%2520P110%25CE%25B1%2520Isoform%2520of%2520PI3K%2520to%2520Control%2520Endothelial%2520Cell%2520Migration%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D662%26epage%3D666%26doi%3D10.1038%2Fnature06892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gesbert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Bcr/Abl Activates Transcription of the Bcl-X Gene through STAT5</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2269</span>â <span class="NLM_lpage">2276</span>, <span class="refDoi">Â DOI: 10.1182/blood.v96.6.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1182%2Fblood.V96.6.2269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10979976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Chtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=2269-2276&author=F.+Gesbertauthor=J.+D.+Griffin&title=Bcr%2FAbl+Activates+Transcription+of+the+Bcl-X+Gene+through+STAT5&doi=10.1182%2Fblood.v96.6.2269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bcr/Abl activates transcription of the Bcl-X gene through STAT5</span></div><div class="casAuthors">Gesbert, Franck; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2276</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Several tyrosine kinase oncogenes have been assocd. with myeloproliferative diseases, including Bcr/Abl, Tel/Abl, Tel/Jak2, and Tel/PDGFR.  One target mol. shared by these oncogenes is known to be STAT5.  We generated sublines of Ba/F3 cells in which either wild-type STAT5 or a constitutively active mutant of STAT5 (STAT5-1*6) were expressed under the control of a tetracycline-inducible promoter.  These cell lines were compared with a Ba/F3 cell line in which the expression of p210Bcr/Abl was made inducible by a similar promoter.  Before induction, all cells were dependent on interleukin 3 (IL-3) for growth and survival.  Both STAT5-1*6 and Bcr/Abl enhanced viability and induced proliferation in the absence of IL-3.  We found that the pro-viability protein Bcl-XL, but not Bcl-2, was induced by both p210Bcr/Abl and STAT5-1*6.  Using a Bcl-X gene promoter construct fused to a luciferase complementary DNA (cDNA), both p210Bcr/Abl and STAT5-1*6 were shown to induce transcription of Bcl-X.  The increase in transcription of the Bcl-X promoter and the increase in Bcl-X protein, due to p210Bcr/Abl, were blocked by expression of a dominant neg. STAT5 mutant.  Interestingly, however, STAT5-1*6 required the continued presence of IL-3 to cause a significant increase in Bcl-XL protein, whereas p210Bcr/Abl did not need IL-3.  Studies with enzyme inhibitors suggest that the extra signal supplied by IL-3 may be supplied by the PI3K pathway.  Overall, these data suggest that constitutively activated STAT5 can increase viability and proliferation of Ba/F3 cells.  This may contribute to, but is not likely sufficient for, the enhanced viability assocd. with Bcr/Abl transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZvnMlwzzoILVg90H21EOLACvtfcHk0lhRfAQjQcGj8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Chtrw%253D&md5=e760e005c111dfe2bf2f883507f114b4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood.V96.6.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V96.6.2269%26sid%3Dliteratum%253Aachs%26aulast%3DGesbert%26aufirst%3DF.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DBcr%252FAbl%2520Activates%2520Transcription%2520of%2520the%2520Bcl-X%2520Gene%2520through%2520STAT5%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D2269%26epage%3D2276%26doi%3D10.1182%2Fblood.v96.6.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2047</span>â <span class="NLM_lpage">2053</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-04-3888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F0008-5472.CAN-04-3888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15781610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2047-2053&author=M.+G.+Kharasauthor=D.+A.+Fruman&title=ABL+Oncogenes+and+Phosphoinositide+3-Kinase%3A+Mechanism+of+Activation+and+Downstream+Effectors&doi=10.1158%2F0008-5472.can-04-3888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors</span></div><div class="casAuthors">Kharas, Michael G.; Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2047-2053</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The BCR-ABL oncogene is responsible for most cases of chronic myelogenous leukemia and some acute lymphoblastic leukemias.  The fusion protein encoded by BCR-ABL possesses an aberrantly regulated tyrosine kinase activity.  Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for addnl. therapies.  Targeting signaling pathways activated by BCR-ABL is a promising approach for drug development.  The study of signaling components downstream of BCR-ABL and the related murine oncogene v-Abl has revealed a complex web of signals that promote cell division and survival.  Of these, activation of phosphoinositide 3-kinase (PI3K) has emerged as one of the essential signaling mechanisms in ABL leukemogenesis.  This review describes mol. mechanisms by which PI3K is activated and the downstream PI3K effectors that propagate the signal to promote myeloid and lymphoid transformation.  Of particular recent interest is the mammalian target of rapamycin, a PI3K-regulated kinase that regulates protein synthesis and contributes to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOdUEF24-suLVg90H21EOLACvtfcHk0lgOHzHFSAwK7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGgtb8%253D&md5=ddc0080fda93244a5a9fd0ed84d0f8c2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3888%26sid%3Dliteratum%253Aachs%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DABL%2520Oncogenes%2520and%2520Phosphoinositide%25203-Kinase%253A%2520Mechanism%2520of%2520Activation%2520and%2520Downstream%2520Effectors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D2047%26epage%3D2053%26doi%3D10.1158%2F0008-5472.can-04-3888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namperumalsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukkaruppan, V.</span></span> <span> </span><span class="NLM_article-title">Proinflammatory Cytokines and Angiogenic and Anti-Angiogenic Factors in Vitreous of Patients with Proliferative Diabetic Retinopathy and Ealesâ² Disease</span>. <i>Retina</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">817</span>â <span class="NLM_lpage">824</span>, <span class="refDoi">Â DOI: 10.1097/iae.0b013e31816576d5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1097%2FIAE.0b013e31816576d5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=18536597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD1cvhs1Orug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=817-824&author=P.+Murugeswariauthor=D.+Shuklaauthor=A.+Rajendranauthor=R.+Kimauthor=P.+Namperumalsamyauthor=V.+Muthukkaruppan&title=Proinflammatory+Cytokines+and+Angiogenic+and+Anti-Angiogenic+Factors+in+Vitreous+of+Patients+with+Proliferative+Diabetic+Retinopathy+and+Eales%E2%80%B2+Disease&doi=10.1097%2Fiae.0b013e31816576d5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease</span></div><div class="casAuthors">Murugeswari Ponnalagu; Shukla Dhananjay; Rajendran Anand; Kim Ramasamy; Namperumalsamy Perumalsamy; Muthukkaruppan Veerappan</div><div class="citationInfo"><span class="NLM_cas:title">Retina (Philadelphia, Pa.)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">817-24</span>
        ISSN:<span class="NLM_cas:issn">0275-004X</span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the mechanism of angiogenesis in proliferative diabetic retinopathy (PDR) and Eales' disease (ED) on the basis of the levels of proinflammatory cytokines, angiogenic growth factor, and antiangiogenic factor in the vitreous humor.  METHODS:  Twenty-five patients with PDR, 10 patients with ED, and 25 with macular hole (MH) as control subjects were studied.  The concentration of the proinflammatory cytokines interleukin-6 (IL-6), IL-8, IL-1 beta; chemokine-monocyte chemoattractant protein-1 (MCP-1); angiogenic factor-vascular endothelial growth factor (VEGF); and antiangiogenic factor-pigment epithelium derived factor (PEDF) in the vitreous fluid obtained from the eyes during vitrectomy were measured by sandwich enzyme linked immunosorbent assay (ELISA).  RESULTS:  IL-6, IL-8, MCP-1, and VEGF levels in the vitreous were significantly higher in PDR (P < 0.0001) and ED (P < 0.0001) than in MH patients.  Conversely, the vitreous level of PEDF was significantly reduced in PDR (P < 0.0001) but not in ED.  A significant correlation was observed between VEGF and IL-6 in ED patients.  CONCLUSION:  The authors demonstrate the importance of VEGF in retinal neovascularization of ED which is an idiopathic inflammatory venous occlusion.  Further study is required to understand the interrelationship between VEGF and inflammatory cytokines in PDR and ED.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1RNGd5aH8Hhjv2lLSLOxFfW6udTcc2eab-SYVGc-xNLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvhs1Orug%253D%253D&md5=27a9a3aa45c09b15fc0b5a3670df821c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FIAE.0b013e31816576d5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIAE.0b013e31816576d5%26sid%3Dliteratum%253Aachs%26aulast%3DMurugeswari%26aufirst%3DP.%26aulast%3DShukla%26aufirst%3DD.%26aulast%3DRajendran%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DNamperumalsamy%26aufirst%3DP.%26aulast%3DMuthukkaruppan%26aufirst%3DV.%26atitle%3DProinflammatory%2520Cytokines%2520and%2520Angiogenic%2520and%2520Anti-Angiogenic%2520Factors%2520in%2520Vitreous%2520of%2520Patients%2520with%2520Proliferative%2520Diabetic%2520Retinopathy%2520and%2520Eales%25E2%2580%25B2%2520Disease%26jtitle%3DRetina%26date%3D2008%26volume%3D28%26spage%3D817%26epage%3D824%26doi%3D10.1097%2Fiae.0b013e31816576d5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PetroviÄ, MG</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoroÅ¡ec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoÅ¡nik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawlina, M.</span></span> <span> </span><span class="NLM_article-title">Association of Preoperative Vitreous IL-8 and VEGF Levels with Visual Acuity after Vitrectomy in Proliferative Diabetic Retinopathy</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">e311</span>â <span class="NLM_lpage">6</span>, <span class="refDoi">Â DOI: 10.1111/j.1755-3768.2010.02030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.1755-3768.2010.02030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=21073666" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=e311-6&author=MG+Petrovi%C4%8Dauthor=P.+Koro%C5%A1ecauthor=M.+Ko%C5%A1nikauthor=M.+Hawlina&title=Association+of+Preoperative+Vitreous+IL-8+and+VEGF+Levels+with+Visual+Acuity+after+Vitrectomy+in+Proliferative+Diabetic+Retinopathy&doi=10.1111%2Fj.1755-3768.2010.02030.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2010.02030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2010.02030.x%26sid%3Dliteratum%253Aachs%26aulast%3DPetrovi%25C4%258D%26aufirst%3DMG%26aulast%3DKoro%25C5%25A1ec%26aufirst%3DP.%26aulast%3DKo%25C5%25A1nik%26aufirst%3DM.%26aulast%3DHawlina%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520Preoperative%2520Vitreous%2520IL-8%2520and%2520VEGF%2520Levels%2520with%2520Visual%2520Acuity%2520after%2520Vitrectomy%2520in%2520Proliferative%2520Diabetic%2520Retinopathy%26jtitle%3DActa%2520Ophthalmol.%26date%3D2010%26volume%3D88%26spage%3De311%26epage%3D6%26doi%3D10.1111%2Fj.1755-3768.2010.02030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">CapitÃ£o, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, R.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2443</span>â <span class="NLM_lpage">2453</span>, <span class="refDoi">Â DOI: 10.1002/jcb.25575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1002%2Fjcb.25575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27128219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SgsrnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=2443-2453&author=M.+Capit%C3%A3oauthor=R.+Soares&title=Angiogenesis+and+Inflammation+Crosstalk+in+Diabetic+Retinopathy&doi=10.1002%2Fjcb.25575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy</span></div><div class="casAuthors">Capitao, Margarida; Soares, Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2443-2453</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes and one of the most frequent causes of blindness in active age.  Etiopathogenesis behind this important complication is related to several biochem., hemodynamic and endocrine mechanisms with a preponderant initial role assumed by polyol pathways, increment of growth factors, accumulation of advanced glycation end products (AGE), activation of protein kinase C (PKC), activation of the renin-angiotensin-aldosterone system (RAAS), and leukostasis.  Chronic and sustained hyperglycemia works as a trigger to the early alterations that culminate in vascular dysfunction.  Hypoxia also plays an essential role in disease progression with promotion of neovascularization and vascular dystrophies with vitreous hemorrhages induction.  Thus, the accumulation of fluids and protein exudates in ocular cavities leads to an opacity augmentation of the cornea that assocd. to neurodegeneration results in vision loss, being this a devastating characteristic of the disease final stage.  During disease progression, inflammatory mols. are produced and angiogenesis occur.  Furthermore, VEGF is overexpressed by the maintained hyperglycemic environment and up-regulated by tissue hypoxia.  Also pro-inflammatory mediators regulated by cytokines, such as tumor necrosis factor (TNF-Î±) and interleukin-1 beta (IL-1Î²), and growth factors leads to the progression of these processes, culminating in vasopermeability (diabetes macular edema) and/or pathol. angiogenesis (proliferative diabetic retinopathy).  It was found a mutual contribution between inflammation and angiogenesis along the process.  J. Cell. Biochem. 9999: 1-11, 2016. Â© 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gGmXT023sLVg90H21EOLACvtfcHk0lgOHzHFSAwK7g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SgsrnL&md5=6bf03ef0caf1d63b5b7b8de7d8eca798</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjcb.25575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.25575%26sid%3Dliteratum%253Aachs%26aulast%3DCapit%25C3%25A3o%26aufirst%3DM.%26aulast%3DSoares%26aufirst%3DR.%26atitle%3DAngiogenesis%2520and%2520Inflammation%2520Crosstalk%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2016%26volume%3D117%26spage%3D2443%26epage%3D2453%26doi%3D10.1002%2Fjcb.25575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span> <span> </span><span class="NLM_article-title">pH-metric Solubility. 1. Solubility-pH Profiles from Bjerrum Plots. Gibbs Buffer and pKa in the Solid State</span>. <i>Pharm. Pharmacol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1111/j.2042-7158.1998.tb00328.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.2042-7158.1998.tb00328.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADyaK1cXitleqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=165-178&author=A.+Avdeef&title=pH-metric+Solubility.+1.+Solubility-pH+Profiles+from+Bjerrum+Plots.+Gibbs+Buffer+and+pKa+in+the+Solid+State&doi=10.1111%2Fj.2042-7158.1998.tb00328.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">pH-metric solubility. 1. Solubility-pH profiles from Bjerrum plots. Gibbs buffer and pKa in the solid state</span></div><div class="casAuthors">Avdeef, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacy and Pharmacology Communications</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-178</span>CODEN:
                <span class="NLM_cas:coden">PPCOFN</span>;
        ISSN:<span class="NLM_cas:issn">1460-8081</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">If measurements of soly. were not so laborious, slow, and consuming of sample, soly.-pH profiles would be used more often at the initial stages of drug discovery to screen out mols. with problematic pharmacokinetic profiles.  An automated potentiometric titrn. method for soly. measurements, which addresses some of the shortcomings of the traditional methods, is described.  A simple graphical procedure for estg. soly. consts., based on Bjerrum difference plots, is developed, and the relationships between titrn. data and soly.-pH profiles for mono- and diprotic ionizable substances are explored, drawing on generalized mass-balance based simulation methods.  One useful derived equation (valid in a soln. where part of the sample ppts. early in the titrn.) is: log S0 = log (C/2) - |ÎpKa| where C is the sample concn., S0 is the intrinsic soly. of the unchanged substance, and ÎpKa = pKaapp - pKa, the difference between the apparent pKa detd. under conditions of pptn. and the true pKa, measured in the absence of the solid phase.  The relationship holds in both aq. and cosolvent solns. (e.g. dimethylsulfoxide-water).  The properties of the state where an unchanged substance (e.g. HX) coppts. with its ionized form (e.g. X- salt) were explored.  A super buffer termed the Gibbs buffer, was formed and characterized by an ionization const., pKa(s), of the substance in the solid state.  It was shown that pKa(s) - pKa = log SHX - log SX, where SHX and Sx refer to the soly. consts. of HX and X species.  Flurbiprofen (acid), benzydamine (base), and buprenorphine (ampholyte) were used to illustrate the exptl. procedure.  The authors' initial studies indicate that these new methods will meet many of the needs of not only discovery-stage researchers but also of preformulation and development scientists, traditionally concerned with soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGMxRxLlRsULVg90H21EOLACvtfcHk0lj5-m8SyLDbPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitleqtL8%253D&md5=4fc6ae518b90971869c32ac2159d939a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1998.tb00328.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1998.tb00328.x%26sid%3Dliteratum%253Aachs%26aulast%3DAvdeef%26aufirst%3DA.%26atitle%3DpH-metric%2520Solubility.%25201.%2520Solubility-pH%2520Profiles%2520from%2520Bjerrum%2520Plots.%2520Gibbs%2520Buffer%2520and%2520pKa%2520in%2520the%2520Solid%2520State%26jtitle%3DPharm.%2520Pharmacol.%2520Commun.%26date%3D1998%26volume%3D4%26spage%3D165%26epage%3D178%26doi%3D10.1111%2Fj.2042-7158.1998.tb00328.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span> <span> </span><span class="NLM_article-title">Determination of Excipient Based Solubility Increases using the CheqSol Method</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">202</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1016/j.ijpharm.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.ijpharm.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=24513529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2mu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2014&pages=202-209&author=K.+Ethersonauthor=G.+Halbertauthor=M.+Elliott&title=Determination+of+Excipient+Based+Solubility+Increases+using+the+CheqSol+Method&doi=10.1016%2Fj.ijpharm.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of excipient based solubility increases using the CheqSol method</span></div><div class="casAuthors">Etherson, Kelly; Halbert, Gavin; Elliott, Moira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is an essential characteristic assessed during drug development to det. a compd.'s drug-likeness since soly. plays an important pharmaceutical role.  However, nearly half of the drug candidates discovered today display poor water soly.; therefore methods have to be applied to increase soly.  Soly. detn. using the CheqSol method is a novel rapid soly. screening technique for ionizable compds.  The aim of this study is to det. if the CheqSol method can be employed to det. soly. increases of four test drugs (ibuprofen, gliclazide, atenolol and propranolol) induced by non-ionizing excipients such as hydroxypropyl-Î²-cyclodextrin and poloxamers 407 and 188.  CheqSol assays were performed for the drugs alone or in combination with varying solubilizer concns.  The measured intrinsic soly. of all four drugs increased with all the excipients tested in an excipient concn. dependent manner providing results consistent with previous literature.  The results demonstrate that it may be possible to use this method to det. the soly. increases induced by non-ionic solubilizing excipients with results that are comparable to std. equil. based soly. techniques.  Since the technique is automated and requires only small drug quantities it may serve as a useful soly. or formulation screening tool providing more detailed physicochem. information than multiwell plate or similar visual systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz1bIs43PWLrVg90H21EOLACvtfcHk0lj5-m8SyLDbPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2mu78%253D&md5=193c8724bb342543fe0c309478568f3a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DEtherson%26aufirst%3DK.%26aulast%3DHalbert%26aufirst%3DG.%26aulast%3DElliott%26aufirst%3DM.%26atitle%3DDetermination%2520of%2520Excipient%2520Based%2520Solubility%2520Increases%2520using%2520the%2520CheqSol%2520Method%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D465%26spage%3D202%26epage%3D209%26doi%3D10.1016%2Fj.ijpharm.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©lias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lj5-m8SyLDbPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of wondonins and schematic representation of the structural design of the new wondonin analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Phenylaminothiazolines <b>35â38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: Cu(OAc)<sub>2</sub>, 2,2â²-bipyridine, Cs<sub>2</sub>CO<sub>3</sub>, DMSO, 70 Â°C, 14 h, 45â62%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1,2,3-Triazole Analogues <b>4â7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, propargyl bromide, DMF, 0 Â°C to rt, 16 h, 92%; (b) CuSO<sub>4</sub>Â·5H<sub>2</sub>O, sodium ascorbate, EtOH/<i>t</i>-BuOH/H<sub>2</sub>O, 60 Â°C, 20 min, 87%; (c) CBr<sub>4</sub>, PPh<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 88%; and (d) different amines, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN (1:1), 50 Â°C, 16â19 h, 63â95%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Straight-Chain Alkyl Analogues <b>8â11</b> and <b>15â34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 50 Â°C, 13 h, 53â79% and (b) different amines, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN (1:1), 50 Â°C, 12â18 h, 37â98%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Straight-Chain Alkyl Analogues <b>12â14</b> with Modification on the Phenyl Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) 1,3-dibromo-propane, NaH, DMF, 50 Â°C, 14 h, 54â70% and (b) piperidine, K<sub>2</sub>CO<sub>3</sub>, DMF/MeCN, 50 Â°C, 14â16 h, 42â56%.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) VEGF-induced tube formation on Matrigel in HUVECs. (B) Chemical structures of <b>31</b> and sunitinib and their effects on VEGF-induced tube formation and cell viability in HUVECs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) After cells reached 90% confluency, HUVECs were starved overnight, and the medium was changed to endothelial basal medium (EBM) containing 2% fetal bovine serum (FBS). <b>31</b> was pretreated for 30 min, followed by VEGF (50 ng/mL) treatment for 30 min. Western bands were quantified using ImageJ, and then, we calculated the relative intensity. The data are presented as the mean fold changes Â± SD of two independent experiments. (B) Scratches were induced in HUVECs, and the medium was changed to EBM containing 2% FBS. Dimethyl sulfoxide (DMSO) or indicated concentrations of <b>31</b> were treated for 18 h, and the cells were photographed using microscopy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of <b>31</b> on ANGPT2 expression induced by high glucose in HRMECs and ARPE-19 cells. (A) HRMECs and ARPE-19 cells were stimulated with <span class="smallcaps smallerCapital">d</span>-glucose for 48 h. The level of ANGPT2 gene expression was analyzed by real-time PCR. The cells were pretreated with <b>31</b> for 30 min and further incubated with <span class="smallcaps smallerCapital">d</span>-glucose (30 mM) for 48 h. The expression levels of ANGPT2 gene and protein were analyzed by (B) real-time PCR and (C) Western blotting analysis, respectively. Western bands were quantified using ImageJ and presented as the mean fold changes Â± SD of two independent experiments. Real-time PCR data are presented as the mean fold changes Â± SD of three independent experiments. (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.005).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Protein interaction network analysis associated with ANGPT2 was performed using STRING v.11. (B) Cells were pretreated with <b>31</b> for 30 min and incubated with the indicated concentration of <span class="smallcaps smallerCapital">d</span>-glucose for 48 h. The effects of <b>31</b> on ANGPT2-linked biomarker expression were evaluated by Western blot analysis in <span class="smallcaps smallerCapital">d</span>-glucose-stimulated HRMECs and ARPE-19 cells. Western bands were quantified using ImageJ and presented as the mean fold changes Â± SD of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Schematic diagram of OIR experiments. At P12, mice received a single intravitreal injection of <b>31</b> (3 Î¼g in 1 Î¼L DMSO) or DMSO (1 Î¼L). Five days later (P17), the eyes were harvested for further analysis. (B) Representative images of whole-mounted retinas of mice with OIR at P17. The retinal vasculature was visualized by staining with isolectin B4 (IB4; black). High-magnification views of the boxed areas are shown at the bottom. Scale bars = 100 Î¼m. (C) Retinal neovascularization and vaso-obliteration in mice with OIR were quantified as a percentage of the number of pixels in the neovascular tuft and avascular regions of retinas with intravitreal injections compared to those of uninjected contralateral controls, respectively. Data are presented as the mean Â± SEM (***<i>P</i> < 0.001, ns = not significant, <i>n</i> > 6 mice per group).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/medium/jm0c01965_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Representative FFA images and corrected total fluorescence (CTF) at 10 days after CNV induction. (A) The CTF of the wounded area was analyzed by ImageJ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 33); G2 (Eylea, IVT, <i>n</i> = 32); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 34). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle). (B) White arrows indicate CNV lesions. The volume of the lesions was measured using ImageJ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 33); G2 (Eylea, IVT, <i>n</i> = 32); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 34). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle). (C) Amplitude of each eye was analyzed using âLabScribeERG Softwareâ. Each group was assigned as follows: G1 (CNV control: vehicle, eye drops, <i>n</i> = 10); G2 (Eylea, IVT, <i>n</i> = 8); and G3 (<b>31</b>, 1%, eye drops, <i>n</i> = 8). Three groups of mice (<i>n</i> = 5) were studied and compared with G1 (vehicle) (*<i>P</i> < 0.05, **<i>P</i> < 0.01, and ****<i>P</i> < 0.0001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01965/20210506/images/large/jm0c01965_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01965&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fallah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeghinia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahroba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidari, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradaran, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molavi, O.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Angiogenesis Molecular Pathways in Angiogenesis-Dependent Diseases</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">775</span>â <span class="NLM_lpage">785</span>, <span class="refDoi">Â DOI: 10.1016/j.biopha.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.biopha.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30554116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFaqur3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2019&pages=775-785&author=A.+Fallahauthor=A.+Sadeghiniaauthor=H.+Kahrobaauthor=A.+Samadiauthor=H.+R.+Heidariauthor=B.+Bradaranauthor=S.+Zeinaliauthor=O.+Molavi&title=Therapeutic+Targeting+of+Angiogenesis+Molecular+Pathways+in+Angiogenesis-Dependent+Diseases&doi=10.1016%2Fj.biopha.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases</span></div><div class="casAuthors">Fallah, Asghar; Sadeghinia, Ali; Kahroba, Houman; Samadi, Amin; Heidari, Hamid Reza; Bradaran, Behzad; Zeinali, Sirous; Molavi, Ommoleila</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">775-785</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Angiogenesis is a crit. step in the progression of almost all human malignancies and some other life-threatening diseases.  Anti-angiogenic therapy is a novel and effective approach for treatment of angiogenesis-dependent diseases such as cancer, diabetic retinopathy, and age-related macular degeneration.  In this article, we will review the main strategies developed for anti-angiogenic therapies beside their clin. applications, the major challenges, and the latest advances in the development of anti-angiogenesis-based targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOVyEzLjxY5rVg90H21EOLACvtfcHk0lj3F8iKnO2dUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFaqur3M&md5=2ea25608fbf980eca0d5a39dcfe1d4be</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFallah%26aufirst%3DA.%26aulast%3DSadeghinia%26aufirst%3DA.%26aulast%3DKahroba%26aufirst%3DH.%26aulast%3DSamadi%26aufirst%3DA.%26aulast%3DHeidari%26aufirst%3DH.%2BR.%26aulast%3DBradaran%26aufirst%3DB.%26aulast%3DZeinali%26aufirst%3DS.%26aulast%3DMolavi%26aufirst%3DO.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Angiogenesis%2520Molecular%2520Pathways%2520in%2520Angiogenesis-Dependent%2520Diseases%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D110%26spage%3D775%26epage%3D785%26doi%3D10.1016%2Fj.biopha.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breier, G.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis in Embryonic Development-A Review</span>. <i>Placenta</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">S11</span>â <span class="NLM_lpage">S15</span>, <span class="refDoi">Â DOI: 10.1053/plac.1999.0525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1053%2Fplac.1999.0525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10831116" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=S11-S15&author=G.+Breier&title=Angiogenesis+in+Embryonic+Development-A+Review&doi=10.1053%2Fplac.1999.0525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1053%2Fplac.1999.0525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fplac.1999.0525%26sid%3Dliteratum%253Aachs%26aulast%3DBreier%26aufirst%3DG.%26atitle%3DAngiogenesis%2520in%2520Embryonic%2520Development-A%2520Review%26jtitle%3DPlacenta%26date%3D2000%26volume%3D21%26spage%3DS11%26epage%3DS15%26doi%3D10.1053%2Fplac.1999.0525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felmeden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blann, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lip, G. Y. H.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis: Basic Pathophysiology and Implications for Disease</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">586</span>â <span class="NLM_lpage">603</span>, <span class="refDoi">Â DOI: 10.1016/s0195-668x(02)00635-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2FS0195-668X%2802%2900635-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=12657217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlWgsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=586-603&author=D.+Felmedenauthor=A.+D.+Blannauthor=G.+Y.+H.+Lip&title=Angiogenesis%3A+Basic+Pathophysiology+and+Implications+for+Disease&doi=10.1016%2Fs0195-668x%2802%2900635-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: basic pathophysiology and implications for disease</span></div><div class="casAuthors">Felmeden, D. C.; Blann, A. D.; Lip, G. Y. H.</div><div class="citationInfo"><span class="NLM_cas:title">European Heart Journal</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">586-603</span>CODEN:
                <span class="NLM_cas:coden">EHJODF</span>;
        ISSN:<span class="NLM_cas:issn">0195-668X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review on the basic mechanisms of blood vessel formation and the potential implications of angiogenesis in disease states.  Angiogenic growth factors such as vascular endothelial growth factor, fibroblast growth factor and angiopoietin are essential to angiogenesis.  The pathophysiol. consequences of the interactions between these growth factors and their receptors are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfbFnI9GZGMrVg90H21EOLACvtfcHk0lj3F8iKnO2dUg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlWgsrc%253D&md5=db79253eb7359a436a4be2c8e5b15c40</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0195-668X%2802%2900635-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0195-668X%252802%252900635-8%26sid%3Dliteratum%253Aachs%26aulast%3DFelmeden%26aufirst%3DD.%26aulast%3DBlann%26aufirst%3DA.%2BD.%26aulast%3DLip%26aufirst%3DG.%2BY.%2BH.%26atitle%3DAngiogenesis%253A%2520Basic%2520Pathophysiology%2520and%2520Implications%2520for%2520Disease%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2003%26volume%3D24%26spage%3D586%26epage%3D603%26doi%3D10.1016%2Fs0195-668x%2802%2900635-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, K. C.</span></span> <span> </span><span class="NLM_article-title">COX-2, VEGF and Tumor Angiogenesis</span>. <i>Surgeon</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">174</span>â <span class="NLM_lpage">180</span>, <span class="refDoi">Â DOI: 10.1016/s1479-666x(09)80042-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2FS1479-666X%2809%2980042-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19580182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD1MvmvVSiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=174-180&author=D.+P.+Toomeyauthor=J.+F.+Murphyauthor=K.+C.+Conlon&title=COX-2%2C+VEGF+and+Tumor+Angiogenesis&doi=10.1016%2Fs1479-666x%2809%2980042-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">COX-2, VEGF and tumour angiogenesis</span></div><div class="casAuthors">Toomey D P; Murphy J F; Conlon K C</div><div class="citationInfo"><span class="NLM_cas:title">The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">174-80</span>
        ISSN:<span class="NLM_cas:issn">1479-666X</span>.
    </div><div class="casAbstract">Epidemiological evidence suggests a protective effective of regular NSAID use against developing cancer.  Cyclooxygenase-2, a target of NSAIDs, is upregulated in many cancers and has been associated with increased VEGF production and angiogenesis.  Angiogenesis is the formation of new vessels from existing vasculature and as an essential process for tumour development represents an important therapeutic target.  Following an extensive review of the literature this article details the current knowledge on the role of COX-2 in tumorigenesis focusing on its relationship to angiogenesis and VEGF production by tumour cells.  While COX-2 is clearly detrimental to prognosis and NSAIDs have a beneficial effect, the possibility of COX-2 independent effects being partly or wholly responsible for this benefit cannot be excluded.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7pKC8rIEEEudfST00W0BcfW6udTcc2eZawTxfd3XIabntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvmvVSiug%253D%253D&md5=5a4b0b68e3d3dc298f6c37d885152483</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1479-666X%2809%2980042-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1479-666X%252809%252980042-5%26sid%3Dliteratum%253Aachs%26aulast%3DToomey%26aufirst%3DD.%2BP.%26aulast%3DMurphy%26aufirst%3DJ.%2BF.%26aulast%3DConlon%26aufirst%3DK.%2BC.%26atitle%3DCOX-2%252C%2520VEGF%2520and%2520Tumor%2520Angiogenesis%26jtitle%3DSurgeon%26date%3D2009%26volume%3D7%26spage%3D174%26epage%3D180%26doi%3D10.1016%2Fs1479-666x%2809%2980042-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loukovaara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robciuc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holopainen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liinamaa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukkonen, K.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jauhiainen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keski-Oja, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immonen, I.</span></span> <span> </span><span class="NLM_article-title">Ang-2 Upregulation Correlates with Increased Levels of MMP-9, VEGF, EPI, and TGFÎ²1 in Diabetic Eyes Undergoing Vitrectomy</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">531</span>â <span class="NLM_lpage">539</span>, <span class="refDoi">Â DOI: 10.1111/j.1755-3768.2012.02473.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.1755-3768.2012.02473.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23106921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSnsr%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2013&pages=531-539&author=S.+Loukovaaraauthor=A.+Robciucauthor=J.+M.+Holopainenauthor=K.+Lehtiauthor=T.+Pessiauthor=J.+Liinamaaauthor=K.-T.+Kukkonenauthor=M.+Jauhiainenauthor=K.+Koliauthor=J.+Keski-Ojaauthor=I.+Immonen&title=Ang-2+Upregulation+Correlates+with+Increased+Levels+of+MMP-9%2C+VEGF%2C+EPI%2C+and+TGF%CE%B21+in+Diabetic+Eyes+Undergoing+Vitrectomy&doi=10.1111%2Fj.1755-3768.2012.02473.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFÎ²1 in diabetic eyes undergoing vitrectomy</span></div><div class="casAuthors">Loukovaara, Sirpa; Robeiuc, Alexandra; Holopainen, Juha M.; Lehti, Kaisa; Pessi, Timo; Liinamaa, Johanna; Kukkonen, Kirsti-Tiina; Jauhiainen, Matti; Koli, Katri; Keski-Oja, Jorma; Immonen, Ilkka</div><div class="citationInfo"><span class="NLM_cas:title">Acta Ophthalmologica</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-539</span>CODEN:
                <span class="NLM_cas:coden">AOOUAQ</span>;
        ISSN:<span class="NLM_cas:issn">1755-375X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Purpose: Angiogenesis in diabetic retinopathy (DR) is a multifactorial process regulated by hypoxia-induced growth factors and inflammatory cytokines.  In addn. to the angiogenic switch, the proteolytic processing and altered synthesis of the extracellular matrix are crit. steps in this disease.  This study was performed to evaluate the levels of matrix metalloproteinase-2 and matrix metalloproteinase-9 (MMP-2 and MMP-9), angiopoietin-1 and angiopoietin-2 (Ang-1 and Ang-2), vascular endothelial growth factor (VEGF), erythropoietin (EPO) and transforming growth factor-Î²1 (totalTGFÎ²1) in the vitreous of diabetic eyes undergoing vitrectomy compared with control eyes operated because of macular hole or pucker.  Methods: Prospective consecutive controlled observational study performed in the unit of vitreoretinal surgery in Finland during the years 2006-2008.  Vitreous samples were collected before the start of the conventional 3-ppp vitrectomy.  Vitreous MMP-2 and MMP-9, Ang-1 and Ang-2, VEGF, EPO and TGFÎ²1 concns. were measured from 69 patients with Type 1 or 2 diabetes and 40 controls.  Results: Comparison of eyes with DR with controls revealed that the mean vitreous concns. of proMMP-2(p = 0.0015), totalMMP-2 (p = 0.0011), proMMP-9(p = 0.00001), total-MMP-9 (p < 0.00001), Ang-2 (p < 0.00001), VEGF (p < 0.00001), EPO (p < 0.00001) and totalTGFÎ²1 (p = 0.000026) were significantly higher in the former group.  A multivariate logistic regression anal. suggested intravitreal Ang-2 concn. being the key marker of PDR (p = 0.00025) (OR = 1507.9).  Conclusion: The main new finding is that the intravitreal concns. of Ang-2 correlated significantly with MMP-9, VEGF, EPO and TGFÎ²1 levels in diabetic eyes undergoing vitrectomy.  Thus, these factors could promote retinal angiogenesis synergistically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmKdKt0TSujbVg90H21EOLACvtfcHk0lghBd5BzD2Yng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSnsr%252FN&md5=68b4eb5a8a09de9943fe13f0161daa77</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2012.02473.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2012.02473.x%26sid%3Dliteratum%253Aachs%26aulast%3DLoukovaara%26aufirst%3DS.%26aulast%3DRobciuc%26aufirst%3DA.%26aulast%3DHolopainen%26aufirst%3DJ.%2BM.%26aulast%3DLehti%26aufirst%3DK.%26aulast%3DPessi%26aufirst%3DT.%26aulast%3DLiinamaa%26aufirst%3DJ.%26aulast%3DKukkonen%26aufirst%3DK.-T.%26aulast%3DJauhiainen%26aufirst%3DM.%26aulast%3DKoli%26aufirst%3DK.%26aulast%3DKeski-Oja%26aufirst%3DJ.%26aulast%3DImmonen%26aufirst%3DI.%26atitle%3DAng-2%2520Upregulation%2520Correlates%2520with%2520Increased%2520Levels%2520of%2520MMP-9%252C%2520VEGF%252C%2520EPI%252C%2520and%2520TGF%25CE%25B21%2520in%2520Diabetic%2520Eyes%2520Undergoing%2520Vitrectomy%26jtitle%3DActa%2520Ophthalmol.%26date%3D2013%26volume%3D91%26spage%3D531%26epage%3D539%26doi%3D10.1111%2Fj.1755-3768.2012.02473.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duh, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stitt, A. W.</span></span> <span> </span><span class="NLM_article-title">Diabetic Retinopathy: Current Understanding, Mechanisms, and Treatment Strategies</span>. <i>JCI insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e93751</span> <span class="refDoi">Â DOI: 10.1172/jci.insight.93751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1172%2Fjci.insight.93751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28724805" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&author=E.+J.+Duhauthor=J.+K.+Sunauthor=A.+W.+Stitt&title=Diabetic+Retinopathy%3A+Current+Understanding%2C+Mechanisms%2C+and+Treatment+Strategies&doi=10.1172%2Fjci.insight.93751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.93751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.93751%26sid%3Dliteratum%253Aachs%26aulast%3DDuh%26aufirst%3DE.%2BJ.%26aulast%3DSun%26aufirst%3DJ.%2BK.%26aulast%3DStitt%26aufirst%3DA.%2BW.%26atitle%3DDiabetic%2520Retinopathy%253A%2520Current%2520Understanding%252C%2520Mechanisms%252C%2520and%2520Treatment%2520Strategies%26jtitle%3DJCI%2520insight%26date%3D2017%26volume%3D2%26doi%3D10.1172%2Fjci.insight.93751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yau, J. W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamoureux, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bek, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauslund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haffner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikram, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, B. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaiah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayurasakorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâHare, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tielsch, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, T. Y.</span></span> <span> </span><span class="NLM_article-title">Global Prevalence and Major Risk Factors of Diabetic Retinopathy</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">556</span>â <span class="NLM_lpage">564</span>, <span class="refDoi">Â DOI: 10.2337/dc11-1909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdc11-1909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=22301125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC38rgt1ajtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=556-564&author=J.+W.+Y.+Yauauthor=S.+L.+Rogersauthor=R.+Kawasakiauthor=E.+L.+Lamoureuxauthor=J.+W.+Kowalskiauthor=T.+Bekauthor=S.-J.+Chenauthor=J.+M.+Dekkerauthor=A.+Fletcherauthor=J.+Grauslundauthor=S.+Haffnerauthor=R.+F.+Hammanauthor=M.+K.+Ikramauthor=T.+Kayamaauthor=B.+E.+K.+Kleinauthor=R.+Kleinauthor=S.+Krishnaiahauthor=K.+Mayurasakornauthor=J.+P.+O%E2%80%99Hareauthor=T.+J.+Orchardauthor=M.+Portaauthor=M.+Remaauthor=M.+S.+Royauthor=T.+Sharmaauthor=J.+Shawauthor=H.+Taylorauthor=J.+M.+Tielschauthor=R.+Varmaauthor=J.+J.+Wangauthor=N.+Wangauthor=S.+Westauthor=L.+Xuauthor=M.+Yasudaauthor=X.+Zhangauthor=P.+Mitchellauthor=T.+Y.+Wong&title=Global+Prevalence+and+Major+Risk+Factors+of+Diabetic+Retinopathy&doi=10.2337%2Fdc11-1909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Global prevalence and major risk factors of diabetic retinopathy</span></div><div class="casAuthors">Yau Joanne W Y; Rogers Sophie L; Kawasaki Ryo; Lamoureux Ecosse L; Kowalski Jonathan W; Bek Toke; Chen Shih-Jen; Dekker Jacqueline M; Fletcher Astrid; Grauslund Jakob; Haffner Steven; Hamman Richard F; Ikram M Kamran; Kayama Takamasa; Klein Barbara E K; Klein Ronald; Krishnaiah Sannapaneni; Mayurasakorn Korapat; O'Hare Joseph P; Orchard Trevor J; Porta Massimo; Rema Mohan; Roy Monique S; Sharma Tarun; Shaw Jonathan; Taylor Hugh; Tielsch James M; Varma Rohit; Wang Jie Jin; Wang Ningli; West Sheila; Xu Liang; Yasuda Miho; Zhang Xinzhi; Mitchell Paul; Wong Tien Y</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">556-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes.  RESEARCH DESIGN AND METHODS:  A pooled analysis using individual participant data from population-based studies around the world was performed.  A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs.  Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors.  Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20-79 years.  RESULTS:  A total of 35 studies (1980-2008) provided data from 22,896 individuals with diabetes.  The overall prevalence was 34.6% (95% CI 34.5-34.8) for any DR, 6.96% (6.87-7.04) for proliferative DR, 6.81% (6.74-6.89) for diabetic macular edema, and 10.2% (10.1-10.3) for VTDR.  All DR prevalence end points increased with diabetes duration, hemoglobin A(1c), and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes.  CONCLUSIONS:  There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide.  Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR.  These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence.  This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROE9nlduqLo0loaUqgkFHkfW6udTcc2ebfLXP9avp3brntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgt1ajtQ%253D%253D&md5=91c2be562a7b55dee1fde96a13f7ddcd</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2337%2Fdc11-1909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc11-1909%26sid%3Dliteratum%253Aachs%26aulast%3DYau%26aufirst%3DJ.%2BW.%2BY.%26aulast%3DRogers%26aufirst%3DS.%2BL.%26aulast%3DKawasaki%26aufirst%3DR.%26aulast%3DLamoureux%26aufirst%3DE.%2BL.%26aulast%3DKowalski%26aufirst%3DJ.%2BW.%26aulast%3DBek%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DS.-J.%26aulast%3DDekker%26aufirst%3DJ.%2BM.%26aulast%3DFletcher%26aufirst%3DA.%26aulast%3DGrauslund%26aufirst%3DJ.%26aulast%3DHaffner%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DR.%2BF.%26aulast%3DIkram%26aufirst%3DM.%2BK.%26aulast%3DKayama%26aufirst%3DT.%26aulast%3DKlein%26aufirst%3DB.%2BE.%2BK.%26aulast%3DKlein%26aufirst%3DR.%26aulast%3DKrishnaiah%26aufirst%3DS.%26aulast%3DMayurasakorn%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DJ.%2BP.%26aulast%3DOrchard%26aufirst%3DT.%2BJ.%26aulast%3DPorta%26aufirst%3DM.%26aulast%3DRema%26aufirst%3DM.%26aulast%3DRoy%26aufirst%3DM.%2BS.%26aulast%3DSharma%26aufirst%3DT.%26aulast%3DShaw%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DH.%26aulast%3DTielsch%26aufirst%3DJ.%2BM.%26aulast%3DVarma%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWest%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYasuda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMitchell%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DT.%2BY.%26atitle%3DGlobal%2520Prevalence%2520and%2520Major%2520Risk%2520Factors%2520of%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%2520Care%26date%3D2012%26volume%3D35%26spage%3D556%26epage%3D564%26doi%3D10.2337%2Fdc11-1909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolanska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohner, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chibber, R.</span></span> <span> </span><span class="NLM_article-title">Retinopathy in Diabetes</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>771</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">106</span>, <span class="refDoi">Â DOI: 10.1007/978-1-4614-5441-0_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1007%2F978-1-4614-5441-0_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23393674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC3szmsleltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=771&publication_year=2012&pages=88-106&author=J.+M.+Tarrauthor=K.+Kaulauthor=K.+Wolanskaauthor=E.+M.+Kohnerauthor=R.+Chibber&title=Retinopathy+in+Diabetes&doi=10.1007%2F978-1-4614-5441-0_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Retinopathy in diabetes</span></div><div class="casAuthors">Tarr Joanna M; Kaul Kirti; Wolanska Katarzyna; Kohner Eva M; Chibber Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Advances in experimental medicine and biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">771</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88-106</span>
        ISSN:<span class="NLM_cas:issn">0065-2598</span>.
    </div><div class="casAbstract">With the incidence, and prevalence of diabetes mellitus increasing worldwide, diabetic retinopathy is expected to reach epidemic proportions.  The aim of this chapter is to introduce diabetic retinopathy, a leading cause of blindness in people of the working age.  The clinical course of retinopathy, anatomical changes, its pathogenesis and current treatment are described, followed by an overview of the emerging drug therapies for the potential treatment of this sight-threatening complication of diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeDurHW-hMkxKDYG3bNImrfW6udTcc2eaa-AIOu2phCLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmsleltQ%253D%253D&md5=95dcbf8e2b8ad9bb132c7c573b1a4f75</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2F978-1-4614-5441-0_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4614-5441-0_10%26sid%3Dliteratum%253Aachs%26aulast%3DTarr%26aufirst%3DJ.%2BM.%26aulast%3DKaul%26aufirst%3DK.%26aulast%3DWolanska%26aufirst%3DK.%26aulast%3DKohner%26aufirst%3DE.%2BM.%26aulast%3DChibber%26aufirst%3DR.%26atitle%3DRetinopathy%2520in%2520Diabetes%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2012%26volume%3D771%26spage%3D88%26epage%3D106%26doi%3D10.1007%2F978-1-4614-5441-0_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harris
Nwanyanwu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talwar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, J. D.</span></span> <span> </span><span class="NLM_article-title">Predicting Development of Proliferative Diabetic Retinopathy</span>. <i>Diabetes Care</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1562</span>â <span class="NLM_lpage">1568</span>, <span class="refDoi">Â DOI: 10.2337/dc12-0790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdc12-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23275374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC3s3lsVSmsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=1562-1568&author=K.+Harris%0ANwanyanwuauthor=N.+Talwarauthor=T.+W.+Gardnerauthor=J.+S.+Wrobelauthor=W.+H.+Hermanauthor=J.+D.+Stein&title=Predicting+Development+of+Proliferative+Diabetic+Retinopathy&doi=10.2337%2Fdc12-0790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting development of proliferative diabetic retinopathy</span></div><div class="casAuthors">Harris Nwanyanwu Kristen; Talwar Nidhi; Gardner Thomas W; Wrobel James S; Herman William H; Stein Joshua D</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes care</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1562-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Identifying individuals most at risk for diabetic retinopathy progression and intervening early can limit vision loss and reduce the costs associated with managing more advanced disease.  The purpose of this study was to identify factors associated with progression from nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR).  RESEARCH DESIGN AND METHODS:  This was a retrospective cohort analysis using a claims database of all eye care recipients age â¥ 30 years enrolled in a large managed-care network from 2001 to 2009.  Individuals with newly diagnosed NPDR were followed longitudinally.  Multivariable Cox regression analyses identified factors associated with progression to PDR.  Three- and five-year probabilities of retinopathy progression were determined.  RESULTS:  Among the 4,617 enrollees with incident NPDR, 307 (6.6%) developed PDR.  After adjustment for confounders, every 1-point increase in HbA1c was associated with a 14% (adjusted hazard ratio 1.14 [95% CI 1.07-1.21]) increased hazard of developing PDR.  Those with nonhealing ulcers had a 54% (1.54 [1.15-2.07]) increased hazard of progressing to PDR, and enrollees with nephropathy had a marginally significant increased hazard of progressing to PDR (1.29 [0.99-1.67]) relative to those without these conditions.  The 5-year probability of progression for low-risk individuals with NPDR was 5% (range 2-8) and for high-risk patients was 38% (14-55).  CONCLUSIONS:  Along with glycemic control, nonophthalmologic manifestations of diabetes mellitus (e.g., nephropathy and nonhealing ulcers) are associated with an increased risk of diabetic retinopathy progression.  Our retinopathy progression risk score can help clinicians stratify patients who are most at risk for disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxCnbyOtQBVuQ4Pl9hzjQhfW6udTcc2eaa-AIOu2phCLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s3lsVSmsA%253D%253D&md5=65e383883cd0f5264f0ad4a054508cd1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2337%2Fdc12-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc12-0790%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%2BNwanyanwu%26aufirst%3DK.%26aulast%3DTalwar%26aufirst%3DN.%26aulast%3DGardner%26aufirst%3DT.%2BW.%26aulast%3DWrobel%26aufirst%3DJ.%2BS.%26aulast%3DHerman%26aufirst%3DW.%2BH.%26aulast%3DStein%26aufirst%3DJ.%2BD.%26atitle%3DPredicting%2520Development%2520of%2520Proliferative%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%2520Care%26date%3D2013%26volume%3D36%26spage%3D1562%26epage%3D1568%26doi%3D10.2337%2Fdc12-0790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glassman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blodi, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellarin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jampol, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, And Ranibizumab</span>. <i>JAMA Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">558</span>â <span class="NLM_lpage">568</span>, <span class="refDoi">Â DOI: 10.1001/jamaophthalmol.2017.0821</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1001%2Fjamaophthalmol.2017.0821" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28448655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC1crhslejtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2017&pages=558-568&author=S.+B.+Bresslerauthor=D.+Liuauthor=A.+R.+Glassmanauthor=B.+A.+Blodiauthor=A.+A.+Castellarinauthor=L.+M.+Jampolauthor=P.+L.+Kaufmanauthor=M.+Meliaauthor=H.+Singhauthor=J.+A.+Wells&title=Change+in+Diabetic+Retinopathy+Through+2+Years%3A+Secondary+Analysis+of+a+Randomized+Clinical+Trial+Comparing+Aflibercept%2C+Bevacizumab%2C+And+Ranibizumab&doi=10.1001%2Fjamaophthalmol.2017.0821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab</span></div><div class="casAuthors">Bressler Susan B; Liu Danni; Glassman Adam R; Melia Michele; Blodi Barbara A; Castellarin Alessandro A; Jampol Lee M; Kaufman Paul L; Singh Harinderjit; Wells John A</div><div class="citationInfo"><span class="NLM_cas:title">JAMA ophthalmology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">558-568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) favorably affects diabetic retinopathy (DR) improvement and worsening.  It is unknown whether these effects differ across anti-VEGF agents.  Objective:  To compare changes in DR severity during aflibercept, bevacizumab, or ranibizumab treatment for DME.  Design, Setting, and Participants:  Preplanned secondary analysis of data from a comparative effectiveness trial for center-involved DME was conducted in 650 participants receiving aflibercept, bevacizumab, or ranibizumab.  Retinopathy improvement and worsening were determined during 2 years of treatment.  Participants were randomized in 2012 through 2013, and the trial concluded on September 23, 2015.  Interventions:  Random assignment to aflibercept, 2.0 mg; bevacizumab, 1.25 mg; ranibizumab, 0.3 mg, up to every 4 weeks through 2 years following a retreatment protocol.  Main Outcomes and Measures:  Percentages with retinopathy improvement at 1 and 2 years and cumulative probabilities for retinopathy worsening through 2-year without adjustment for multiple outcomes.  Results:  A total of 650 participants (495 [76.2%] nonproliferative DR [NPDR], 155 proliferative DR [PDR]) were analyzed; 302 (46.5%) were women and mean (SD) age was 61 (10) years; 425 (65.4%) were white.  At 1 year, among 423 NPDR eyes, 44 of 141 (31.2%) treated with aflibercept, 29 of 131 (22.1%) with bevacizumab, and 57 of 151 (37.7%) with ranibizumab had improvement of DR severity (adjusted difference: 11.7%; 95% CI, 2.9% to 20.6%; P = .004 for aflibercept vs bevacizumab; 8.9%; 95% CI, 1.7% to 16.1%; P = .01 for ranibizumab vs bevacizumab; and 2.9%; 95% CI, -5.7% to 11.4%; P = .51 for aflibercept vs ranibizumab).  At 2 years, 33 eyes (24.8%) in the aflibercept group, 25 eyes (22.1%) in the bevacizumab group, and 40 eyes (31.0%) in the ranibizumab group had DR improvement; no treatment group differences were identified.  For 93 eyes with PDR at baseline, 1-year improvement rates were 75.9% for aflibercept, 31.4% for bevacizumab, and 55.2% for ranibizumab (adjusted difference: 50.4%; 95% CI, 26.8% to 74.0%; P < .001 for aflibercept vs bevacizumab; 20.4%; 95% CI, -3.1% to 44.0%; P = .09 for ranibizumab vs bevacizumab; and 30.0%; 95% CI, 4.4% to 55.6%; P = .02 for aflibercept vs ranibizumab).  These rates and treatment group differences appeared to be maintained at 2 years.  Despite the reduced numbers of injections in the second year, 66 (59.5%) of NPDR and 28 (70.0%) of PDR eyes that manifested improvement at 1 year maintained improvement at 2 years.  Two-year cumulative rates for retinopathy worsening ranged from 7.1% to 10.2% and 17.2% to 26.4% among anti-VEGF groups for NPDR and PDR eyes, respectively.  No statistically significant treatment differences were noted.  Conclusions and Relevance:  At 1 and 2 years, eyes with NPDR receiving anti-VEGF treatment for DME may experience improvement in DR severity.  Less improvement was demonstrated with bevacizumab at 1 year than with aflibercept or ranibizumab.  Aflibercept was associated with more improvement at 1 and 2 years in the smaller subgroup of participants with PDR at baseline.  All 3 anti-VEGF treatments were associated with low rates of DR worsening.  These data provide additional outcomes that might be considered when choosing an anti-VEGF agent to treat DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRylYUBtyUvJpotVjB3IRIyfW6udTcc2eaa-AIOu2phCLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhslejtQ%253D%253D&md5=78ba6d358e9e0f94e1f14fa0e4aab1bc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1001%2Fjamaophthalmol.2017.0821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaophthalmol.2017.0821%26sid%3Dliteratum%253Aachs%26aulast%3DBressler%26aufirst%3DS.%2BB.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DGlassman%26aufirst%3DA.%2BR.%26aulast%3DBlodi%26aufirst%3DB.%2BA.%26aulast%3DCastellarin%26aufirst%3DA.%2BA.%26aulast%3DJampol%26aufirst%3DL.%2BM.%26aulast%3DKaufman%26aufirst%3DP.%2BL.%26aulast%3DMelia%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DChange%2520in%2520Diabetic%2520Retinopathy%2520Through%25202%2520Years%253A%2520Secondary%2520Analysis%2520of%2520a%2520Randomized%2520Clinical%2520Trial%2520Comparing%2520Aflibercept%252C%2520Bevacizumab%252C%2520And%2520Ranibizumab%26jtitle%3DJAMA%2520Ophthalmol.%26date%3D2017%26volume%3D135%26spage%3D558%26epage%3D568%26doi%3D10.1001%2Fjamaophthalmol.2017.0821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span> <span> </span><span class="NLM_article-title">New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1066</span>â <span class="NLM_lpage">1071</span>, <span class="refDoi">Â DOI: 10.1021/acsmedchemlett.7b00281</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00281" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVOrsb%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1066-1071&author=S.+Yuauthor=J.+Ohauthor=F.+Liauthor=Y.+Kwonauthor=H.+Choauthor=J.+Shinauthor=S.+K.+Leeauthor=S.+Kim&title=New+Scaffold+for+Angiogenesis+Inhibitors+Discovered+by+Targeted+Chemical+Transformations+of+Wondonin+Natural+Products&doi=10.1021%2Facsmedchemlett.7b00281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products</span></div><div class="casAuthors">Yu, Shuai; Oh, Jedo; Li, Feng; Kwon, Yongseok; Cho, Hyunkyung; Shin, Jongheon; Lee, Sang Kook; Kim, Sanghee</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1066-1071</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The structure of wondonin marine natural products was renovated to attain new drug-like scaffolds.  Wondonins have novel antiangiogenic properties without overt cytotoxicity.  However, the chem. instability and synthetic complexity of wondonins have hindered their development as a new type of antiangiogenesis agent.  Using a structure-based bioisosterism, the benzodioxole moiety was changed to benzothiazole, and the imidazole moiety was replaced by 1,2,3-triazole.  The authors' efforts resulted in a new scaffold with enhanced antiangiogenic activity and minimized cytotoxicity.  One compd. with this scaffold effectively inhibited hyaloid vessel formation in diabetic retinopathy mimic zebrafish model.  The biol. findings together suggested the potential of the scaffold as a lead structure for development of antiangiogenic drugs with novel functions and as a probe to elucidate new biol. mechanisms assocd. with angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpje8l61l36ELVg90H21EOLACvtfcHk0lgBtl4uURpARA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVOrsb%252FF&md5=7ae303dfa823b91a4cb37b07a8968b65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00281%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DS.%26aulast%3DOh%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DKwon%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DKim%26aufirst%3DS.%26atitle%3DNew%2520Scaffold%2520for%2520Angiogenesis%2520Inhibitors%2520Discovered%2520by%2520Targeted%2520Chemical%2520Transformations%2520of%2520Wondonin%2520Natural%2520Products%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1066%26epage%3D1071%26doi%3D10.1021%2Facsmedchemlett.7b00281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cifuentes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayupi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis-Barros, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata-Torres, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros-Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abarca, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jullian, C.</span></span> <span> </span><span class="NLM_article-title">Spectroscopic Studies of the Interaction of 3-(2-Thienyl)-[1,2,3]Triazolo[1,5-<i>a</i>] Pyridine with 2,6-Dimethyl-Î²-Cyclodextrin and <i>ct</i>DNA</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9760</span>â <span class="NLM_lpage">9767</span>, <span class="refDoi">Â DOI: 10.1039/c6ob01573e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1039%2FC6OB01573E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27714322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOhs7vF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=9760-9767&author=T.+Cifuentesauthor=J.+Cayupiauthor=C.+Celis-Barrosauthor=G.+Zapata-Torresauthor=R.+Ballesterosauthor=R.+Ballesteros-Garridoauthor=B.+Abarcaauthor=C.+Jullian&title=Spectroscopic+Studies+of+the+Interaction+of+3-%282-Thienyl%29-%5B1%2C2%2C3%5DTriazolo%5B1%2C5-a%5D+Pyridine+with+2%2C6-Dimethyl-%CE%B2-Cyclodextrin+and+ctDNA&doi=10.1039%2Fc6ob01573e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Spectroscopic studies of the interaction of 3-(2-thienyl)-[1,2,3]triazolo[1,5-a]pyridine with 2,6-dimethyl-Î²-cyclodextrin and ctDNA</span></div><div class="casAuthors">Cifuentes, T.; Cayupi, J.; Celis-Barros, C.; Zapata-Torres, G.; Ballesteros, Rafael; Ballesteros-Garrido, Rafael; Abarca, B.; Jullian, C.</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">9760-9767</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The inclusion complexation behavior of 3-(2-thienyl)-[1,2,3]triazolo[1,5-a] pyridine (TTP) with native Î²-cyclodextrin and derivatized cyclodextrins was investigated.  Stability consts. for complexes with 1 : 1 molar ratios were calcd. from phase soly. diagrams.  The solubilizing efficiency of the TTP inclusion complex is enhanced in the order of DMÎ²CD > HPÎ²CD > Î²CD.  The TTP-DMÎ²CD inclusion complex was further characterized in soln. by means of absorption, fluorescence, 2D NMR and mol. modeling methods.  The thermodn. studies indicate that the inclusion of TTP into the cyclodextrin cavity is mainly an enthalpy-driven process.  The 2D NMR studies revealed that the thienyl moiety of TTP is inserted into the CD cavity while the triazolopyridine protrudes the primary rim of the DMÎ²CD, which are in good agreement with docking results.  The fluorescence titrn. of TTP by ctDNA suggested that the quenching mechanism is a dynamic quenching procedure resulting from the temp. dependence of the TTP-ctDNA complex.  Thermodn. of the interaction revealed that the pos. values of ÎH and ÎS announced that the binding process was primarily driven by hydrophobic forces indicating that TTP interacts with ctDNA by means of the minor groove.  These results are in good agreement with docking expts. and iodide expts. which reinforce TTP's interactions in the minor groove.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcjmnylHoEt7Vg90H21EOLACvtfcHk0lgBtl4uURpARA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOhs7vF&md5=7fdfba16bb6501d07b3fa77338ae62ca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1039%2FC6OB01573E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB01573E%26sid%3Dliteratum%253Aachs%26aulast%3DCifuentes%26aufirst%3DT.%26aulast%3DCayupi%26aufirst%3DJ.%26aulast%3DCelis-Barros%26aufirst%3DC.%26aulast%3DZapata-Torres%26aufirst%3DG.%26aulast%3DBallesteros%26aufirst%3DR.%26aulast%3DBallesteros-Garrido%26aufirst%3DR.%26aulast%3DAbarca%26aufirst%3DB.%26aulast%3DJullian%26aufirst%3DC.%26atitle%3DSpectroscopic%2520Studies%2520of%2520the%2520Interaction%2520of%25203-%25282-Thienyl%2529-%255B1%252C2%252C3%255DTriazolo%255B1%252C5-a%255D%2520Pyridine%2520with%25202%252C6-Dimethyl-%25CE%25B2-Cyclodextrin%2520and%2520ctDNA%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D9760%26epage%3D9767%26doi%3D10.1039%2Fc6ob01573e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirose, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, A.</span></span> <span> </span><span class="NLM_article-title">Fluorescence Properties of 5-(5,6-Dimethoxybenzothiazol-2-yl)-2â²-deoxyuridine (d<sup>bt</sup>U) and Oligodeoxyribonucleotides Containing d<sup>bt</sup>U</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">6206</span>â <span class="NLM_lpage">6217</span>, <span class="refDoi">Â DOI: 10.1002/ejoc.201100818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1002%2Fejoc.201100818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2gsbvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=6206-6217&author=W.+Hiroseauthor=K.+Satoauthor=A.+Matsuda&title=Fluorescence+Properties+of+5-%285%2C6-Dimethoxybenzothiazol-2-yl%29-2%E2%80%B2-deoxyuridine+%28dbtU%29+and+Oligodeoxyribonucleotides+Containing+dbtU&doi=10.1002%2Fejoc.201100818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorescence Properties of 5-(5,6-Dimethoxybenzothiazol-2-yl)-2'-deoxyuridine (dbtU) and Oligodeoxyribonucleotides Containing dbtU</span></div><div class="casAuthors">Hirose, Wataru; Sato, Kousuke; Matsuda, Akira</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6206-6217, S6206/1-S6206/43</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We describe the synthesis and photo-phys. properties of 11 substituted 5-(benzothiazol-2-yl)-2'-deoxyuridine derivs. and oligodeoxyribonucleotides (ODNs) contg. 5-(5,6-dimethoxybenzothiazol-2-yl)-2'-deoxyuridine (dbtU), which was the strongest fluorescent deriv. among those prepd.  The fluorescence properties of dbtU itself and ODNs contg. dbtU show the same tendency of being weaker in both neutral and acidic soln. and stronger in basic soln.  The ODNs (15mer) contg. 16 combinations of 5'-XbtU-3' and 5'-btUY-3', where X, Y = A, T, G, or C, were synthesized, and their fluorescence intensity and quantum yield in basic soln. were compared.  On av., only the ODN with the 5'-GbtU-3' sequence shows a 7.9-fold lower fluorescence intensity than the other sequences.  Ab initio calcns. of 5'-GbtU-3' and 5'-btUG-3' as models under basic conditions suggest that the lower fluorescence of the ODN contg. the 5'-GbtU-3' sequence is caused by a wider overlap between stacked guanine (Gua) and btUra than that of the 5'-btUG-3' sequence and that the HOMO is delocalized not only on btUra but also on Gua.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6KEFkAz7xELVg90H21EOLACvtfcHk0lgBtl4uURpARA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2gsbvE&md5=fb8079bf06d7c4372e19ad6f344b0ea6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201100818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201100818%26sid%3Dliteratum%253Aachs%26aulast%3DHirose%26aufirst%3DW.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DA.%26atitle%3DFluorescence%2520Properties%2520of%25205-%25285%252C6-Dimethoxybenzothiazol-2-yl%2529-2%25E2%2580%25B2-deoxyuridine%2520%2528dbtU%2529%2520and%2520Oligodeoxyribonucleotides%2520Containing%2520dbtU%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D6206%26epage%3D6217%26doi%3D10.1002%2Fejoc.201100818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaendler, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimar, V.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Racemic Ethanolamine Plasmalogen</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>1996</i></span>,  <span class="NLM_fpage">1345</span>â <span class="NLM_lpage">1349</span>, <span class="refDoi">Â DOI: 10.1055/s-1996-4390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1055%2Fs-1996-4390" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1996&publication_year=1996&pages=1345-1349&author=H.+R.+Pfaendlerauthor=V.+Weimar&title=Synthesis+of+Racemic+Ethanolamine+Plasmalogen&doi=10.1055%2Fs-1996-4390"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1055%2Fs-1996-4390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1996-4390%26sid%3Dliteratum%253Aachs%26aulast%3DPfaendler%26aufirst%3DH.%2BR.%26aulast%3DWeimar%26aufirst%3DV.%26atitle%3DSynthesis%2520of%2520Racemic%2520Ethanolamine%2520Plasmalogen%26jtitle%3DSynthesis%26date%3D1996%26volume%3D1996%26spage%3D1345%26epage%3D1349%26doi%3D10.1055%2Fs-1996-4390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abhinand, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumya, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arya, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhakaran, P. R.</span></span> <span> </span><span class="NLM_article-title">VEGF-A/VEGFR2 Signaling Network in Endothelial Cells Relevant to Angiogenesis</span>. <i>J. Cell Comm. Signal.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">347</span>â <span class="NLM_lpage">354</span>, <span class="refDoi">Â DOI: 10.1007/s12079-016-0352-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1007%2Fs12079-016-0352-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27619687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BC2szpslaqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=347-354&author=C.+S.+Abhinandauthor=R.+Rajuauthor=S.+J.+Soumyaauthor=P.+S.+Aryaauthor=P.+R.+Sudhakaran&title=VEGF-A%2FVEGFR2+Signaling+Network+in+Endothelial+Cells+Relevant+to+Angiogenesis&doi=10.1007%2Fs12079-016-0352-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis</span></div><div class="casAuthors">Abhinand Chandran S; Arya Prabha S; Sudhakaran Perumana R; Raju Rajesh; Soumya Sasikumar J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cell communication and signaling</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-354</span>
        ISSN:<span class="NLM_cas:issn">1873-9601</span>.
    </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF-A) is essential for endothelial cell functions associated with angiogenesis.  Signal transduction networks initiated by VEGFA/VEGFR2, the most prominent ligand-receptor complex in the VEGF system, leads to endothelial cell proliferation, migration, survival and new vessel formation involved in angiogenesis.  Considering its biomedical importance, we have developed the first comprehensive map of endothelial cell-specific signaling events of VEGFA/VEGFR2 system pertaining to angiogenesis.  Screening over 20,000 published research articles and following the post-translational modification (PTM) and site specificity of VEGFR2, we have documented 240 proteins and their diverse PTM-dependent reactions involved in VEGFA/VEGFR2 signal transduction.  From the ligand-receptor complex, this map has been extended to the level of major transcriptionally regulated genes for which the signaling cascades leading to their transcription factors are reported.  We believe that this map would serve as a novel platform for reference, integration, and representation and more significantly, the progressive analysis of dynamic features of VEGF signaling in endothelial cells including their cross-talks with other ligand-receptor systems involved in angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa74p-KSP5he_Q9URG6Dx8fW6udTcc2eYuOQvHlAYlcrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szpslaqtg%253D%253D&md5=d00c7849b4004ab93903460e383ab846</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs12079-016-0352-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12079-016-0352-8%26sid%3Dliteratum%253Aachs%26aulast%3DAbhinand%26aufirst%3DC.%2BS.%26aulast%3DRaju%26aufirst%3DR.%26aulast%3DSoumya%26aufirst%3DS.%2BJ.%26aulast%3DArya%26aufirst%3DP.%2BS.%26aulast%3DSudhakaran%26aufirst%3DP.%2BR.%26atitle%3DVEGF-A%252FVEGFR2%2520Signaling%2520Network%2520in%2520Endothelial%2520Cells%2520Relevant%2520to%2520Angiogenesis%26jtitle%3DJ.%2520Cell%2520Comm.%2520Signal.%26date%3D2016%26volume%3D10%26spage%3D347%26epage%3D354%26doi%3D10.1007%2Fs12079-016-0352-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamalice, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Boeuf, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huot, J.</span></span> <span> </span><span class="NLM_article-title">Endothelial Cell Migration during Angiogenesis</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">782</span>â <span class="NLM_lpage">794</span>, <span class="refDoi">Â DOI: 10.1161/01.res.0000259593.07661.1e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1161%2F01.RES.0000259593.07661.1e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=17395884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtlWmsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=782-794&author=L.+Lamaliceauthor=F.+Le+Boeufauthor=J.+Huot&title=Endothelial+Cell+Migration+during+Angiogenesis&doi=10.1161%2F01.res.0000259593.07661.1e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial Cell Migration During Angiogenesis</span></div><div class="casAuthors">Lamalice, Laurent; Le Boeuf, Fabrice; Huot, Jacques</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">782-794</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Endothelial cell migration is essential to angiogenesis.  This motile process is directionally regulated by chemotactic, haptotactic, and mechanotactic stimuli and further involves degrdn. of the extracellular matrix to enable progression of the migrating cells.  It requires the activation of several signaling pathways that converge on cytoskeletal remodeling.  Then, it follows a series of events in which the endothelial cells extend, contract, and throw their rear toward the front and progress forward.  The aim of this review is to give an integrative view of the signaling mechanisms that govern endothelial cell migration in the context of angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB2etwgW2fV7Vg90H21EOLACvtfcHk0lh4dFGUt0JVtA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtlWmsr4%253D&md5=0bfb1f8f86194eb66a8fc729fdaa43d4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000259593.07661.1e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000259593.07661.1e%26sid%3Dliteratum%253Aachs%26aulast%3DLamalice%26aufirst%3DL.%26aulast%3DLe%2BBoeuf%26aufirst%3DF.%26aulast%3DHuot%26aufirst%3DJ.%26atitle%3DEndothelial%2520Cell%2520Migration%2520during%2520Angiogenesis%26jtitle%3DCirc.%2520Res.%26date%3D2007%26volume%3D100%26spage%3D782%26epage%3D794%26doi%3D10.1161%2F01.res.0000259593.07661.1e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hykin, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregor, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boulton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I. A.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin Concentrations in Diabetic Retinopathy</span>. <i>Br. J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">480</span>â <span class="NLM_lpage">483</span>, <span class="refDoi">Â DOI: 10.1136/bjo.2004.049940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1136%2Fbjo.2004.049940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15774928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD2M7kt1SmtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2005&pages=480-483&author=J.+I.+Patelauthor=P.+G.+Hykinauthor=Z.+J.+Gregorauthor=M.+Boultonauthor=I.+A.+Cree&title=Angiopoietin+Concentrations+in+Diabetic+Retinopathy&doi=10.1136%2Fbjo.2004.049940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin concentrations in diabetic retinopathy</span></div><div class="casAuthors">Patel J I; Hykin P G; Gregor Z J; Boulton M; Cree I A</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of ophthalmology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">480-3</span>
        ISSN:<span class="NLM_cas:issn">0007-1161</span>.
    </div><div class="casAbstract">BACKGROUND/AIM:  Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models.  Although VEGF concentrations are elevated, there is little information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy.  METHODS:  Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy.  RESULTS:  Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml).  Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14 329 pg/ml).  For both macular hole and PDR patients angiopoietin 2 was below the limit of detection.  CONCLUSIONS:  Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO.  Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent.  The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO.  The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuk3hiGspp5Aqdek-gHSrIfW6udTcc2eYuOQvHlAYlcrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7kt1SmtA%253D%253D&md5=d82cff7ffcfdb2fdc3311b1ba5ec4990</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1136%2Fbjo.2004.049940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbjo.2004.049940%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DJ.%2BI.%26aulast%3DHykin%26aufirst%3DP.%2BG.%26aulast%3DGregor%26aufirst%3DZ.%2BJ.%26aulast%3DBoulton%26aufirst%3DM.%26aulast%3DCree%26aufirst%3DI.%2BA.%26atitle%3DAngiopoietin%2520Concentrations%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DBr.%2520J.%2520Ophthalmol.%26date%3D2005%26volume%3D89%26spage%3D480%26epage%3D483%26doi%3D10.1136%2Fbjo.2004.049940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammes, H.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">vom Hagen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzizok, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownlee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deutsch, U.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin-2 Causes Pericyte Dropout in the Normal Retina: Evidence for Involvement in Diabetic Retinopathy</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1104</span>â <span class="NLM_lpage">1110</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.53.4.1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.2337%2Fdiabetes.53.4.1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15047628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFyqtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=1104-1110&author=H.-P.+Hammesauthor=J.+Linauthor=P.+Wagnerauthor=Y.+Fengauthor=F.+vom+Hagenauthor=T.+Krzizokauthor=O.+Rennerauthor=G.+Breierauthor=M.+Brownleeauthor=U.+Deutsch&title=Angiopoietin-2+Causes+Pericyte+Dropout+in+the+Normal+Retina%3A+Evidence+for+Involvement+in+Diabetic+Retinopathy&doi=10.2337%2Fdiabetes.53.4.1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy</span></div><div class="casAuthors">Hammes, Hans-Peter; Lin, Jihong; Wagner, Patrick; Feng, Yuxi; vom Hagen, Franziska; Krzizok, Thomas; Renner, Oliver; Breier, Georg; Brownlee, Michael; Deutsch, Urban</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1104-1110</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Pericyte loss is an early pathol. feature of diabetic retinopathy, consistently present in retinae of diabetic humans and animals.  Because pericyte recruitment and endothelial cell survival are controlled, in part, by the angiopoietin/Tie2 ligand/receptor system, we studied the expression of angiopoietin-2 and -1 in relation to the evolution of pericyte loss in diabetic rat retinae, using quant. retinal morphometry, and in retinae from mice with heterozygous angiopoietin deficiency (Ang-2 LacZ knock-in mice).  Finally, recombinant angiopoietin-2 was injected into eyes of nondiabetic rats, and pericyte nos. were quantitated in retinal capillaries.  Angiopoietin-1 protein was present in the normal maturing retina and was upregulated 2.5-fold in diabetic retinae over 3 mo of diabetes.  In contrast, angiopoietin-2 protein was consistently upregulated more than 30-fold in the retinae of diabetic rats, preceding the onset of pericyte loss.  Heterozygous angiopoietin-2 deficiency completely prevented diabetes-induced pericyte loss and reduced the no. of acellular capillary segments.  Injection of angiopoietin-2 into the eyes of normal rats induced a dose-dependent pericyte loss.  These data show that upregulation of angiopoietin-2 plays a crit. role in the loss of pericytes in the diabetic retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMwn67TgRG4bVg90H21EOLACvtfcHk0lhE9iGClKzwCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFyqtrw%253D&md5=8b834d296e92a303f313da368d6bfe67</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.53.4.1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.53.4.1104%26sid%3Dliteratum%253Aachs%26aulast%3DHammes%26aufirst%3DH.-P.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWagner%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3Dvom%2BHagen%26aufirst%3DF.%26aulast%3DKrzizok%26aufirst%3DT.%26aulast%3DRenner%26aufirst%3DO.%26aulast%3DBreier%26aufirst%3DG.%26aulast%3DBrownlee%26aufirst%3DM.%26aulast%3DDeutsch%26aufirst%3DU.%26atitle%3DAngiopoietin-2%2520Causes%2520Pericyte%2520Dropout%2520in%2520the%2520Normal%2520Retina%253A%2520Evidence%2520for%2520Involvement%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DDiabetes%26date%3D2004%26volume%3D53%26spage%3D1104%26epage%3D1110%26doi%3D10.2337%2Fdiabetes.53.4.1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seike, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, Y.</span></span> <span> </span><span class="NLM_article-title">Potential Role of the Angiopoietin/Tie2 System in Ischemia-Induced Retinal Neovascularization</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">393</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1167/iovs.02-0276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1167%2Fiovs.02-0276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=12506101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD38jktFOmtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2003&pages=393-402&author=H.+Takagiauthor=S.+Koyamaauthor=H.+Seikeauthor=H.+Ohauthor=A.+Otaniauthor=M.+Matsumuraauthor=Y.+Honda&title=Potential+Role+of+the+Angiopoietin%2FTie2+System+in+Ischemia-Induced+Retinal+Neovascularization&doi=10.1167%2Fiovs.02-0276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization</span></div><div class="casAuthors">Takagi Hitoshi; Koyama Shinji; Seike Hisayuki; Oh Hideyasu; Otani Atsushi; Matsumura Miyo; Honda Yoshihito</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">393-402</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  Ischemia-induced neovascularization can cause catastrophic loss of vision in retinal disorders such as diabetic retinopathy.  Recent studies have shown that the angiopoietin-Tie2 system is a major regulator of vascular integrity and is involved in pathologic angiogenesis.  In the study described herein, the role of these molecules in ischemic retinal disorders was investigated.  METHODS:  Human epiretinal membranes were examined by immunohistochemistry, In situ hybridization, and reverse transcription-polymerase chain reaction (RT-PCR) analysis.  Effects of angiopoietins on tube formation were studied in vitro in bovine retinal capillary endothelial cells (BRECs) and in a murine model of ischemia-induced retinal neovascularization.  RESULTS:  In human epiretinal membranes surgically obtained from eyes with ischemic retinal disorders, substantial upregulation of angiopoietin 2 (Ang2) and the receptor Tie2 was recorded than in those from eyes with nonischemic diseases, whereas expression of Ang1 was constant in all membranes.  Both Ang1 and Ang2 promoted tube-forming activity and enhanced the effects of vascular endothelial growth factor (VEGF) in cultured BRECs.  Soluble Tie2 fusion protein (sTie2-Fc), which precluded modulation of VEGF-dependent tube formation by the angiopoietins, suppressed both VEGF and hypoxia-conditioned, medium-induced tube-forming activity in BRECs.  Intravitreal injection of sTie2-Fc, soluble Flt-1 fusion protein (sFlt-1-Fc), and both chimeric proteins suppressed retinal angiogenesis in a murine model of retinal ischemia in the order of sTie2-Fc < sFlt-1-Fc < sTie2-Fc+sFlt-1-Fc.  CONCLUSIONS:  These results reinforce the substantial role of the angiopoietins/Tie2 system in ischemia-induced angiogenesis as well as the VEGF system and suggest that combined inhibition of Tie2 and VEGF signaling may be more effective in halting or preventing pathologic angiogenesis in ischemic retinal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBZdWOugH4ZPSAs_PE1QvifW6udTcc2eaA0Cm4pGfebbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jktFOmtw%253D%253D&md5=38fb52a411995c49a43c6ac00c67bd5d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1167%2Fiovs.02-0276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.02-0276%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DH.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DSeike%26aufirst%3DH.%26aulast%3DOh%26aufirst%3DH.%26aulast%3DOtani%26aufirst%3DA.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DHonda%26aufirst%3DY.%26atitle%3DPotential%2520Role%2520of%2520the%2520Angiopoietin%252FTie2%2520System%2520in%2520Ischemia-Induced%2520Retinal%2520Neovascularization%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2003%26volume%3D44%26spage%3D393%26epage%3D402%26doi%3D10.1167%2Fiovs.02-0276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cree, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ockrim, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joussen, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziemssen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hykin, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, S. E.</span></span> <span> </span><span class="NLM_article-title">Angiopoietin Modulation of Vascular Endothelial Growth Factor: Effects on Retinal Endothelial Cell Permeability</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">144</span>â <span class="NLM_lpage">150</span>, <span class="refDoi">Â DOI: 10.1016/j.cyto.2007.09.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.cyto.2007.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=17959386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyhsr7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=144-150&author=S.+Petersauthor=I.+A.+Creeauthor=R.+Alexanderauthor=P.+Turowskiauthor=Z.+Ockrimauthor=J.+Patelauthor=S.+R.+Boydauthor=A.+M.+Joussenauthor=F.+Ziemssenauthor=P.+G.+Hykinauthor=S.+E.+Moss&title=Angiopoietin+Modulation+of+Vascular+Endothelial+Growth+Factor%3A+Effects+on+Retinal+Endothelial+Cell+Permeability&doi=10.1016%2Fj.cyto.2007.09.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability</span></div><div class="casAuthors">Peters, Swaantje; Cree, Ian A.; Alexander, Robert; Turowski, Patric; Ockrim, Zoe; Patel, Jignesh; Boyd, Shelley R.; Joussen, Antonia M.; Ziemssen, Focke; Hykin, Philip G.; Moss, Stephen E.</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-150</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vascular permeability is important at many sites, but particularly so in diabetic retinopathy where macular edema is the major cause of blindness.  Angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) are important factors involved in neovascularization and vascular leakage, but there is little data on their interaction to promote increased vascular permeability.  Porcine retinal endothelial cells (PREC) were seeded into permeable inserts and cultured in 24-well plates that permit measurement of permeability using fluorescent dextrans.  Cell purity was assessed immunohistochem.  At confluency, PREC were treated with increasing concns. of VEGF (20-100 ng/mL) and Ang-2 (15-75 ng/mL).  The effect on tight junctions was assessed by visualization with an anti-ZO-1 antibody.  Immunohistochem. showed high purity of isolated PREC.  Permeability of untreated PREC monolayers was low.  The increase in permeability in Ang-2 treated cells (25-30% compared with non-treated cells) was less than that for cells treated with VEGF only (20-100% compared with untreated cells).  Highest permeability was seen with a combination of Ang-2 and VEGF (100-400% compared with untreated cells).  Permeability increased with time after growth factor application.  Preliminary ZO-1 immunohistochem. appeared to demonstrate the presence of tight junctions between untreated PREC, and loss of tight junctions after treatment with VEGF and Ang-2.  VEGF alone is twice as potent in interrupting tight junctions in an endothelial cell monolayer as Ang-2.  However, both growth factors acting together increase permeability three times as much as VEGF alone.  Treatments designed to reduce vascular permeability in diabetic macular edema should consider that crosstalk between growth factors including VEGF and the Ang-2/Tie-2 system can multiply their effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU8BcbgwlhFbVg90H21EOLACvtfcHk0lhE9iGClKzwCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyhsr7E&md5=d35e60446fb7fc90d3b2fa998ca42e98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2007.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2007.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DCree%26aufirst%3DI.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DTurowski%26aufirst%3DP.%26aulast%3DOckrim%26aufirst%3DZ.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DBoyd%26aufirst%3DS.%2BR.%26aulast%3DJoussen%26aufirst%3DA.%2BM.%26aulast%3DZiemssen%26aufirst%3DF.%26aulast%3DHykin%26aufirst%3DP.%2BG.%26aulast%3DMoss%26aufirst%3DS.%2BE.%26atitle%3DAngiopoietin%2520Modulation%2520of%2520Vascular%2520Endothelial%2520Growth%2520Factor%253A%2520Effects%2520on%2520Retinal%2520Endothelial%2520Cell%2520Permeability%26jtitle%3DCytokine%26date%3D2007%26volume%3D40%26spage%3D144%26epage%3D150%26doi%3D10.1016%2Fj.cyto.2007.09.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neiweem, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulla, T. A.</span></span> <span> </span><span class="NLM_article-title">Tie-2/Angiopoietin Pathway Modulation as a Therapeutic Strategy for Retinal Disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">861</span>â <span class="NLM_lpage">869</span>, <span class="refDoi">Â DOI: 10.1080/13543784.2019.1667333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1080%2F13543784.2019.1667333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=31513439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVGntL%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=861-869&author=R.+M.+Hussainauthor=A.+E.+Neiweemauthor=V.+Kansaraauthor=A.+Harrisauthor=T.+A.+Ciulla&title=Tie-2%2FAngiopoietin+Pathway+Modulation+as+a+Therapeutic+Strategy+for+Retinal+Disease&doi=10.1080%2F13543784.2019.1667333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease</span></div><div class="casAuthors">Hussain, Rehan M.; Neiweem, Ashley E.; Kansara, Viral; Harris, Alon; Ciulla, Thomas A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">861-869</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).  Activation of Tie-2 receptor via Ang-1 maintains vascular stability to limit exudation.  Ang-2, a competitive antagonist to Ang-1, and VE-PTP, an endothelial-specific phosphatase, interfere with the Tie-2-Ang-1 axis, resulting in vascular leakage.: Faricimab, a bispecific antibody that inhibits VEGF-A and Ang-2, is in phase 3 trials for nAMD and DME.  Nesvacumab is an Ang-2 inhibitor; when coformulated with aflibercept, it failed to show benefit over aflibercept monotherapy in achieving visual gains in phase 2 studies of nAMD and DME.  ARP-1536 is an intravitreally administered VE-PTP inhibitor undergoing preclin. studies.  AKB-9778 is a s.c. administered VE-PTP inhibitor that, when combined with monthly ranibizumab, reduced DME more effectively than ranibizumab monotherapy in a phase 2 study.  AKB-9778 monotherapy did not reduce diabetic retinopathy severity score compared to placebo.  AXT107, currently in the preclin. phase, promotes conversion of Ang-2 into a Tie-2 agonist and blocks signaling through VEGFR2 and other receptor tyrosine-kinases.: Tie-2/Angiopoietin pathway modulators show promise to reduce treatment burden and improve visual outcomes in nAMD and DME, with potential to treat cases refractory to current treatment modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjxY1pL8K5abVg90H21EOLACvtfcHk0ljt8tXFDECqYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVGntL%252FP&md5=d782ac40c606cbb612a5fa29e8c2caf9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1080%2F13543784.2019.1667333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2019.1667333%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DR.%2BM.%26aulast%3DNeiweem%26aufirst%3DA.%2BE.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DCiulla%26aufirst%3DT.%2BA.%26atitle%3DTie-2%252FAngiopoietin%2520Pathway%2520Modulation%2520as%2520a%2520Therapeutic%2520Strategy%2520for%2520Retinal%2520Disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2019%26volume%3D28%26spage%3D861%26epage%3D869%26doi%3D10.1080%2F13543784.2019.1667333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J.-P.</span></span> <span> </span><span class="NLM_article-title">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10533</span>â <span class="NLM_lpage">10593</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVCksbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10533-10593&author=K.-J.+Chengauthor=C.-M.+Hsiehauthor=K.+Nepaliauthor=J.-P.+Liou&title=Ocular+Disease+Therapeutics%3A+Design+and+Delivery+of+Drugs+for+Diseases+of+the+Eye&doi=10.1021%2Facs.jmedchem.9b01033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye</span></div><div class="casAuthors">Cheng, Kuei-Ju; Hsieh, Chien-Ming; Nepali, Kunal; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10533-10593</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ocular drug discovery field has evidenced significant advancement in the past decade.  The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet age-related macular degeneration (wet AMD), Luxturna for retinitis pigmentosa, Dextenza (0.4 mg dexamethasone intracanalicular insert) for ocular inflammation, ReSure sealant to seal corneal incisions, and Lifitegrast for dry eye represent some of the major developments in the field of ocular therapeutics.  A literature survey also indicates that gene therapy, stem cell therapy, and target discovery through genomic research represent significant promise as potential strategies to achieve tissue repair or regeneration and to attain therapeutic benefits in ocular diseases.  Overall, the emergence of new technologies coupled with first-in-class entries in ophthalmol. are highly anticipated to restructure and boost the future trends in the field of ophthalmic drug discovery.  This perspective focuses on various aspects of ocular drug discovery and the recent advances therein.  Recent medicinal chem. campaigns along with a brief overview of the structure-activity relationships of the diverse chem. classes and developments in ocular drug delivery (ODD) are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv-gUombQ8yrVg90H21EOLACvtfcHk0ljt8tXFDECqYw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVCksbvF&md5=79da37197a60945cac9e3ff4f0c9da6f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01033%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DK.-J.%26aulast%3DHsieh%26aufirst%3DC.-M.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLiou%26aufirst%3DJ.-P.%26atitle%3DOcular%2520Disease%2520Therapeutics%253A%2520Design%2520and%2520Delivery%2520of%2520Drugs%2520for%2520Diseases%2520of%2520the%2520Eye%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10533%26epage%3D10593%26doi%3D10.1021%2Facs.jmedchem.9b01033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Razak, A. R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van
Loon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedard, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfaro, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adriaens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brownstein, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trail, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCioccio, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, L. L.</span></span> <span> </span><span class="NLM_article-title">A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1348</span>â <span class="NLM_lpage">1355</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-15-1221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F1078-0432.CCR-15-1221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=26490310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28Xktlajs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1348-1355&author=K.+P.+Papadopoulosauthor=R.+K.+Kelleyauthor=A.+W.+Tolcherauthor=A.+R.+A.+Razakauthor=K.+Van%0ALoonauthor=A.+Patnaikauthor=P.+L.+Bedardauthor=A.+A.+Alfaroauthor=M.+Beeramauthor=L.+Adriaensauthor=C.+M.+Brownsteinauthor=I.+Lowyauthor=A.+Kosticauthor=P.+A.+Trailauthor=B.+Gaoauthor=A.+T.+DiCioccioauthor=L.+L.+Siu&title=A+Phase+I+First-in-Human+Study+of+Nesvacumab+%28REGN910%29%2C+a+Fully+Human+Anti-Angiopoietin-2+%28Ang2%29+Monoclonal+Antibody%2C+in+Patients+with+Advanced+Solid+Tumors&doi=10.1158%2F1078-0432.ccr-15-1221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Papadopoulos, Kyriakos P.; Kelley, Robin Kate; Tolcher, Anthony W.; Abdul Razak, Albiruni R.; Van Loon, Katherine; Patnaik, Amita; Bedard, Philippe L.; Alfaro, Ariceli A.; Beeram, Muralidhar; Adriaens, Lieve; Brownstein, Carrie M.; Lowy, Israel; Kostic, Ana; Trail, Pamela A.; Gao, Bo; DiCioccio, A. Thomas; Siu, Lillian L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1348-1355</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Nesvacumab (REGN910) is a fully human IgG1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Ang2 with high affinity, but shows no binding to Ang1.  The main objectives of this trial were to det. the safety, tolerability, dose-limiting toxicities (DLT), and recommended phase II dose (RP2D) of nesvacumab.  Exptl. Design: Nesvacumab was administered i.v. every two weeks with dose escalations from 1 to 20 mg/kg in patients with advanced solid tumors.  Results: A total of 47 patients were treated with nesvacumab.  No patients in the dose escalation phase experienced DLTs, therefore a max. tolerated dose (MTD) was not reached.  The most common nesvacumab-related adverse events were fatigue (23.4%), peripheral edema (21.3%), decreased appetite, and diarrhea (each 10.6%; all grade â¤ 2).  Nesvacumab was characterized by linear kinetics and had a terminal half-life of 6.35 to 9.66 days in a dose-independent manner.  Best response by RECIST 1.1 in 43 evaluable patients included 1 partial response (adrenocortical carcinoma) of 24 wk duration.  Two patients with hepatocellular carcinoma had stable disease (SD) > 16 wk, with tumor regression and >50% decrease in Î±-fetoprotein.  Analyses of putative angiogenesis biomarkers in serum and tumor biopsies were uninformative for treatment duration.  Conclusions: Nesvacumab safety profile was acceptable at all dose levels tested.  Preliminary antitumor activity was obsd. in patients with treatment-refractory advanced solid tumors.  On the basis of cumulative safety, antitumor activity, pharmacokinetic and pharmacodynamic data, the 20 mg/kg dose was detd. to be the RP2D.  Clin Cancer Res; 22(6); 1348-55. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc8IKdHdjydLVg90H21EOLACvtfcHk0lhA5mHnIXvvYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xktlajs7w%253D&md5=43f1fc21b79c12b9dd5054acf089af23</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1221%26sid%3Dliteratum%253Aachs%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DKelley%26aufirst%3DR.%2BK.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DRazak%26aufirst%3DA.%2BR.%2BA.%26aulast%3DVan%2BLoon%26aufirst%3DK.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DBedard%26aufirst%3DP.%2BL.%26aulast%3DAlfaro%26aufirst%3DA.%2BA.%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DAdriaens%26aufirst%3DL.%26aulast%3DBrownstein%26aufirst%3DC.%2BM.%26aulast%3DLowy%26aufirst%3DI.%26aulast%3DKostic%26aufirst%3DA.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DDiCioccio%26aufirst%3DA.%2BT.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DA%2520Phase%2520I%2520First-in-Human%2520Study%2520of%2520Nesvacumab%2520%2528REGN910%2529%252C%2520a%2520Fully%2520Human%2520Anti-Angiopoietin-2%2520%2528Ang2%2529%2520Monoclonal%2520Antibody%252C%2520in%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D1348%26epage%3D1355%26doi%3D10.1158%2F1078-0432.ccr-15-1221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini-Tenzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heldmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SÃ¼ssmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GrÃ¼newald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, M.</span></span> <span> </span><span class="NLM_article-title">Novel TIE-2 Inhibitor BAY-826 Displays <i>in vivo</i> Efficacy in Experimental Syngeneic Murine Glioma Models</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">182</span>, <span class="refDoi">Â DOI: 10.1111/jnc.13877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fjnc.13877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27787897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGmt7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=170-182&author=H.+Schneiderauthor=E.+Szaboauthor=R.+A.+C.+Machadoauthor=A.+Broggini-Tenzerauthor=A.+Walterauthor=M.+Lobellauthor=D.+Heldmannauthor=F.+S%C3%BCssmeierauthor=S.+Gr%C3%BCnewaldauthor=M.+Weller&title=Novel+TIE-2+Inhibitor+BAY-826+Displays+in+vivo+Efficacy+in+Experimental+Syngeneic+Murine+Glioma+Models&doi=10.1111%2Fjnc.13877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel TIE-2 inhibitor BAY-826 displays in vivo efficacy in experimental syngeneic murine glioma models</span></div><div class="casAuthors">Schneider, Hannah; Szabo, Emese; Machado, Raquel A. C.; Broggini-Tenzer, Angela; Walter, Alexander; Lobell, Mario; Heldmann, Dieter; Suessmeier, Frank; Gruenewald, Sylvia; Weller, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">170-182</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Targeting the vascular endothelial growth factor signaling axis in glioblastoma inevitably leads to tumor recurrence and a more aggressive phenotype.  Therefore, other angiogenic pathways, like the angiopoietin/tunica interna endothelial cell kinase (TIE) signaling axis, have become addnl. targets for therapeutic intervention.  Here, we explored whether targeting the receptor tyrosine kinase TIE-2 using a novel, highly potent, orally available small mol. TIE-2 inhibitor (BAY-826) improves tumor control in syngeneic mouse glioma models.  BAY-826 inhibits TIE-2 phosphorylation in vitro and in vivo as demonstrated by suppression of Angiopoietin-1- or Na3VO4-induced TIE-2 phosphorylation in glioma cells or exts. of lungs from BAY-826-treated mice.  There was a trend toward prolonged survival upon single-agent treatment in two of four models (SMA-497 and SMA-540) and there was a significant survival benefit in one model (SMA-560).  Co-treatment with BAY-826 and irradn. was ineffective in one model (SMA-497), but provided synergistic prolongation of survival in another (SMA-560).  Decreased vessel densities and increased leukocyte infiltration were obsd., but might be independent processes as the effect was also obsd. in single treatment modalities.  These data demonstrate that TIE-2 inhibition may improve tumor response to treatment in highly vascularized tumors such as glioblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSM7CpumxyGLVg90H21EOLACvtfcHk0lhA5mHnIXvvYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGmt7%252FK&md5=bd7b5a44b6c3c51f56e90f1e4f89f47d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13877%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DH.%26aulast%3DSzabo%26aufirst%3DE.%26aulast%3DMachado%26aufirst%3DR.%2BA.%2BC.%26aulast%3DBroggini-Tenzer%26aufirst%3DA.%26aulast%3DWalter%26aufirst%3DA.%26aulast%3DLobell%26aufirst%3DM.%26aulast%3DHeldmann%26aufirst%3DD.%26aulast%3DS%25C3%25BCssmeier%26aufirst%3DF.%26aulast%3DGr%25C3%25BCnewald%26aufirst%3DS.%26aulast%3DWeller%26aufirst%3DM.%26atitle%3DNovel%2520TIE-2%2520Inhibitor%2520BAY-826%2520Displays%2520in%2520vivo%2520Efficacy%2520in%2520Experimental%2520Syngeneic%2520Murine%2520Glioma%2520Models%26jtitle%3DJ.%2520Neurochem.%26date%3D2017%26volume%3D140%26spage%3D170%26epage%3D182%26doi%3D10.1111%2Fjnc.13877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harney, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karagiannis, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignatelli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadioglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Ani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oktay, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Palma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Condeelis, J. S.</span></span> <span> </span><span class="NLM_article-title">The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2<sup>Hi</sup> Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2486</span>â <span class="NLM_lpage">2501</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-17-0241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F1535-7163.MCT-17-0241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=28838996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGisrjI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2486-2501&author=A.+S.+Harneyauthor=G.+S.+Karagiannisauthor=J.+Pignatelliauthor=B.+D.+Smithauthor=E.+Kadiogluauthor=S.+C.+Wiseauthor=M.+M.+Hoodauthor=M.+D.+Kaufmanauthor=C.+B.+Learyauthor=W.-P.+Luauthor=G.+Al-Aniauthor=X.+Chenauthor=D.+Entenbergauthor=M.+H.+Oktayauthor=Y.+Wangauthor=L.+Chunauthor=M.+De+Palmaauthor=J.+G.+Jonesauthor=D.+L.+Flynnauthor=J.+S.+Condeelis&title=The+Selective+Tie2+Inhibitor+Rebastinib+Blocks+Recruitment+and+Function+of+Tie2Hi+Macrophages+in+Breast+Cancer+and+Pancreatic+Neuroendocrine+Tumors&doi=10.1158%2F1535-7163.mct-17-0241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors</span></div><div class="casAuthors">Harney, Allison S.; Karagiannis, George S.; Pignatelli, Jeanine; Smith, Bryan D.; Kadioglu, Ece; Wise, Scott C.; Hood, Molly M.; Kaufman, Michael D.; Leary, Cynthia B.; Lu, Wei-Ping; Al-Ani, Gada; Chen, Xiaoming; Entenberg, David; Oktay, Maja H.; Wang, Yarong; Chun, Lawrence; De Palma, Michele; Jones, Joan G.; Flynn, Daniel L.; Condeelis, John S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2486-2501</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor-infiltrating myeloid cells promote tumor progression by mediating angiogenesis, tumor cell intravasation, and metastasis, which can offset the effects of chemotherapy, radiation, and antiangiogenic therapy.  Here, we show that the kinase switch control inhibitor rebastinib inhibits Tie2, a tyrosine kinase receptor expressed on endothelial cells and protumoral Tie2-expressing macrophages in mouse models of metastatic cancer.  Rebastinib reduces tumor growth and metastasis in an orthotopic mouse model of metastatic mammary carcinoma through redn. of Tie2+ myeloid cell infiltration, antiangiogenic effects, and blockade of tumor cell intravasation mediated by perivascular Tie2Hi/Vegf-AHi macrophages in the tumor microenvironment of metastasis (TMEM).  The antitumor effects of rebastinib enhance the efficacy of microtubule inhibiting chemotherapeutic agents, either eribulin or paclitaxel, by reducing tumor vol., metastasis, and improving overall survival.  Rebastinib inhibition of angiopoietin/Tie2 signaling impairs multiple pathways in tumor progression mediated by protumoral Tie2+ macrophages, including TMEM-dependent dissemination and angiopoietin/Tie2-dependent angiogenesis.  Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients.  Mol Cancer Ther; 16(11); 2486-501. Â©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwpn_ZOd8hLVg90H21EOLACvtfcHk0lgEnmrxfkf2Xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGisrjI&md5=7dfc9791d4afab12f0c94467e9d29069</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0241%26sid%3Dliteratum%253Aachs%26aulast%3DHarney%26aufirst%3DA.%2BS.%26aulast%3DKaragiannis%26aufirst%3DG.%2BS.%26aulast%3DPignatelli%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DKadioglu%26aufirst%3DE.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLeary%26aufirst%3DC.%2BB.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DAl-Ani%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DEntenberg%26aufirst%3DD.%26aulast%3DOktay%26aufirst%3DM.%2BH.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DDe%2BPalma%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DJ.%2BG.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DCondeelis%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520Selective%2520Tie2%2520Inhibitor%2520Rebastinib%2520Blocks%2520Recruitment%2520and%2520Function%2520of%2520Tie2Hi%2520Macrophages%2520in%2520Breast%2520Cancer%2520and%2520Pancreatic%2520Neuroendocrine%2520Tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D2486%26epage%3D2501%26doi%3D10.1158%2F1535-7163.mct-17-0241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugel, P. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanani, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhaveri, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wykoff, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauly-Evers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadikhov, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesny, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogoceke, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weikert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fauser, S.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial</span>. <i>Ophthalmology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1155</span>â <span class="NLM_lpage">1170</span>, <span class="refDoi">Â DOI: 10.1016/j.ophtha.2019.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.ophtha.2019.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30905643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BB3cbnsFCmuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2019&pages=1155-1170&author=J.+Sahniauthor=S.+S.+Patelauthor=P.+U.+Dugelauthor=A.+M.+Khananiauthor=C.+D.+Jhaveriauthor=C.+C.+Wykoffauthor=V.+S.+Hershbergerauthor=M.+Pauly-Eversauthor=S.+Sadikhovauthor=P.+Szczesnyauthor=D.+Schwabauthor=E.+Nogocekeauthor=A.+Osborneauthor=R.+Weikertauthor=S.+Fauser&title=Simultaneous+Inhibition+of+Angiopoietin-2+and+Vascular+Endothelial+Growth+Factor-A+with+Faricimab+in+Diabetic+Macular+Edema%3A+BOULEVARD+Phase+2+Randomized+Trial&doi=10.1016%2Fj.ophtha.2019.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial</span></div><div class="casAuthors">Sahni Jayashree; Patel Sunil S; Dugel Pravin U; Khanani Arshad M; Jhaveri Chirag D; Wykoff Charles C; Hershberger Vrinda S; Pauly-Evers Meike; Szczesny Piotr; Schwab Dietmar; Nogoceke Everson; Weikert Robert; Fauser Sascha; Sadikhov Shamil; Osborne Aaron</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1155-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME).  DESIGN:  The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States.  PARTICIPANTS:  The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 Î¼m or more.  METHODS:  Anti-VEGF treatment-naive patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to 6.0 mg faricimab or 0.3 mg ranibizumab.  Patients were dosed monthly for 20 weeks, followed by an observation period up to week 36 to assess durability.  MAIN OUTCOME MEASURES:  The prespecified primary outcome measure was mean change in BCVA from baseline at week 24 for faricimab versus ranibizumab in treatment-naive patients.  Key secondary and exploratory outcome measures included CST, Diabetic Retinopathy Severity Scale (DRSS) score, and durability as assessed by time to re-treatment.  RESULTS:  The trial enrolled 229 patients (168 treatment-naive and 61 previously treated with anti-VEGF).  In treatment-naive patients, 6.0 mg faricimab, 1.5 mg faricimab, and 0.3 mg ranibizumab resulted in mean improvements of 13.9, 11.7, and 10.3 ETDRS letters from baseline, respectively.  The 6.0-mg faricimab dose demonstrated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03).  In both patient populations, faricimab resulted in dose-dependent reductions in CST, improvements in DRSS score, and longer time to re-treatment during the observation period compared with ranibizumab.  Faricimab showed no new or unexpected safety signals.  CONCLUSIONS:  The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naive patients.  Central subfield thickness reduction, DRSS score improvement, and extended durability outcomes support the primary outcome.  These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQQ15QcwhY7IOIHSmpohpd0fW6udTcc2eYNhSOrDLG8Zrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbnsFCmuw%253D%253D&md5=21447179f36dc5307a36f43d8dbcb53a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ophtha.2019.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ophtha.2019.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DSahni%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DS.%2BS.%26aulast%3DDugel%26aufirst%3DP.%2BU.%26aulast%3DKhanani%26aufirst%3DA.%2BM.%26aulast%3DJhaveri%26aufirst%3DC.%2BD.%26aulast%3DWykoff%26aufirst%3DC.%2BC.%26aulast%3DHershberger%26aufirst%3DV.%2BS.%26aulast%3DPauly-Evers%26aufirst%3DM.%26aulast%3DSadikhov%26aufirst%3DS.%26aulast%3DSzczesny%26aufirst%3DP.%26aulast%3DSchwab%26aufirst%3DD.%26aulast%3DNogoceke%26aufirst%3DE.%26aulast%3DOsborne%26aufirst%3DA.%26aulast%3DWeikert%26aufirst%3DR.%26aulast%3DFauser%26aufirst%3DS.%26atitle%3DSimultaneous%2520Inhibition%2520of%2520Angiopoietin-2%2520and%2520Vascular%2520Endothelial%2520Growth%2520Factor-A%2520with%2520Faricimab%2520in%2520Diabetic%2520Macular%2520Edema%253A%2520BOULEVARD%2520Phase%25202%2520Randomized%2520Trial%26jtitle%3DOphthalmology%26date%3D2019%26volume%3D126%26spage%3D1155%26epage%3D1170%26doi%3D10.1016%2Fj.ophtha.2019.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szklarczyk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gable, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta-Cepas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doncheva, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bork, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mering, C. V.</span></span> <span> </span><span class="NLM_article-title">STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">D607</span>â <span class="NLM_lpage">D613</span>, <span class="refDoi">Â DOI: 10.1093/nar/gky1131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1093%2Fnar%2Fgky1131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=30476243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Gqtr%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=D607-D613&author=D.+Szklarczykauthor=A.+L.+Gableauthor=D.+Lyonauthor=A.+Jungeauthor=S.+Wyderauthor=J.+Huerta-Cepasauthor=M.+Simonovicauthor=N.+T.+Donchevaauthor=J.+H.+Morrisauthor=P.+Borkauthor=L.+J.+Jensenauthor=C.+V.+Mering&title=STRING+V11%3A+Protein-Protein+Association+Networks+with+Increased+Coverage%2C+Supporting+Functional+Discovery+in+Genome-Wide+Experimental+Datasets&doi=10.1093%2Fnar%2Fgky1131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">STRING v11: protein-protein association networks with increased coverage supporting functional discovery in genome-wide experimental datasets</span></div><div class="casAuthors">Szklarczyk, Damian; Gable, Annika L.; Lyon, David; Junge, Alexander; Wyder, Stefan; Huerta-Cepas, Jaime; Simonovic, Milan; Doncheva, Nadezhda T.; Morris, John H.; Bork, Peer; Jensen, Lars J.; von Mering, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D607-D613</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">1362-4962</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Proteins and their functional interactions form the backbone of the cellular machinery.  Their connectivity network needs to be considered for the full understanding of biol. phenomena, but the available information on protein-protein assocns. is incomplete and exhibits varying levels of annotation granularity and reliability.  The STRING database aims to collect, score and integrate all publicly available sources of protein-protein interaction information, and to complement these with computational predictions.  Its goal is to achieve a comprehensive and objective global network, including direct (phys.) as well as indirect (functional) interactions.  The latest version of STRING (11.0) more than doubles the no. of organisms it covers, to 5090.  The most important new feature is an option to upload entire, genome-wide datasets as input, allowing users to visualize subsets as interaction networks and to perform gene-set enrichment anal. on the entire input.  For the enrichment anal., STRING implements well-known classification systems such as Gene Ontol. and KEGG, but also offers addnl., new classification systems based on high-throughput text-mining as well as on a hierarchical clustering of the assocn. network itself.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7UX25KcxhhbVg90H21EOLACvtfcHk0lgEnmrxfkf2Xw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Gqtr%252FM&md5=43df05a2de505f1df210fb4aaa200f58</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgky1131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgky1131%26sid%3Dliteratum%253Aachs%26aulast%3DSzklarczyk%26aufirst%3DD.%26aulast%3DGable%26aufirst%3DA.%2BL.%26aulast%3DLyon%26aufirst%3DD.%26aulast%3DJunge%26aufirst%3DA.%26aulast%3DWyder%26aufirst%3DS.%26aulast%3DHuerta-Cepas%26aufirst%3DJ.%26aulast%3DSimonovic%26aufirst%3DM.%26aulast%3DDoncheva%26aufirst%3DN.%2BT.%26aulast%3DMorris%26aufirst%3DJ.%2BH.%26aulast%3DBork%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DL.%2BJ.%26aulast%3DMering%26aufirst%3DC.%2BV.%26atitle%3DSTRING%2520V11%253A%2520Protein-Protein%2520Association%2520Networks%2520with%2520Increased%2520Coverage%252C%2520Supporting%2520Functional%2520Discovery%2520in%2520Genome-Wide%2520Experimental%2520Datasets%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2019%26volume%3D47%26spage%3DD607%26epage%3DD613%26doi%3D10.1093%2Fnar%2Fgky1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, A.</span></span> <span> </span><span class="NLM_article-title">Signal Transducers and Activators of Transcription Mediate Fibroblast Growth Factor-Induced Vascular Endothelial Morphogenesis</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1668</span>â <span class="NLM_lpage">1677</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-07-6385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F0008-5472.CAN-07-6385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19176400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslyntr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=1668-1677&author=X.+Yangauthor=D.+Qiaoauthor=K.+Meyerauthor=A.+Friedl&title=Signal+Transducers+and+Activators+of+Transcription+Mediate+Fibroblast+Growth+Factor-Induced+Vascular+Endothelial+Morphogenesis&doi=10.1158%2F0008-5472.can-07-6385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis</span></div><div class="casAuthors">Yang, Xinhai; Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1668-1677</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The fibroblast growth factors (FGF) play diverse roles in development, wound healing, and angiogenesis.  The intracellular signal transduction pathways, which mediate these pleiotropic activities, remain incompletely understood.  We show here that the proangiogenic factors FGF2 and FGF8b can activate signal transducers and activators of transcription (STAT) in mouse microvascular endothelial cells (EC).  Both FGF2 and FGF8b activate STAT5 and to a lesser extent STAT1, but not STAT3.  The FGF2-dependent activation of endothelial STAT5 was confirmed in vivo with the Matrigel plug angiogenesis assay.  In tissue samples of human gliomas, a tumor type wherein FGF-induced angiogenesis is important, STAT5 is detected in tumor vessel EC nuclei, consistent with STAT5 activation.  By forced expression of constitutively active or dominant-neg. mutant STAT5A in mouse brain ECs, we further show that STAT5 activation is both necessary and sufficient for FGF-induced cell migration, invasion, and tube formation, which are key events in vascular endothelial morphogenesis and angiogenesis.  In contrast, STAT5 is not required for brain EC mitogenesis.  The cytoplasmic tyrosine kinases Src and Janus kinase 2 (Jak2) both seem to be involved in the activation of STAT5, as their inhibition reduces FGF2- and FGF8b-induced STAT5 phosphorylation and EC tube formation.  Constitutively active STAT5A partially restores tube formation in the presence of Src or Jak2 inhibitors.  These observations show that FGFs use distinct signaling pathways to induce angiogenic phenotypes.  Together, our findings implicate the FGF-Jak2/Src-STAT5 cascade as a crit. angiogenic FGF signaling pathway. [Cancer Res 2009;69(4):1668-77].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprD1Oim8vZobVg90H21EOLACvtfcHk0likxUquSP0prQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslyntr0%253D&md5=dc4e4e34a75bb08177327b966314ee8c</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6385%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DQiao%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DFriedl%26aufirst%3DA.%26atitle%3DSignal%2520Transducers%2520and%2520Activators%2520of%2520Transcription%2520Mediate%2520Fibroblast%2520Growth%2520Factor-Induced%2520Vascular%2520Endothelial%2520Morphogenesis%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D1668%26epage%3D1677%26doi%3D10.1158%2F0008-5472.can-07-6385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedl, A.</span></span> <span> </span><span class="NLM_article-title">STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">21184</span>â <span class="NLM_lpage">21196</span>, <span class="refDoi">Â DOI: 10.1074/jbc.m113.481119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1074%2Fjbc.M113.481119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=23729680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeksL3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=21184-21196&author=X.+Yangauthor=K.+Meyerauthor=A.+Friedl&title=STAT5+and+Prolactin+Participate+in+a+Positive+Autocrine+Feedback+Loop+That+Promotes+Angiogenesis&doi=10.1074%2Fjbc.m113.481119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">STAT5 and Prolactin Participate in a Positive Autocrine Feedback Loop That Promotes Angiogenesis</span></div><div class="casAuthors">Yang, Xinhai; Meyer, Kristy; Friedl, Andreas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">21184-21196</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">We have shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal role in angiogenesis induced by the FGF2/STAT5 signaling cascade.  To delineate the signaling pathway downstream of STAT5 in the human system, where proliferin does not exist, we expressed constitutively active (CA) or dominant-neg. (DN) mutant STAT5A in hCMEC/D3 human brain endothelial cells.  We found that conditioned medium from CA-STAT5A- but not from DN-STAT5A-overexpressing endothelial cells (EC) is sufficient to induce EC migration and tube formation but not proliferation, indicating that STAT5A regulates the secretion of autocrine proangiogenic factors.  We identified prolactin (PRL) as a candidate autocrine factor.  CA-STAT5A expression stimulates PRL prodn. at the RNA and protein level, and STAT5A binds to the PRL promoter region, suggesting direct transcriptional regulation.  Medium conditioned by CA-STAT5A-overexpressing EC induces phosphorylation of the PRL receptor and activates MAPK.  Knockdown of PRL expression by shRNA or blocking of PRL activity with neutralizing antibodies removed the CA-STAT5A-dependent proangiogenic activity from the conditioned medium of EC.  The addn. of recombinant PRL restores this activity.  STAT5A-induced PRL in the conditioned medium can activate STAT5, STAT1, and to a lesser extent STAT3 in hCMEC/D3 cells, suggesting the existence of a pos. feedback loop between STAT5 and PRL that promotes angiogenesis.  Furthermore, we find that VEGF, a potent proangiogenic factor, is induced by activation of STAT5A, and VEGF induction depends on PRL expression.  These observations demonstrate a STAT5/PRL/VEGF signaling cascade in human brain EC and implicate PRL and VEGF as autocrine regulators of EC migration, invasion, and tube formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYh_1y9l4_2bVg90H21EOLACvtfcHk0likxUquSP0prQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeksL3L&md5=b205eef56dd2d0516b63ffacbaec3a70</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.481119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.481119%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DFriedl%26aufirst%3DA.%26atitle%3DSTAT5%2520and%2520Prolactin%2520Participate%2520in%2520a%2520Positive%2520Autocrine%2520Feedback%2520Loop%2520That%2520Promotes%2520Angiogenesis%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D21184%26epage%3D21196%26doi%3D10.1074%2Fjbc.m113.481119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. D.</span></span> <span> </span><span class="NLM_article-title">Enalapril Alters Expression of Key Growth Factors in Experimental Diabetic Retinopathy</span>. <i>Curr. Eye Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">976</span>â <span class="NLM_lpage">987</span>, <span class="refDoi">Â DOI: 10.3109/02713680903249913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.3109%2F02713680903249913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=19958114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSqsb3K" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=976-987&author=H.+W.+Kimauthor=J.+L.+Kimauthor=H.+K.+Leeauthor=D.+Y.+Hurauthor=I.+H.+Yunauthor=S.+D.+Kim&title=Enalapril+Alters+Expression+of+Key+Growth+Factors+in+Experimental+Diabetic+Retinopathy&doi=10.3109%2F02713680903249913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Enalapril Alters Expression of Key Growth Factors in Experimental Diabetic Retinopathy</span></div><div class="casAuthors">Kim, Hyun Woong; Kim, Jung Lim; Lee, Han Kee; Hur, Dae Young; Yun, Il Han; Kim, Sin Dong</div><div class="citationInfo"><span class="NLM_cas:title">Current Eye Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">976-987</span>CODEN:
                <span class="NLM_cas:coden">CEYRDM</span>;
        ISSN:<span class="NLM_cas:issn">0271-3683</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Purpose: Angiogenic factors such as vascular endothelial growth factor (VEGF), erythropoietin, and angiopoietin play important roles in the development of diabetic retinopathy.  However, the suppression of a single factor does not inhibit angiogenesis completely.  This study simultaneously evaluated the expression of several angiogenic factors in the retinas of diabetes-induced rats and detd. the effects of an angiotensin-converting enzyme inhibitor (enalapril) on the expression of angiogenic factors.  Methods: Diabetes was chem. induced by injecting 14 of 21 Sprague-Dawley rats with streptozotocin.  After induction of diabetes, enalapril (10 mg/kg) was administered orally to seven rats.  The rats were divided into normal, diabetes mellitus (DM), and enalapril-treated groups (each group, n = 7).  The eyeballs were removed at 8 wk after the induction of diabetes, and the retinal expression of VEGF, the signal transducer and activator of transcription (STAT)3/5, erythropoietin, and angiopoietin were examd. using immunohistochem., RT-PCR, and Western blotting.  Results: RT-PCR revealed that the expression of VEGF, VEGF receptors, STAT3, erythropoietin, erythropoietin receptor, STAT5, angiopoietin 2, and Tie2 mRNA increased in the DM group, whereas angiopoietin 1 expression decreased.  The enalapril-treated group showed no increase in mRNA expression of angiogenic factors.  Immunohistochem. staining and Western blotting showed that the expression of VEGF, STAT3, and erythropoietin receptor proteins increased in the DM group but not in the enalapril-treated group.  Erythropoietin and angiopoietin proteins were not detected by immunohistochem. staining or Western blotting.  STAT5 protein expression was detected only in the DM group using immunohistochem. staining and Western blotting.  The mRNA expression of the angiogenic factors VEGF, erythropoietin, and angiopoietin 2 increased in the DM group but not in the enalapril-treated group.  In contrast, angiopoietin 1 mRNA expression decreased in the DM group.  Conclusions: Enalapril treatment prevented increased angiogenic factor levels in the retinas of exptl. induced diabetic rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBvKF91BI3k7Vg90H21EOLACvtfcHk0likxUquSP0prQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSqsb3K&md5=4deedf399ef7f324fe55d981b501a1c2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3109%2F02713680903249913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F02713680903249913%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DH.%2BK.%26aulast%3DHur%26aufirst%3DD.%2BY.%26aulast%3DYun%26aufirst%3DI.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BD.%26atitle%3DEnalapril%2520Alters%2520Expression%2520of%2520Key%2520Growth%2520Factors%2520in%2520Experimental%2520Diabetic%2520Retinopathy%26jtitle%3DCurr.%2520Eye%2520Res.%26date%3D2009%26volume%3D34%26spage%3D976%26epage%3D987%26doi%3D10.3109%2F02713680903249913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez-Mendez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinyard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraehling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brudvig, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyriakides, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, W. C.</span></span> <span> </span><span class="NLM_article-title">Endothelial Cell Autonomous Role of Akt1</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">870</span>â <span class="NLM_lpage">879</span>, <span class="refDoi">Â DOI: 10.1161/atvbaha.118.310748</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1161%2FATVBAHA.118.310748" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=29449333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFentL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=870-879&author=M.+Y.+Leeauthor=A.+Gamez-Mendezauthor=J.+Zhangauthor=Z.+Zhuangauthor=D.+J.+Vinyardauthor=J.+Kraehlingauthor=H.+Velazquezauthor=G.+W.+Brudvigauthor=T.+R.+Kyriakidesauthor=M.+Simonsauthor=W.+C.+Sessa&title=Endothelial+Cell+Autonomous+Role+of+Akt1&doi=10.1161%2Fatvbaha.118.310748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis</span></div><div class="casAuthors">Lee, Monica Y.; Gamez-Mendez, Ana; Zhang, Jiasheng; Zhuang, Zhenwu; Vinyard, David J.; Kraehling, Jan; Velazquez, Heino; Brudvig, Gary W.; Kyriakides, Themis R.; Simons, Michael; Sessa, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">870-879</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: The importance of PI3K/Akt signaling in the vasculature has been demonstrated in several models, as global loss of Akt1 results in impaired postnatal ischemia- and VEGF-induced angiogenesis.  The ubiquitous expression of Akt1, however, raises the possibility of cell-type-dependent Akt1-driven actions, thereby necessitating tissue-specific characterization.  APPROACH AND RESULTS-: Herein, we used an inducible, endothelial-specific Akt1-deleted adult mouse model (Akt1iECKO) to characterize the endothelial cell autonomous functions of Akt1 in the vascular system.  Endothelial-targeted ablation of Akt1 reduces eNOS (endothelial nitric oxide synthase) phosphorylation and promotes both increased vascular contractility in isolated vessels and elevated diastolic blood pressures throughout the diurnal cycle in vivo.  Furthermore, Akt1iECKO mice subject to the hindlimb ischemia model display impaired blood flow and decreased arteriogenesis.  CONCLUSIONS-: Endothelial Akt1 signaling is necessary for ischemic resoln. post-injury and likely reflects the consequence of NO insufficiency crit. for vascular repair.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPJgIaj-WiobVg90H21EOLACvtfcHk0lg8IH0_UKjU8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFentL4%253D&md5=c4583567e21b66218ee3baec2c6521d5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.118.310748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.118.310748%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DGamez-Mendez%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DZ.%26aulast%3DVinyard%26aufirst%3DD.%2BJ.%26aulast%3DKraehling%26aufirst%3DJ.%26aulast%3DVelazquez%26aufirst%3DH.%26aulast%3DBrudvig%26aufirst%3DG.%2BW.%26aulast%3DKyriakides%26aufirst%3DT.%2BR.%26aulast%3DSimons%26aufirst%3DM.%26aulast%3DSessa%26aufirst%3DW.%2BC.%26atitle%3DEndothelial%2520Cell%2520Autonomous%2520Role%2520of%2520Akt1%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2018%26volume%3D38%26spage%3D870%26epage%3D879%26doi%3D10.1161%2Fatvbaha.118.310748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Graupera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillermet-Guibert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foukas, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phng, L.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cain, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salpekar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutillas, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruhrberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis Selectively Requires the P110Î± Isoform of PI3K to Control Endothelial Cell Migration</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">662</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1038/nature06892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1038%2Fnature06892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=18449193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsVKqtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=662-666&author=M.+Grauperaauthor=J.+Guillermet-Guibertauthor=L.+C.+Foukasauthor=L.-K.+Phngauthor=R.+J.+Cainauthor=A.+Salpekarauthor=W.+Pearceauthor=S.+Meekauthor=J.+Millanauthor=P.+R.+Cutillasauthor=A.+J.+H.+Smithauthor=A.+J.+Ridleyauthor=C.+Ruhrbergauthor=H.+Gerhardtauthor=B.+Vanhaesebroeck&title=Angiogenesis+Selectively+Requires+the+P110%CE%B1+Isoform+of+PI3K+to+Control+Endothelial+Cell+Migration&doi=10.1038%2Fnature06892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis selectively requires the p110Î± isoform of PI3K to control endothelial cell migration</span></div><div class="casAuthors">Graupera, Mariona; Guillermet-Guibert, Julie; Foukas, Lazaros C.; Phng, Li-Kun; Cain, Robert J.; Salpekar, Ashreena; Pearce, Wayne; Meek, Stephen; Millan, Jaime; Cutillas, Pedro R.; Smith, Andrew J. H.; Ridley, Anne J.; Ruhrberg, Christiana; Gerhardt, Holger; Vanhaesebroeck, Bart</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">453</span>
        (<span class="NLM_cas:issue">7195</span>),
    <span class="NLM_cas:pages">662-666</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinases (PI3Ks) signal downstream of multiple cell-surface receptor types.  Class IA PI3K isoforms couple to tyrosine kinases and consist of a p110 catalytic subunit (p110Î±, p110Î² or p110Î´), constitutively bound to one of five distinct p85 regulatory subunits.  PI3Ks have been implicated in angiogenesis, but little is known about potential selectivity among the PI3K isoforms and their mechanism of action in endothelial cells during angiogenesis in vivo.  Here we show that only p110Î± activity is essential for vascular development.  Ubiquitous or endothelial cell-specific inactivation of p110Î± led to embryonic lethality at mid-gestation because of severe defects in angiogenic sprouting and vascular remodelling. p110Î± exerts this crit. endothelial cell-autonomous function by regulating endothelial cell migration through the small GTPase RhoA. p110Î± activity is particularly high in endothelial cells and preferentially induced by tyrosine kinase ligands (such as vascular endothelial growth factor (VEGF)-A).  In contrast, p110Î² in endothelial cells signals downstream of G-protein-coupled receptor (GPCR) ligands such as SDF-1Î±, whereas p110Î´ is expressed at low level and contributes only minimally to PI3K activity in endothelial cells.  These results provide the first in vivo evidence for p110-isoform selectivity in endothelial PI3K signalling during angiogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW9rOrqV5M9bVg90H21EOLACvtfcHk0lg8IH0_UKjU8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsVKqtb4%253D&md5=27a919eea8bd0688b1c2e530012bb569</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1038%2Fnature06892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06892%26sid%3Dliteratum%253Aachs%26aulast%3DGraupera%26aufirst%3DM.%26aulast%3DGuillermet-Guibert%26aufirst%3DJ.%26aulast%3DFoukas%26aufirst%3DL.%2BC.%26aulast%3DPhng%26aufirst%3DL.-K.%26aulast%3DCain%26aufirst%3DR.%2BJ.%26aulast%3DSalpekar%26aufirst%3DA.%26aulast%3DPearce%26aufirst%3DW.%26aulast%3DMeek%26aufirst%3DS.%26aulast%3DMillan%26aufirst%3DJ.%26aulast%3DCutillas%26aufirst%3DP.%2BR.%26aulast%3DSmith%26aufirst%3DA.%2BJ.%2BH.%26aulast%3DRidley%26aufirst%3DA.%2BJ.%26aulast%3DRuhrberg%26aufirst%3DC.%26aulast%3DGerhardt%26aufirst%3DH.%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26atitle%3DAngiogenesis%2520Selectively%2520Requires%2520the%2520P110%25CE%25B1%2520Isoform%2520of%2520PI3K%2520to%2520Control%2520Endothelial%2520Cell%2520Migration%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D662%26epage%3D666%26doi%3D10.1038%2Fnature06892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gesbert, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Bcr/Abl Activates Transcription of the Bcl-X Gene through STAT5</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">2269</span>â <span class="NLM_lpage">2276</span>, <span class="refDoi">Â DOI: 10.1182/blood.v96.6.2269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1182%2Fblood.V96.6.2269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10979976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Chtrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=2269-2276&author=F.+Gesbertauthor=J.+D.+Griffin&title=Bcr%2FAbl+Activates+Transcription+of+the+Bcl-X+Gene+through+STAT5&doi=10.1182%2Fblood.v96.6.2269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Bcr/Abl activates transcription of the Bcl-X gene through STAT5</span></div><div class="casAuthors">Gesbert, Franck; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2269-2276</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Several tyrosine kinase oncogenes have been assocd. with myeloproliferative diseases, including Bcr/Abl, Tel/Abl, Tel/Jak2, and Tel/PDGFR.  One target mol. shared by these oncogenes is known to be STAT5.  We generated sublines of Ba/F3 cells in which either wild-type STAT5 or a constitutively active mutant of STAT5 (STAT5-1*6) were expressed under the control of a tetracycline-inducible promoter.  These cell lines were compared with a Ba/F3 cell line in which the expression of p210Bcr/Abl was made inducible by a similar promoter.  Before induction, all cells were dependent on interleukin 3 (IL-3) for growth and survival.  Both STAT5-1*6 and Bcr/Abl enhanced viability and induced proliferation in the absence of IL-3.  We found that the pro-viability protein Bcl-XL, but not Bcl-2, was induced by both p210Bcr/Abl and STAT5-1*6.  Using a Bcl-X gene promoter construct fused to a luciferase complementary DNA (cDNA), both p210Bcr/Abl and STAT5-1*6 were shown to induce transcription of Bcl-X.  The increase in transcription of the Bcl-X promoter and the increase in Bcl-X protein, due to p210Bcr/Abl, were blocked by expression of a dominant neg. STAT5 mutant.  Interestingly, however, STAT5-1*6 required the continued presence of IL-3 to cause a significant increase in Bcl-XL protein, whereas p210Bcr/Abl did not need IL-3.  Studies with enzyme inhibitors suggest that the extra signal supplied by IL-3 may be supplied by the PI3K pathway.  Overall, these data suggest that constitutively activated STAT5 can increase viability and proliferation of Ba/F3 cells.  This may contribute to, but is not likely sufficient for, the enhanced viability assocd. with Bcr/Abl transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZvnMlwzzoILVg90H21EOLACvtfcHk0lg8IH0_UKjU8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Chtrw%253D&md5=e760e005c111dfe2bf2f883507f114b4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1182%2Fblood.V96.6.2269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V96.6.2269%26sid%3Dliteratum%253Aachs%26aulast%3DGesbert%26aufirst%3DF.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DBcr%252FAbl%2520Activates%2520Transcription%2520of%2520the%2520Bcl-X%2520Gene%2520through%2520STAT5%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D2269%26epage%3D2276%26doi%3D10.1182%2Fblood.v96.6.2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kharas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2047</span>â <span class="NLM_lpage">2053</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.can-04-3888</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1158%2F0008-5472.CAN-04-3888" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15781610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisFGgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=2047-2053&author=M.+G.+Kharasauthor=D.+A.+Fruman&title=ABL+Oncogenes+and+Phosphoinositide+3-Kinase%3A+Mechanism+of+Activation+and+Downstream+Effectors&doi=10.1158%2F0008-5472.can-04-3888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors</span></div><div class="casAuthors">Kharas, Michael G.; Fruman, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2047-2053</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The BCR-ABL oncogene is responsible for most cases of chronic myelogenous leukemia and some acute lymphoblastic leukemias.  The fusion protein encoded by BCR-ABL possesses an aberrantly regulated tyrosine kinase activity.  Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for addnl. therapies.  Targeting signaling pathways activated by BCR-ABL is a promising approach for drug development.  The study of signaling components downstream of BCR-ABL and the related murine oncogene v-Abl has revealed a complex web of signals that promote cell division and survival.  Of these, activation of phosphoinositide 3-kinase (PI3K) has emerged as one of the essential signaling mechanisms in ABL leukemogenesis.  This review describes mol. mechanisms by which PI3K is activated and the downstream PI3K effectors that propagate the signal to promote myeloid and lymphoid transformation.  Of particular recent interest is the mammalian target of rapamycin, a PI3K-regulated kinase that regulates protein synthesis and contributes to leukemogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOdUEF24-suLVg90H21EOLACvtfcHk0lgOOhZL5tbvZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisFGgtb8%253D&md5=ddc0080fda93244a5a9fd0ed84d0f8c2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-3888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-3888%26sid%3Dliteratum%253Aachs%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DABL%2520Oncogenes%2520and%2520Phosphoinositide%25203-Kinase%253A%2520Mechanism%2520of%2520Activation%2520and%2520Downstream%2520Effectors%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D2047%26epage%3D2053%26doi%3D10.1158%2F0008-5472.can-04-3888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murugeswari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namperumalsamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muthukkaruppan, V.</span></span> <span> </span><span class="NLM_article-title">Proinflammatory Cytokines and Angiogenic and Anti-Angiogenic Factors in Vitreous of Patients with Proliferative Diabetic Retinopathy and Ealesâ² Disease</span>. <i>Retina</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">817</span>â <span class="NLM_lpage">824</span>, <span class="refDoi">Â DOI: 10.1097/iae.0b013e31816576d5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1097%2FIAE.0b013e31816576d5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=18536597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A280%3ADC%252BD1cvhs1Orug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=817-824&author=P.+Murugeswariauthor=D.+Shuklaauthor=A.+Rajendranauthor=R.+Kimauthor=P.+Namperumalsamyauthor=V.+Muthukkaruppan&title=Proinflammatory+Cytokines+and+Angiogenic+and+Anti-Angiogenic+Factors+in+Vitreous+of+Patients+with+Proliferative+Diabetic+Retinopathy+and+Eales%E2%80%B2+Disease&doi=10.1097%2Fiae.0b013e31816576d5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease</span></div><div class="casAuthors">Murugeswari Ponnalagu; Shukla Dhananjay; Rajendran Anand; Kim Ramasamy; Namperumalsamy Perumalsamy; Muthukkaruppan Veerappan</div><div class="citationInfo"><span class="NLM_cas:title">Retina (Philadelphia, Pa.)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">817-24</span>
        ISSN:<span class="NLM_cas:issn">0275-004X</span>.
    </div><div class="casAbstract">PURPOSE:  To investigate the mechanism of angiogenesis in proliferative diabetic retinopathy (PDR) and Eales' disease (ED) on the basis of the levels of proinflammatory cytokines, angiogenic growth factor, and antiangiogenic factor in the vitreous humor.  METHODS:  Twenty-five patients with PDR, 10 patients with ED, and 25 with macular hole (MH) as control subjects were studied.  The concentration of the proinflammatory cytokines interleukin-6 (IL-6), IL-8, IL-1 beta; chemokine-monocyte chemoattractant protein-1 (MCP-1); angiogenic factor-vascular endothelial growth factor (VEGF); and antiangiogenic factor-pigment epithelium derived factor (PEDF) in the vitreous fluid obtained from the eyes during vitrectomy were measured by sandwich enzyme linked immunosorbent assay (ELISA).  RESULTS:  IL-6, IL-8, MCP-1, and VEGF levels in the vitreous were significantly higher in PDR (P < 0.0001) and ED (P < 0.0001) than in MH patients.  Conversely, the vitreous level of PEDF was significantly reduced in PDR (P < 0.0001) but not in ED.  A significant correlation was observed between VEGF and IL-6 in ED patients.  CONCLUSION:  The authors demonstrate the importance of VEGF in retinal neovascularization of ED which is an idiopathic inflammatory venous occlusion.  Further study is required to understand the interrelationship between VEGF and inflammatory cytokines in PDR and ED.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1RNGd5aH8Hhjv2lLSLOxFfW6udTcc2eYSkn6lHtWarbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvhs1Orug%253D%253D&md5=27a9a3aa45c09b15fc0b5a3670df821c</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1097%2FIAE.0b013e31816576d5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIAE.0b013e31816576d5%26sid%3Dliteratum%253Aachs%26aulast%3DMurugeswari%26aufirst%3DP.%26aulast%3DShukla%26aufirst%3DD.%26aulast%3DRajendran%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DR.%26aulast%3DNamperumalsamy%26aufirst%3DP.%26aulast%3DMuthukkaruppan%26aufirst%3DV.%26atitle%3DProinflammatory%2520Cytokines%2520and%2520Angiogenic%2520and%2520Anti-Angiogenic%2520Factors%2520in%2520Vitreous%2520of%2520Patients%2520with%2520Proliferative%2520Diabetic%2520Retinopathy%2520and%2520Eales%25E2%2580%25B2%2520Disease%26jtitle%3DRetina%26date%3D2008%26volume%3D28%26spage%3D817%26epage%3D824%26doi%3D10.1097%2Fiae.0b013e31816576d5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PetroviÄ, MG</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoroÅ¡ec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoÅ¡nik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawlina, M.</span></span> <span> </span><span class="NLM_article-title">Association of Preoperative Vitreous IL-8 and VEGF Levels with Visual Acuity after Vitrectomy in Proliferative Diabetic Retinopathy</span>. <i>Acta Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">e311</span>â <span class="NLM_lpage">6</span>, <span class="refDoi">Â DOI: 10.1111/j.1755-3768.2010.02030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.1755-3768.2010.02030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=21073666" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2010&pages=e311-6&author=MG+Petrovi%C4%8Dauthor=P.+Koro%C5%A1ecauthor=M.+Ko%C5%A1nikauthor=M.+Hawlina&title=Association+of+Preoperative+Vitreous+IL-8+and+VEGF+Levels+with+Visual+Acuity+after+Vitrectomy+in+Proliferative+Diabetic+Retinopathy&doi=10.1111%2Fj.1755-3768.2010.02030.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1755-3768.2010.02030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1755-3768.2010.02030.x%26sid%3Dliteratum%253Aachs%26aulast%3DPetrovi%25C4%258D%26aufirst%3DMG%26aulast%3DKoro%25C5%25A1ec%26aufirst%3DP.%26aulast%3DKo%25C5%25A1nik%26aufirst%3DM.%26aulast%3DHawlina%26aufirst%3DM.%26atitle%3DAssociation%2520of%2520Preoperative%2520Vitreous%2520IL-8%2520and%2520VEGF%2520Levels%2520with%2520Visual%2520Acuity%2520after%2520Vitrectomy%2520in%2520Proliferative%2520Diabetic%2520Retinopathy%26jtitle%3DActa%2520Ophthalmol.%26date%3D2010%26volume%3D88%26spage%3De311%26epage%3D6%26doi%3D10.1111%2Fj.1755-3768.2010.02030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">CapitÃ£o, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soares, R.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">2443</span>â <span class="NLM_lpage">2453</span>, <span class="refDoi">Â DOI: 10.1002/jcb.25575</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1002%2Fjcb.25575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=27128219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1SgsrnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=2443-2453&author=M.+Capit%C3%A3oauthor=R.+Soares&title=Angiogenesis+and+Inflammation+Crosstalk+in+Diabetic+Retinopathy&doi=10.1002%2Fjcb.25575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy</span></div><div class="casAuthors">Capitao, Margarida; Soares, Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2443-2453</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes and one of the most frequent causes of blindness in active age.  Etiopathogenesis behind this important complication is related to several biochem., hemodynamic and endocrine mechanisms with a preponderant initial role assumed by polyol pathways, increment of growth factors, accumulation of advanced glycation end products (AGE), activation of protein kinase C (PKC), activation of the renin-angiotensin-aldosterone system (RAAS), and leukostasis.  Chronic and sustained hyperglycemia works as a trigger to the early alterations that culminate in vascular dysfunction.  Hypoxia also plays an essential role in disease progression with promotion of neovascularization and vascular dystrophies with vitreous hemorrhages induction.  Thus, the accumulation of fluids and protein exudates in ocular cavities leads to an opacity augmentation of the cornea that assocd. to neurodegeneration results in vision loss, being this a devastating characteristic of the disease final stage.  During disease progression, inflammatory mols. are produced and angiogenesis occur.  Furthermore, VEGF is overexpressed by the maintained hyperglycemic environment and up-regulated by tissue hypoxia.  Also pro-inflammatory mediators regulated by cytokines, such as tumor necrosis factor (TNF-Î±) and interleukin-1 beta (IL-1Î²), and growth factors leads to the progression of these processes, culminating in vasopermeability (diabetes macular edema) and/or pathol. angiogenesis (proliferative diabetic retinopathy).  It was found a mutual contribution between inflammation and angiogenesis along the process.  J. Cell. Biochem. 9999: 1-11, 2016. Â© 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6gGmXT023sLVg90H21EOLACvtfcHk0lhRg0eR296LRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1SgsrnL&md5=6bf03ef0caf1d63b5b7b8de7d8eca798</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fjcb.25575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.25575%26sid%3Dliteratum%253Aachs%26aulast%3DCapit%25C3%25A3o%26aufirst%3DM.%26aulast%3DSoares%26aufirst%3DR.%26atitle%3DAngiogenesis%2520and%2520Inflammation%2520Crosstalk%2520in%2520Diabetic%2520Retinopathy%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2016%26volume%3D117%26spage%3D2443%26epage%3D2453%26doi%3D10.1002%2Fjcb.25575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avdeef, A.</span></span> <span> </span><span class="NLM_article-title">pH-metric Solubility. 1. Solubility-pH Profiles from Bjerrum Plots. Gibbs Buffer and pKa in the Solid State</span>. <i>Pharm. Pharmacol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">178</span>, <span class="refDoi">Â DOI: 10.1111/j.2042-7158.1998.tb00328.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1111%2Fj.2042-7158.1998.tb00328.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADyaK1cXitleqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=165-178&author=A.+Avdeef&title=pH-metric+Solubility.+1.+Solubility-pH+Profiles+from+Bjerrum+Plots.+Gibbs+Buffer+and+pKa+in+the+Solid+State&doi=10.1111%2Fj.2042-7158.1998.tb00328.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">pH-metric solubility. 1. Solubility-pH profiles from Bjerrum plots. Gibbs buffer and pKa in the solid state</span></div><div class="casAuthors">Avdeef, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacy and Pharmacology Communications</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-178</span>CODEN:
                <span class="NLM_cas:coden">PPCOFN</span>;
        ISSN:<span class="NLM_cas:issn">1460-8081</span>.
    
            (<span class="NLM_cas:orgname">Royal Pharmaceutical Society of Great Britain</span>)
        </div><div class="casAbstract">If measurements of soly. were not so laborious, slow, and consuming of sample, soly.-pH profiles would be used more often at the initial stages of drug discovery to screen out mols. with problematic pharmacokinetic profiles.  An automated potentiometric titrn. method for soly. measurements, which addresses some of the shortcomings of the traditional methods, is described.  A simple graphical procedure for estg. soly. consts., based on Bjerrum difference plots, is developed, and the relationships between titrn. data and soly.-pH profiles for mono- and diprotic ionizable substances are explored, drawing on generalized mass-balance based simulation methods.  One useful derived equation (valid in a soln. where part of the sample ppts. early in the titrn.) is: log S0 = log (C/2) - |ÎpKa| where C is the sample concn., S0 is the intrinsic soly. of the unchanged substance, and ÎpKa = pKaapp - pKa, the difference between the apparent pKa detd. under conditions of pptn. and the true pKa, measured in the absence of the solid phase.  The relationship holds in both aq. and cosolvent solns. (e.g. dimethylsulfoxide-water).  The properties of the state where an unchanged substance (e.g. HX) coppts. with its ionized form (e.g. X- salt) were explored.  A super buffer termed the Gibbs buffer, was formed and characterized by an ionization const., pKa(s), of the substance in the solid state.  It was shown that pKa(s) - pKa = log SHX - log SX, where SHX and Sx refer to the soly. consts. of HX and X species.  Flurbiprofen (acid), benzydamine (base), and buprenorphine (ampholyte) were used to illustrate the exptl. procedure.  The authors' initial studies indicate that these new methods will meet many of the needs of not only discovery-stage researchers but also of preformulation and development scientists, traditionally concerned with soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGMxRxLlRsULVg90H21EOLACvtfcHk0lhRg0eR296LRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitleqtL8%253D&md5=4fc6ae518b90971869c32ac2159d939a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.2042-7158.1998.tb00328.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.2042-7158.1998.tb00328.x%26sid%3Dliteratum%253Aachs%26aulast%3DAvdeef%26aufirst%3DA.%26atitle%3DpH-metric%2520Solubility.%25201.%2520Solubility-pH%2520Profiles%2520from%2520Bjerrum%2520Plots.%2520Gibbs%2520Buffer%2520and%2520pKa%2520in%2520the%2520Solid%2520State%26jtitle%3DPharm.%2520Pharmacol.%2520Commun.%26date%3D1998%26volume%3D4%26spage%3D165%26epage%3D178%26doi%3D10.1111%2Fj.2042-7158.1998.tb00328.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etherson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, M.</span></span> <span> </span><span class="NLM_article-title">Determination of Excipient Based Solubility Increases using the CheqSol Method</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">202</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1016/j.ijpharm.2014.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1016%2Fj.ijpharm.2014.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=24513529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2mu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2014&pages=202-209&author=K.+Ethersonauthor=G.+Halbertauthor=M.+Elliott&title=Determination+of+Excipient+Based+Solubility+Increases+using+the+CheqSol+Method&doi=10.1016%2Fj.ijpharm.2014.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of excipient based solubility increases using the CheqSol method</span></div><div class="casAuthors">Etherson, Kelly; Halbert, Gavin; Elliott, Moira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">202-209</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is an essential characteristic assessed during drug development to det. a compd.'s drug-likeness since soly. plays an important pharmaceutical role.  However, nearly half of the drug candidates discovered today display poor water soly.; therefore methods have to be applied to increase soly.  Soly. detn. using the CheqSol method is a novel rapid soly. screening technique for ionizable compds.  The aim of this study is to det. if the CheqSol method can be employed to det. soly. increases of four test drugs (ibuprofen, gliclazide, atenolol and propranolol) induced by non-ionizing excipients such as hydroxypropyl-Î²-cyclodextrin and poloxamers 407 and 188.  CheqSol assays were performed for the drugs alone or in combination with varying solubilizer concns.  The measured intrinsic soly. of all four drugs increased with all the excipients tested in an excipient concn. dependent manner providing results consistent with previous literature.  The results demonstrate that it may be possible to use this method to det. the soly. increases induced by non-ionic solubilizing excipients with results that are comparable to std. equil. based soly. techniques.  Since the technique is automated and requires only small drug quantities it may serve as a useful soly. or formulation screening tool providing more detailed physicochem. information than multiwell plate or similar visual systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz1bIs43PWLrVg90H21EOLACvtfcHk0lhRg0eR296LRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2mu78%253D&md5=193c8724bb342543fe0c309478568f3a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DEtherson%26aufirst%3DK.%26aulast%3DHalbert%26aufirst%3DG.%26aulast%3DElliott%26aufirst%3DM.%26atitle%3DDetermination%2520of%2520Excipient%2520Based%2520Solubility%2520Increases%2520using%2520the%2520CheqSol%2520Method%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2014%26volume%3D465%26spage%3D202%26epage%3D209%26doi%3D10.1016%2Fj.ijpharm.2014.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©lias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+Small+Molecule-Kinase+Interaction+Map+for+Clinical+Kinase+Inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhRg0eR296LRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520Small%2520Molecule-Kinase%2520Interaction%2520Map%2520for%2520Clinical%2520Kinase%2520Inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i74"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01965">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63221"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01965?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01965</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Selective index of all the final target compounds, IC<sub>50</sub> graphs for tube formation and cell viability of <b>31</b>, VEGFR-2 kinase activity of <b>31</b>, DiscoverX KINOMEscan profiling of <b>31</b>, experimental procedures and spectroscopic data for all new compounds, and HRMS and HPLC analysis of the biologically tested compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_002.csv">CSV</a>)</p></li><li><p class="inline">DiscoverX KINOMEscan profiling of <b>31</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_001.pdf">jm0c01965_si_001.pdf (12.2 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_002.csv">jm0c01965_si_002.csv (2.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01965/suppl_file/jm0c01965_si_003.csv">jm0c01965_si_003.csv (8.68 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01965&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01965%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01965" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679973b7ed313cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
